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Abstract 
Prostate cancer is the second most common cancer affecting men worldwide. All prostate 
cancer however, is not equal: some forms of the disease are inert and do not require 
intervention; other, more aggressive forms benefit from early detection and treatment.  
Thus, accurate risk stratification is paramount.  Inadequacies in the current diagnostic 
pathway for prostate cancer lead to incorrect risk assignment. Ways of enhancing the 
diagnostic pathway and improving risk stratification using novel bio-markers are being 
actively researched worldwide. 
This thesis focuses on work carried out at University College London (UCL)/University 
College London Hospitals (UCLH), investigating imaging as a biomarker in prostate cancer. 
The development of an enhanced form of ultrasound imaging - Prostate HistoScanning 
(PHS), and the use of multi-parametric magnetic resonance imaging (mpMRI) for prostate 
cancer detection and risk stratification are investigated.  
The main body of work: Prostate Imaging Compared to Transperineal Ultrasound guided 
biopsy for significant prostate cancer Risk Evaluation; the acronym for this is the PICTURE 
Study, was designed and carried out at UCLH between 2012 and 2014. 
This research aimed to establish if imaging has a role in improving prostate cancer 
detection and, if by utilizing imaging in the form of either multi-parametric MRI (mpMRI) or 
prostate HistoScanning (PHS), men with a negative test may be spared further prostate 
biopsy.  
Additionally, for men with a lesion detected on imaging, could a targeted sampling strategy 
afford accurate disease detection and risk stratification.  
Despite initial promising results, prostate HistoScanning was found to have no role in 
prostate cancer detection.  
Multiparametric MRI however, demonstrated high performance characteristics for the 
detection of disease. It shows potential as a useful tool for men in whom diagnostic 
uncertainty remains following primary biopsy; it is asserted that it should therefore be used 
to help risk stratify these men. Moreover, mpMRI targeted biopsy provides accurate risk 
stratification; and is an approach that should be adopted. 
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1 Introduction and Background  
1.1 Introduction  
 Prostate Anatomy and Physiology 1.1.1
The prostate is a small walnut sized exocrine gland that sits beneath the bladder and in 
front of the rectum in males; the prostatic urethra passes through the prostate en-route 
from the bladder base to the urogenital diaphragm. 
The seminal vesicles sit adjacent to the prostate and the ejaculatory ducts join the prostatic 
urethra at the verumontanum. 
The prostate is divided into four zones, comprising the three glandular zones - the 
peripheral zone (PZ), the central zone (CZ), the transition zone (TZ) and the non-glandular 
anterior fibromuscular stroma (AFMS) (Figure 1) (McNeal, 1981). 
The peripheral zone surrounds the distal urethra and is the most postero-lateral aspect of 
the prostate and makes up around 75% of the prostate. Historically most cancers have 
been found to be located in the peripheral zone. 
The central zone makes up approximately 20% of the prostate. It extends from the 
transition zone to encapsulate the ejaculatory ducts and peri-urethral glandular tissue.  
The transition zone surrounds the proximal urethra occupying around 5% of the prostate 
gland at puberty. However, it is the area of the prostate responsible for benign prostatic 
hypertrophy (BPH) and continues to grow throughout male adult life. 
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Figure 1. Schematic of prostate anatomy1 
 
 
1= Peripheral Zone; 2= Central zone; 3= Transition zone 
1.2 Prostate Gland Function 
The prostate gland secretes alkaline prostatic fluid that makes up about a third of the 
proportion of semen. This alkaline fluid is responsible for helping protect spermatozoa in 
the acidic environment of the vagina.  
Prostatic fluid is composed of a number of electrolytes including very high levels of the 
anion citrate and lower concentrations of chloride. Other ions are mainly sodium, 
potassium, calcium, magnesium and zinc (Kavanagh, 1985). 
There has been some suggestion that observation of the change of composition of prostatic 
fluid may be a useful biomarker for prostate cancer (Costello and Franklin, 2009). 
Prostate specific antigen (PSA), a glycoprotein enzyme secreted by prostate epithelial cells, 
is also found in the prostatic fluid. Very small quantities of PSA are found in blood serum 
and at present PSA testing is one of the gold standard diagnostic tests for identifying men 
at risk of prostate cancer. However PSA rises are non- specific and can be associated with 
any of the major prostatic diseases, or urinary tract infections. 
 
                                                          
1 Image kindly reproduced with permission from  http://www.harvardprostateknowledge.org/choosing-and-sticking-with-
active-surveillance-a-patients-story accessed 3/6/13 
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1.3 Prostate Disease 
There exist three major prostatic diseases: - benign prostatic hypertrophy (BPH); 
prostatitis; and prostate cancer. All are predominantly found in men over 50 years of age.  
Benign prostatic hyperplasia is a non-cancerous enlargement of the prostate gland that 
arises from the glandular element of the transition zone. On account of the prostate’s 
anatomical connection with the urethra, this enlargement can cause a decrease in urinary 
flow and may require treatment if symptomatic. 
Prostatitis is an inflammatory condition of the prostate gland that is characterised by pelvic 
pain; it can be either acute or chronic, and in most cases the aetiology is unknown. 
The third and most worrying prostatic disease is prostate cancer. The main aetiological 
factors for prostate cancer are: - age; race; and positive family history. 
 
 Prostate Cancer  1.3.1
The majority of prostate cancers are adenocarcinoma’s that arise from the acini of the 
prostatic ducts. On a microscopic level the features that differentiate prostate cancer from 
benign tissue are the loss of the glandular architecture, increased neo-vascularity and 
micro vessel density, and increased cellular density. Gleason grading devised in the late 
1960’s (Figure 2) is still used to histologically quantify and grade prostate cancers. 
Gleason grading is represented by two numbers which identify the most prevalent pattern 
and the second most prevalent pattern of disease seen by the histopathologist when 
assessing prostate cancer tissue under a microscope. 
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Figure 2. The Gleason grading system 
 
 
Prostate cancer is a significant public health issue in the United Kingdom (UK) and 
worldwide. In 1998 prostate cancer became the most commonly diagnosed solid organ 
cancer in the UK overtaking both bowel and lung cancer.  
Figure 3 shows the 20 most common cancers in the UK in 2011 (Cancer Research UK, 2011). 
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Figure 3. The 20 most common cancers in the UK in 20112 
 
Between 2008 - 2010 there was an average of 40,460 newly diagnosed cases of prostate 
cancer each year in the UK. (Office for National Statistics, 2010). Their report states that 
‘the age standardised incidence over the same period was 105 new cases per 100,000 men, 
with the average number of men dying from prostate cancer each year being 10,427, a 
mortality rate of 24 deaths per 100,000 men’ (Office for National Statistics, 2010). 
In the United States, the SEER (Surveillance, Epidemiology and End Results) database age- 
adjusted incidence rates between 2005 - 2009 were 154.8 per 100,000 men, with almost 
250,000 men per year in the United States receiving a new diagnosis of prostate cancer 
(Siegel et al., 2011). Mortality rates in the US during the same time period were 23.6 per 
100,000 men per year. 
                                                          
2 CANCER RESEARCH UK. 2011. http://www.cancerresearchuk.org/. Available: http://www.cancerresearchuk.org/cancer-
info/cancerstats/incidence/commoncancers/#Twenty [Accessed 19/04/2014 2014]. 
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There have been significant increases in the reported incidence of prostate cancer in many 
countries including the UK over recent years. Figure 4 demonstrates the Prostate Cancer 
(C61), European Age-Standardised Incidence Rates, Males, UK, 1976-2011 (Cancer Research 
UK, 2014). 
Figure 4. Prostate Cancer (C61), European Age-Standardised Incidence Rates, 
Males, UK, 1993-20113 
 
The rise in incidence is in part due to the use of the serum blood test Prostate Specific 
Antigen (PSA) (Thompson et al., 2008) as a screening test both formally in the USA and 
informally in Europe. However, PSA is false positive-prone - 7 out of 10 men (Thompson et 
al., 2004) with a raised PSA will not have prostate cancer.  
In addition, it is accepted that not all men with localised prostate cancer need treatment 
and a significant proportion with low to intermediate risk disease could be kept under 
surveillance (Bill-Axelson et al., 2005). Indeed, many men over the age of 50 have indolent 
or insignificant prostate cancer that does not impact upon their life expectancy (Haas et al., 
2008).  
                                                          
3 CANCER RESEARCH UK 2014. CancerStats. Available: http://www.cancerresearchuk.org/health-professional/cancer-
statistics/statistics-by-cancer-type/prostate-cancer/incidence#heading-Zero [Accessed 21/06/2015] 
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The results of a recent large randomised trial the PIVOT study (Wilt et al., 2012) have 
shown that in men with low to intermediate risk prostate cancer there appears to be little 
if any survival benefit from radical treatment, and if anything morbidity increased amongst 
those men with low to intermediate risk prostate cancer with radical treatment. The 
incidence of low volume, low risk prostate cancer that in all likelihood does not need 
treatment is also increasing (Cooperberg et al., 2005).  
The increasing use of PSA screening and the inability of the current diagnostic pathway 
(PSA and then prostate biopsy) to differentiate between significant and indolent cancer is 
contributing to the over-diagnosis and over-treatment of low risk prostate cancer. The 
healthcare and economic implications of detecting and treating this group of men are 
significant. 
 
1.4 Current Prostate Cancer Diagnostic Pathway 
In most countries in the developed world, when men present with a raised PSA or 
abnormal DRE they are advised to undergo a trans-rectal ultrasound guided prostate biopsy 
(TRUS biopsy). Between 65 - 80 000 men have a prostate biopsy in the UK annually (Cross 
and McPhail, 2008)  and over one million biopsies are carried out in the USA.  
National Institute for Health and Care Excellence (NICE) guidelines state: “To help men 
decide whether to have a prostate biopsy, discuss with them their prostate specific antigen 
(PSA) level, digital rectal examination (DRE) findings (including an estimate of prostate size) 
and co-morbidities, together with their risk factors (including increasing age and black 
African-Caribbean family origin) and any history of a previous negative prostate biopsy” 
(National Institute for Health and Care Excellence, 2014a). 
The initial diagnostic test performed for most men at risk of prostate cancer is a standard 6 
to 12 core transrectal ultrasound (TRUS) guided biopsy. There is a significant healthcare 
burden resulting from TRUS biopsy in terms of over-diagnosis, over-treatment and test-
related side effects (Bangma et al., 2007). 
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 Problems with TRUS Biopsy 1.4.1
Many men have a negative initial biopsy 
Overall, men undergoing trans-rectal ultrasound (TRUS) guided biopsy of 6-12 cores of 
prostatic tissue have approximately a 1 in 3 probability of being diagnosed with prostate 
cancer. Of these, about half are diagnosed with low risk disease (Singh et al., 2004).  
It therefore follows that the majority of men presenting with an abnormal PSA do not have 
prostate cancer or have insignificant disease that need not be treated. If this group of men 
could be identified by a test that could reliably reassure them that they were free of 
clinically significant cancer, they could avoid biopsy.  
 
Men with low risk disease on trans-rectal biopsy  
Around two thirds of men diagnosed with low risk prostate cancer will have this status 
confirmed on radical prostatectomy examination. One in three will be seen to have 
intermediate or occasionally high risk prostate cancer at radical prostatectomy.  
One of the current diagnostic challenges is in distinguishing these two groups. If an imaging 
test were able to assist with this, it would be a very valuable test. Men with very low risk 
disease, if there was greater certainty attached to that diagnosis, could be discharged from 
further biopsy or follow up (Klotz, 2007).  
Men diagnosed with low or very low risk prostate cancer are subjected to the psychological 
morbidity of having a ‘cancer’, with many undergoing radical therapy (surgery or 
radiotherapy) when their disease poses little risk of affecting their life expectancy 
(Thompson et al., 2004) (Klotz, 2007). Some will choose surveillance, in order to avoid the 
side effects of immediate radical treatment. However, this is still associated with anxiety 
(Latini et al., 2007) as well as the burden and cost of repeat biopsies every 2-3 years and 3 
monthly clinic visits for PSA tests.  
If an imaging tool could reliably rule out significant prostate cancer, and prevent diagnosis 
of low risk disease, this would represent a significant breakthrough. It may also potentially 
reduce the negative health impact attached to a cancer diagnosis for the patient and 
reduce the burden on health services by allowing these men to be discharged from routine 
follow-up. 
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Morbidity from the diagnostic process 
As well as the diagnostic inaccuracy inherent in TRUS biopsy, there is also a significant risk 
of: - infection/sepsis; haematuria; haematospermia; pain/discomfort; dysuria, and urinary 
retention (de Jesus et al., 2006). There is also evidence to suggest that the rate of infection 
with multi-resistant organisms is increasing (Grummet et al., 2013, Chang et al., 2013). 
If an imaging modality could be found that reliably allowed men at low risk of significant 
prostate cancer to avoid biopsy, these unpleasant and potentially life-threatening side 
effects could be avoided. 
 
 Prostate Cancer Significance 1.4.2
The issue of what is and what is not clinically important disease is also important to 
address. The observation from post mortem studies is that most men, were they to live 
long enough, will harbour foci of cancer within their prostate, with, on average 50% over 
the age of 50 years having foci of prostate cancer (Haas et al., 2008). Yet the observation 
that only 3% of men die of prostate cancer makes it evident that most men with prostate 
cancer die of other unrelated causes.  
There have been numerous attempts to define the characteristics of ‘indolent’ disease 
from disease that might progress in a clinically significant manner and affect life 
expectancy. Whilst no absolute consensus exists, most experts agree that currently Gleason 
grade and tumour volume remain the key determinants of disease significance. Stamey et 
al, investigated tumour volume in defining significant cancer using a cysto-prostatectomy 
series and proposed that tumours less than 0.5 cc, were likely to be insignificant cancers 
(Stamey et al., 1993). Epstein et al, showed that a tumour volume of 0.2cc with a Gleason 
grade <7 are likely to be insignificant cancers based on analysis of radical prostatectomy 
specimens (Epstein and Potter, 2001).  
Since then, many studies have used these tumour volumes, with 0.5 cc or 0.2 cc as 
thresholds for defining significant or insignificant disease. More recently, however, Wolters 
et al examined the data from the ERSPC cancer screening trial and suggested that in fact 
1.3 cc index lesion and 2.5 cc total cancer volumes may more accurately reflect significant 
cancer thresholds (Wolters et al., 2011).  
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Using the more established Stamey and Epstein criteria computer simulation studies 
performed at University College London have shown show that a maximum cancer core 
length (MCCL) involvement of 6 mm or greater in any one location derived from Template 
Prostate Mapping biopsies (TPM), identified 95% of lesions that are 0.5 ml or more in 
volume.  Involvement of any core by 4 mm or greater identified over 95% of lesions 0.2ml 
or more in volume. These definitions required further validation within prospective trials, 
and were used within projects outlined later in this thesis. 
 
1.5  Imaging as a Diagnostic Test for Prostate Cancer  
In other cancer care pathways imaging plays a large role in diagnosis by identifying patients 
at risk and specifying a target towards which biopsies are directed. In contrast, in the 
prostate cancer care pathway, imaging is mainly used at a late stage to identify spread of 
disease, if at all. 
Currently, imaging of the prostate gland is performed to detect the presence of extra 
capsular extension, the involvement of nodal disease, or distant metastases. Thus, the role 
of imaging in diagnosing prostate cancer is very limited and diagnosis primarily relies on 
invasive biopsy procedures.  
The prostate is a small organ which is histologically heterogeneous with malignancy, benign 
prostatic hypertrophy and inflammation, often all occurring at the same time. This 
histological heterogeneity makes radiological interpretation difficult. 
However, as outlined above, with the rising incidence of prostate cancer there is an urgent 
need for a triage test that can identify those men who are unlikely to have clinically 
significant prostate cancer, and could therefore avoid invasive testing.   
Imaging would be ideal as those with a negative test could be spared invasive biopsy 
procedures and any areas of suspicion at imaging could be targeted with a biopsy needle.  
Currently there are two main imaging platforms demonstrating promise for the detection 
of cancer: - enhanced ultrasound techniques; and Magnetic Resonance Imaging (MRI). 
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1.6  Thesis Aims and Hypothesis  
This thesis will examine the role of imaging modalities in the prostate cancer diagnostic 
pathway. It will focus primarily on the role of Prostate HistoScanning (PHS) – an enhanced 
ultrasound technique - and multi parametric Magnetic Resonance Imaging (mp-MRI). 
The hypothesis of this thesis is: imaging has a role in improving prostate cancer detection 
and that by utilising imaging in the form of either multi-parametric MRI (mpMRI) or 
Prostate HistoScanning (PHS), men with a negative test may be spared further prostate 
biopsy, and those with an imaging lesion may be afforded more accurate disease detection 
and risk stratification.  
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2 Imaging in Prostate Cancer 
2.1 Current Role of Imaging in Prostate Cancer 
Currently in the UK, men identified at risk of prostate cancer undergo a routine trans-rectal 
biopsy guided by ultrasound. The ultrasound is used only to direct the biopsy to the 
prostate, not to identify lesions within the prostate.   
According to UK NICE guidelines in 2008: ‘further imaging is not routinely recommended 
for men in whom no radical treatment is intended. For men with high risk prostate cancer, 
optional pelvic imaging with CT or MRI may be performed and also Isotope bone scans may 
be undertaken’ (National Institute for Health and Care Excellence, 2008).   
However, new NICE guidance issued in January 2014 suggested that ‘Magnetic resonance 
imaging for re-biopsy should be for men with a negative transrectal ultrasound 10–12 core 
biopsy to determine whether another biopsy is needed’ (National Institute for Health and 
Care Excellence, 2014b).   
This recommendation is strongly in keeping with the hypothesis of this thesis - that imaging 
may be a useful adjunct to the prostate cancer diagnostic pathway.  
The issue remains however, one of debate amongst experts, with many suggesting more 
robust evidence is required. 
There are many imaging modalities that are in use or under investigation to assess their 
role within the prostate cancer pathway. As mentioned previously, the main two 
contenders appear to be multi-parametric MRI and enhanced ultrasound techniques. 
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2.2 Review of Transrectal Ultrasound and Enhanced Ultrasound 
Imaging 
Ultrasonography has many advantages as an imaging modality as it is relatively easy to use; 
it is portable and readily available to most urologists. It is low cost in comparison to other 
forms of imaging, and images are available in real time. Trans-rectal ultrasound (TRUS) was 
originally developed to assess rectal pathology. In 1963 Takahashi et al  used TRUS for the 
evaluation of the prostate, but these images were of fairly poor quality and not medically 
diagnostic (Takahashi H, 1963). In 1974 Wantanabe et al produced the first images with 
clinical utility using a 3.5MHz transducer (Watanabe et al., 1974).  
TRUS has since developed to become the primary imaging modality for structural 
assessment of the prostate and seminal vesicles. It is also used as the primary method for 
guiding needles into the prostate for diagnostic biopsy. Estimates of sensitivity and 
specificity of conventional Brightness mode (B-mode) TRUS imaging for detection of 
prostate cancer range from 44% to 90% from 30% to 74%, respectively (Aigner et al., 2010). 
Many technologies have been developed to try to enhance the diagnostic utility of TRUS 
scanning. 
 
 Enhanced TRUS - Colour Flow Doppler/Power Doppler Imaging 2.2.1
Prostate cancer tends to have an increased vascularity in comparison to healthy prostate 
tissue, particularly the micro vessel density (Erbersdobler et al., 2010). Colour flow Doppler 
(CFD) aims to detect these differences in prostate tumour neo-vascularity. By identifying 
the flow of blood away from or towards the TRUS transducer and superimposing this blood 
flow on the B-mode ultrasound image as a colour (Figure 5) it was hoped that colour 
doppler would increase the diagnostic accuracy of TRUS.  
Since its initial use in prostate imaging in the early 1990’s a number of studies have 
assessed the added value of colour and power doppler, with varied results (Table 1). Power 
Doppler imaging (PDI) is a special form of colour doppler imaging. It is an amplitude based 
technique, that it is reported to be able to detect slower flow and be less angle dependent 
than Colour Doppler imaging (Frauscher et al., 2005) and is therefore generally considered 
to be better.  
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Figure 5. TRUS image A, with colour doppler B 4 
 
 
Table 1. Colour and Power doppler imaging studies 
Modality Study Year Number 
of 
patients 
Sensitivity 
(%) 
Specificity 
(%) 
PPV 
(%) 
NPV 
(%) 
Colour 
(Kelly et 
al., 1993) 
1993 158 86.6 - 77 - 
Colour/Power 
Doppler 
(Cho et 
al., 1998) 
1998 40 82.6 76.5 82.6 - 
Power 
(Sauvain 
et al., 
2003) 
2003 282 92.4 72 80.6 88.2 
Colour/(Elastography
) 
(Nelson et 
al., 2007) 
2007 137 29 80 18 88 
Power 
(Eisenberg 
et al., 
2010) 
2010 620 40 35 88 6 
 
 
 
 
 
                                                          
4
 Reprinted from GHAI, S. & TOI, A. 2012. Role of transrectal ultrasonography in prostate cancer. Radiol Clin North 
Am, 50, 1061-73., with permission from Elsevier. 
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Figure 6. Power doppler5 
 
Figure 6 shows a power doppler image, in image A there is a small posterior hypoechoic 
cancer nodule (arrow). In image B, however power doppler shows that the small nodule is 
not vascular (arrow) even though it is cancer (Ghai and Toi, 2012). 
Additional information from colour doppler and power doppler imaging has not yet been 
conclusively proven to add significant diagnostic value for prostate cancer. There are a 
wide range of results in the published literature, with most studies showing little or no 
improvement in cancer detection over grey scale TRUS. The variability of the results in the 
literature (Kelly et al., 1993, Cho et al., 1998, Sauvain et al., 2003, Nelson et al., 2007, 
Eisenberg et al., 2010) suggests that the use of colour and power doppler is heavily user 
and interpreter dependent.   
 
 Contrast Enhanced Doppler- Microbubble 2.2.2
Contrast enhanced doppler (CED) imaging is a further enhancement added to standard B-
mode TRUS to attempt improve to the diagnostic ability of TRUS. The most promising agent 
is Microbubble CED. 
 
Contrast enhanced doppler ultrasound (CEUS) imaging utilises the neo-vascularity in 
prostate adenocarcinoma, the microbubble contrast agents being small enough to 
negotiate the microvasculature of the tumours and enable better visualisation of the 
tumours.  
                                                          
5 Reprinted from GHAI, S. & TOI, A. 2012. Role of transrectal ultrasonography in prostate cancer. Radiol Clin North Am, 50, 
1061-73., with permission from Elsevier. 
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Figure 7 demonstrates a lesion seen and demonstrated by arrows at grey scale imaging 
(left) and CED (right). 
  
Figure 7. Grey scale and contrast enhanced image of prostate lesion6 
 
 
Contrast microbubbles are visible in the vasculature for several minutes after intravenous 
injection, and can be visualized with the use of grey scale harmonic and doppler imaging. 
One of the disadvantages of CEUS is the subjective interpretation by the investigator (Sano 
and Uemura, 2015). 
  
Earlier versions of CEUS agents were degraded by the doppler imaging which uses fairly 
high force and therefore the agents were destroyed before they reached the 
microvasculature. Newer contrast agents (Dindyal and Kyriakides, 2011) and newer imaging 
methods specific for contrast enhanced imaging such as narrow band imaging, flash echo 
imaging and harmonic imaging have improved the technology (Trabulsi et al., 2010) with 
lower imaging powers leading to less microbubble destruction and improved imaging 
times.  
 
Many investigators have evaluated the use of contrast enhanced doppler for the detection 
of prostate cancer.  Halpern et al investigated the use of CEUS prior to TRUS and directed 
biopsies to abnormal areas on imaging followed by routine TRUS: 34% of their cohort 
(n=103/301) had prostate cancer.  They found that targeted cores were twice as likely to be 
                                                          
6 Reprinted from Xie, S.W. et al; Contrast-enhanced ultrasonography with contrast-tuned imaging technology for the 
detection of prostate cancer: Comparison with conventional ultrasonography. BJU Int. 2012, 109, 1620–1626 , with permission 
from John Wiley and Sons. 
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positive, odds ratio [OR] = 2.0, P<0.001, and the ROC AUC for contrast enhanced imaging 
ranged from 0.60-0.65 (Halpern et al., 2005).  
 
Xie et al investigated the use of CEUS vs grey scale and power doppler imaging in 150 men 
undergoing TRUS biopsies. They found no statistical difference in the number of patients 
diagnosed on grey scale imaging, power doppler or contrast enhanced, but a combination 
of the three detected more than grey scale alone with 48% of their cohort having cancer 
detected (Xie et al., 2012). 
 
Performance characteristics of CEUS per biopsy site for this study are shown in Table 2: it is 
important to keep in mind that Xie et al looked only at peripheral zone (PZ) areas for biopsy 
for this study, because enhancement by the microbubbles in the TZ makes interpretation 
and differentiation between cancerous and non- cancerous areas of the TZ near impossible. 
 
Seitz et al publish favourable sensitivity results for their series of CEUS prior to radical 
prostatectomy; however, their paper also states that only a 54.5% agreement on the 
prostate lobe containing the cancer was achieved when considering a per patient lobe 
analysis rather than whole gland detection i.e. CEUS was detecting cancer on the opposite 
side of the prostate to RP in nearly 50% of cases (Seitz et al., 2011). Table 2 shows a 
selection of performance characteristics in published literature for this technology. 
Table 2. Contrast enhanced doppler 
Study Year Number 
of 
patients 
Sensitivity 
(%) 
Specificity 
(%) 
PPV 
(%) 
NPV 
(%) 
Reference test 
(Halpern et 
al., 2005) 
2002 40 40 79 - - TRUS biopsy 
(Xie et al., 
2012) 
2012 150 73.1 87.3 66.4 90.4 
TRUS biopsy, 
by site 
(Seitz et 
al., 2011) 
2009 35 71 50 91.7 18.2 
RP, whole 
gland 
 
MD (Res) Thesis       - 34 - 
 
 Page 34 of 363 
 Elastography 2.2.3
Elastography works on the principle that benign and malignant tissues have different 
stiffness, caused by the increased cellular density of prostatic adenocarcinoma. There are 
two types of elastography - static/strain elastography (SE) and sheer wave elastography 
(SWE). They work by slightly different mechanisms, but both aim to predict the presence or 
absence of prostate cancer depending on the different tissue stiffness.  
Static elastography requires the operator to submit pressure on the prostate to produce its 
effect, and examines the strain or deformation of tissue due to that force: it is a qualitative 
form of imaging. 
Sheer wave elastography (SWE) works by using acoustic radiation to produce a sheer wave 
force across the prostate, and analysing the propagation speed of the sheer wave, and is 
able to provide quantitative measure of stiffness.  
Early studies on RTE were mainly with static RTE, with sheer wave being developed more 
recently. Shear wave elastography (SWE) facilitates a more quantitative assessment of 
tissue elasticity during elastography; it measures this elasticity in Young’s modulus (kPa). 
SWE is thought to overcome some of the limitations of quasistatic RTE and the errors 
caused by operator skill, lack of reproducibility and subjectivity.  
Figure 8. Elastography7 
 
                                                          
7
 Reprinted from GHAI, S. & TOI, A. 2012. Role of transrectal ultrasonography in prostate cancer. Radiol Clin North Am, 50, 
1061-73., with permission from Elsevier. 
Figure 8a Figure 8b 
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In Figure 8a the elastography image shows a stiffer blue area (arrow) that is suspicious for 
cancer. The area is less obvious on the corresponding grey-scale image figure 8b (arrow). 
Salomon et al studied the use of static RTE in 109 men with biopsy proven prostate cancer 
prior to radical prostatectomy (RP). Pre-operative elastography was performed and a 
report of suspicious areas made. 439 areas were deemed to be suspicious at RTE compared 
to 451 tumour foci at histology. Performance characteristics are in Table 3, sensitivity 
ranged from 72-84% and specificity from 67-84%. The range of sensitivity and specificities 
was produced by looking at the performance of RTE in different areas of the gland. RTE 
demonstrated better tumour correlation with lesions in the apical regions, and also showed 
better detection of higher grade tumours (Salomon et al., 2008).  
Tsutsumi et al investigated a novel form of elastography called real time balloon inflation 
elastography (RBIE) to try to overcome some of the issues around unequal compression of 
tissues using standard RTE. They investigated the use of RBIE in 55 men undergoing RP, and 
once again divided the prostate into regions to assess the performance of RBIE in prostate 
cancer detection. They also aimed to assess if their novel balloon system could reduce 
artefact at RTE.  
They identified that although the RBIE did lead to less slippage artefact; it produced further 
issues due to air in the balloon. Using the RBIE technique, 88% of the images obtained were 
available for analysis. Previous studies by the same authors with a manual compression RTE 
had a 32% artefact rate, thus the balloon reduced artefact by 20% (Tsutsumi et al., 2010).  
Cancer detection characteristics were similar to those found by Salomon et al: however, 
the divisions of the prostate used by Tsutsumi were able to demonstrate acceptable 
performance for RTE in the anterior gland. 
Brock et al investigated 353 men with increased PSA or suspicious DRE. The men were 
randomized to receive grey scale ultrasound (GSU) or static real time elastography (RTE). 
Systematic TRUS biopsies were taken and depending on the imaging the analyst predicted 
whether histology would be benign or malignant (Brock et al., 2012).  
Overall cancer detection was 45.3% (n=160/353), with significantly higher detection in the 
RTE group versus grey scale ultrasound (11.7% p=0.027). Sensitivity for cancer detection 
using RTE differed from the apex to the base of the prostate, apex (60-76.9%) vs. base 
(34.2-45%).  
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The study also demonstrated that 8.1% of the sectors (n=87/1068) contained prostate 
cancer, that were not deemed suspicious on RTE. RTE had a false positive rate of 24.2%, 
with 258 areas showing features of malignancy on RTE without histological confirmation of 
disease. Performance characteristics for RTE are shown in table 3, and were significantly 
better than those for grey scale ultrasound.  
Of note once again with the study by Brock et al, the transition zone was excluded from 
investigation. It was concluded by the authors that “RTE guided systematic biopsy 
improved prostate cancer detection compared to grey scale ultrasound guidance”, (Brock 
et al., 2012) but they also specified that as RTE sensitivity for prostate cancer detection was 
low systematic biopsies were still required. 
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Table 3. Elastography performance characteristics 
 Study Year Number 
of 
patients 
Sensitivity 
(%) 
Specificity 
(%) 
PPV 
(%) 
NPV 
(%) 
RTE 
(colour 
doppler) 
(Nelson et 
al., 2007) 
2007 137 25 86 20 88 
RTE vs. RP 
(Salomon 
et al., 
2008) 
2008 109 75.4 76.6 87.8 59 
RBIE vs. RP 
(Tsutsumi 
et al., 
2010) 
2010 55 60-84 80-96 75-93 71-94 
RTE vs. 
TRUS 
biopsy 
(Brock et 
al., 2012) 
2012 353 60.8 68.4 32.4 87.8 
Meta-
analysis 
RTE vs. RP 
(Zhang et 
al., 2014) 
2014 508 72 76   
SWE vs. 
TRUS 
biopsy 
(Ahmad et 
al., 2013) 
2013 50 90 88 93 83 
SWE vs. 
TRUS 
(Barr et al., 
2012) 
2012 53 96 96 69 100 
SWE vs. RP 
(Boehm et 
al., 2015) 
2013 
60 
(28 in 
validation 
cohort) 
81 69.1   
 
A meta-analysis performed on elastography by Zhang et al included 7 studies investigating 
RTE vs RP, and showed a pooled sensitivity of 72% (95% CI 70-74) and a specificity 76% 
(95% CI 74-78). Nine studies comparing RTE to TRUS biopsy were not included in the meta-
analysis (Zhang et al., 2014). 
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Figure 9 demonstrates a Forest plot of sensitivity (a) and specificity (b) for real-time 
elastography in the diagnosis of prostate cancer, for the studies included in the meta-
analysis.  
The receiver operator characteristic (ROC) curves for elastography for the articles included 
in the meta-analysis are shown below in Figure 10, with the AUC for elastography in this 
analysis being 84.1%. The meta analysis is limited by the fact that all men in all studies were 
scheduled for RP and thus all had cancer of significant gravitas to warrant radical 
treatment. Whether these favourable results would translate to a population of men 
without known cancer is unclear. 
Figure 9. Forest plots of sensitivity (a) and specificity (b) for real-time elastography 
in the diagnosis of prostate cancer.8 
 
                                                          
8 Reprinted from ZHANG, B., MA, X., ZHAN, W., ZHU, F., LI, M., HUANG, J., LI, Y., XUE, L., LIU, L. & WEI, Y. 2014. Real-time 
elastography in the diagnosis of patients suspected of having prostate cancer: a meta-analysis. Ultrasound Med Biol, 40, 
1400-7. With permission from Elselvier. 
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Figure 10. Summary receiver operating characteristic (SROC) curve for prostate 
cancer detection9 
 
 
Data on shear wave elastography is more limited than for static/strain elastography; 
Ahmad et al examined SWE in 50 men suspected of prostate cancer, prior to 12 zone biopsy 
SWE being performed. Men had at least one biopsy from each of the 12 zones. Additional 
biopsies were obtained from areas of SWE suspicion (Ahmad et al., 2013). 
The results were spilt into two groups men with PSA ≥4 but <20ug/L (n=39), and those with 
PSA ≥20 (n=11).  In the PSA<20 group sensitivity 0.9 (95% CI 0.6-0.69) and specificity 0.88 
(95%CI 0.82-0.92). In PSA≥20 group these performance characteristics improved, sensitivity 
0.93 (95%CI 0.86-0.97) and specificity 0.93 (95%CI 0.77-0.98) but it is worth considering 
that in this sub-group all 11 men had cancer.  
                                                          
9
 Reprinted from ZHANG, B., MA, X., ZHAN, W., ZHU, F., LI, M., HUANG, J., LI, Y., XUE, L., LIU, L. & WEI, Y. 2014. Real-time 
elastography in the diagnosis of patients suspected of having prostate cancer: a meta-analysis. Ultrasound Med Biol, 40, 1400-
7, with permission from Elselvier. 
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The study also contained a small number of men from a single centre, giving unreliable 
estimates of these performance characteristics as demonstrated by the wide confidence 
intervals. No cut off for stiffness was mentioned in the paper by Ahmed et al.   
Despite these limitations, it showed that SWE may be a promising technique for prostate 
cancer detection. This study has also suggested that there may be a correlation between 
Young’s modulus and Gleason grade- which, if this association can be proven in subsequent 
studies could prove very helpful in risk stratification. The Young’s modulus is the measure 
of the stiffness of tissues that is produced by SWE.  
Barr et al investigated SWE against sextant TRUS biopsy with a Young’s modulus cut off of 
37kPa, (Barr et al., 2012). They demonstrated 96.2% sensitivity and 96.2% specificity. They 
also noted that the Young’s modulus was higher in areas of malignant tissue than in atypia 
or inflammation. It is important to note that out of 53 patients examined in the study only 
11 patients had cancer (26 foci in 11 men); thus these results are based on a small sample 
size. Also a further limitation of SWE is highlighted by the authors as a shear wave pulse is 
known to only penetrate 3-4cm, and in large prostates may not be able to penetrate deep 
enough into tissues to scan the entire gland. 
A further study on SWE by Boehm et al investigating SWE prior to RP in 60 men did not 
show any correlation between Young’s modulus and Gleason grade, in contrast to the 
results of Ahmad et al. Once again the performance characteristics for SWE were promising 
with 80.9% sensitivity and 69.1% specificity (Boehm et al., 2015). 
Although sheer wave has removed the limitation from static RTE of non-uniform 
compression over the gland, elastography still has a number of limitations including: 
- Lack of penetration into the anterior gland, and different performance 
characteristics in different areas of the prostate 
- Steep learning curve for the performance and interpretation of elastography 
images 
- False positives are prevalent, especially in areas of previous prostatitis or BPH 
nodules. 
- Small number of studies investigating SWE 
Also elastography suffers from the fundamental limitation in that not all prostate cancers 
have increased tissue stiffness. Furthermore, there are areas within the prostate which 
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harbour calcifications or fibrosis that can be much firmer and therefore detected as false 
positives on elastography. 
Despite these limitations, the evidence available so far on elastography suggests that 
further investigations of this technology in larger cohorts of men - and in multi-centre trials 
- are warranted. 
 
 Artificial Neural Network Analysis/Computerised-TRUS  2.2.4
First devised in 1990, Artificial neural network analysis/Computerised TRUS (ANNA/C-TRUS) 
aimed to distinguish benign from malignant tissues using an artificial neural network. This 
network utilises static TRUS images that are transmitted to a static computer server by a 
secure web connection. The images are then analysed using the ANNA algorithms to 
highlight suspicious areas and data sent back to the referring clinician. Data sent back to 
the referring clinician indicates C-TRUS predicted presence or absence of prostate cancer 
and the Gleason grade. 
In the first series of C-TRUS vs. Radical Prostatectomy (RP) step sectioned histopathology, 
the image analysis system yielded 90% sensitivity, and a 5% false positive ratio (Loch et al., 
1990). The study was performed only in the peripheral zone of the prostate and this 
training set of 5 patients was the basis for further work with C-TRUS ANNA. 
In a further study looked at ANNA vs. Radical prostatectomy (Loch et al., 1999), 61 patients 
had 289 whole mount slices, in which 553 matched pathological lesions were confirmed. 
Fifty three were used for further training and 500 for a blinded analysis.  
This early study on the ANNA found that ANNA correctly classified 99% (378 lesions) as 
benign and incorrectly called 1% (n=3) malignant, out of the 381 pathology confirmed 
benign specimens. Of the 119 malignant samples – 94 (79%) were correctly classified as 
cancer, 25 (21%) falsely classified as benign. These figures correspond to 79% sensitivity 
and 99% specificity. 
Grabski et al investigated the use of C-TRUS on a network capable module, thus allowing 
the patient and the C-TRUS analysis to occur in different locations, as up until this point the 
C-TRUS computer had been a static stand-alone piece of equipment (Grabski et al., 2011). 
The new system allowed TRUS images to be sent from an internet platform for analysis, the 
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C-TRUS analysis centre then analysed the images and returned a report to the urologist 
with suspicious areas transposed onto the TRUS image.  
In this study, 1545 digital images were examined, and following C-TRUS analysis TRUS 
biopsies were obtained from suspicious areas in the prostate. Using the C-TRUS analysis to 
guide biopsy, 91 prostate malignancies were identified in this group of men whom on 
average had 8 (Range 0-54) prior negative biopsies.  
More recently Strunk et al investigated a combination of C-TRUS and mpMRI in 20 men 
(Strunk et al., 2014). Each patient underwent a 3 Tesla MRI and TRUS imaging, which were 
sent for C-TRUS reporting. Based on the results of the C-TRUS and mpMRI patients 
underwent targeted biopsy. 
C-TRUS found suspicious lesions in 20/20 men, the median number of lesions was 7 (range 
4-8). 17/20 men showed lesions on MRI, with the median number of lesions being 1 (range 
1-3). Nineteen out of 20 men underwent targeted biopsy, in only 11/19 biopsies (58%) was 
a prostate adenocarcinoma detected.  However, it must be mentioned that the study is 
severely limited by the low number of patients involved and the lack of an adequate 
reference standard. 
From information available to date on C-TRUS/ANNA, it is difficult to recommend its use in 
clinical practice as there is not enough data from well-designed, high number patient 
studies. 
 
 Prostate HistoScanning 2.2.5
A novel tissue characterisation technology – Prostate HistoScanning™ has shown some 
promise.  
In its first clinical study comparing pre-operative HistoScanning™ with radical 
prostatectomy specimen histology, it was shown to detect all cancers above 0.5cc - and 
accurately matched the location of these significant cancers (Braeckman et al. 2008a; 
Braeckman et al. 2008b). 
Studies published during the evolution of this thesis have shown less optimistic results for 
PHS in its ability to detect prostate cancer (Macek et al., 2014, Schiffmann et al., 2013, 
Javed et al., 2013). 
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HistoScanning is often compared to C-TRUS/ANNA in its use of algorithms to determine the 
presence or absence of prostate cancer; their technologies, however, are fundamentally 
different. Whilst C-TRUS analyses the 2D grey scale image produced by any ultrasound 
machine, prostate HistoScanning extracts the raw radiofrequency data of the ultrasound 
wave, prior to its processing and loss of information by the ultrasound machine. It is on the 
basis of the RF data for each voxel of a 3-dimensional TRUS scan that HistoScanning applies 
its tissue characterisation algorithms. 
Chapter 3 explores the evolution and initial interrogation of HistoScanning technology in 
further detail. The main body of work for this thesis, the PICTURE Study, aimed to 
determine if HistoScanning has a role in prostate cancer detection and is discussed in depth 
in later chapters. 
 
 Multiparametric Ultrasound 2.2.6
There are several enhanced ultrasound modalities that have shown promising performance 
characteristics for the detection of prostate cancer lesions. To date there has been little 
work to assess if a combination of these modalities enhances these performance 
characteristics further.  
Several groups have postulated that multi-parametric ultrasound (mpUS), may be possible, 
and several literature reviews have been published with this question in mind. They 
conclude that “By effectively combining these ultrasound techniques, all targeting different 
properties of malignant tissue, a valuable clinical tool with all the advantages of ultrasound 
could be constructed. The literature shows that combining ultrasound modalities in a crude 
fashion can already improve sensitivity by 13–59 %” (Postema et al., 2015a, Postema et al., 
2015b). 
The only study of multiparametric ultrasound, to date, has been performed by Brock et al 
who investigated the combination of contrast enhanced ultrasound and real time 
elastography. 100 patients with TRUS biopsy proven prostate cancer underwent an mpUS- 
following RTE suspicious target lesion were highlighted and assigned a prostate sector, then 
further evaluated using CEUS. These findings were correlated to final pathology following 
RP (Brock et al., 2013). 
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Figure 11. RTE images and corresponding CEUS and RP histology10 
 
14 men were excluded as correlation between their imaging and pathology slides could not 
be performed accurately due to fixation artefacts or slide disruption. 1032 prostate sectors 
were examined from 86 men (12 per patient), 621 sectors contained prostate cancer. RTE 
identified cancer with overall sensitivity 49% and specificity 73.6%, and had a false positive 
rate in 30 out of 86 target lesions (34.9%). The addition of CEUS to RTE decreased the false 
positive rate to 6 out of 58 target lesions (10.3%).  
The group found that “if the RTE positive target lesion showed a suspicious perfusion 
pattern, the likelihood of correctly detecting histopathological cancer was 89.7%” (Brock et 
al., 2013).  
The results are promising for the ability of CEUS to reduce the false positive rate of RTE; 
however, the study has a major limitation in that the authors evaluated the detection of 
what they defined as target lesions only - not the whole prostate; these targeted lesions 
were defined by RTE and then further imaged using CEUS. The authors acknowledge the 
difficulty of visualising the whole gland in a short time using CEUS; thus, these limitations 
and inability to image the whole gland is a major barrier to using the technology reliably in 
routine clinical practice. 
 
                                                          
10
 Reprinted from BROCK, M., EGGERT, T., PALISAAR, R. J., ROGHMANN, F., BRAUN, K., LOPPENBERG, B., SOMMERER, F., 
NOLDUS, J. & VON BODMAN, C. 2013. Multiparametric ultrasound of the prostate: adding contrast enhanced ultrasound to 
real-time elastography to detect histopathologically confirmed cancer. J Urol, 189, 93-8.with permission from Elselvier.  
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 Ultrasound Summary 2.2.7
There are mixed findings in the literature about the accuracy of enhanced ultrasound 
techniques for the detection of prostate cancer. Whilst they are attractive in that they are 
more affordable and easier to use/interpret than costly MRI images, the use of ultrasound 
modalities for the detection of disease is hampered by a number of limitations. 
Ultrasound is known to be a highly user dependent technique and the enhancements to 
ultrasound suffer from this same user variability. There is also poor penetration of 
ultrasound signal in to the transition zone of the prostate and this can affect the 
performance of the technologies. 
Many of the studies for enhanced ultrasound modalities that are published in the literature 
are small series or contain methodological flaws such as selection bias (all men known to 
have cancer), verification bias (TRUS biopsy used as the verification test which is in itself 
not an accurate test), this reduces the confidence with which we can interpret the findings.  
It is important that the ultrasound techniques be compared to MRI in large well designed 
studies, as is discussed later in this thesis. 
There are, however, increasing arguments for combining the ultrasound modalities, as they 
each target different properties of malignant tissue. With a combination of ultrasound 
techniques, it is likely that more accurate prostate cancer detection and risk stratification 
could be performed than with one technology alone.  
As such, further well designed studies of mpUS are recommended to further assess the 
usefulness of the technologies. 
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2.3 Review of Magnetic Resonance Imaging 
MRI has been conventionally used in the prostate cancer pathway as a staging investigation 
to identify extra capsular disease due to its superior soft tissue delineation, but had been 
thought to be poor in characterising the disease within the prostate gland. The sensitivity 
of unenhanced MRI in the detection of prostate cancer varies from 37% - 96%, (Ahmed et 
al., 2009) but is accepted to be on average approximately 50%. 
The variation is due to the criteria for a positive result and exclusion of incidental cancers 
as well as using various numbers of regions of interest and many studies excluding the 
transition zone.  
The current practice of performing MRI after TRUS biopsy makes the interpretation even 
more difficult due to post biopsy haemorrhagic changes within the gland (Qayyum et al., 
2004, Tamada et al., 2008b). These post biopsy artefacts can last over 3 months and can 
significantly affect diagnostic performance (White et al. 1995). 
Magnetic resonance imaging can include a number of different sequences that exploit the 
different physical and anatomical properties of the tissues and of the movement of water 
molecules within the tissues. Combining these sequences together has been labelled a 
multi-parametric MRI (mpMRI). 
MRI of the prostate can be performed at 1.5 Tesla; however, the development of new 
scanners with 3 Tesla magnets has seen an improvement in the signal-to-noise ratio, as has 
the use of pelvic array coils - this coupled with the mpMRI approach being adopted for MRI 
has led to an improvement in performance characteristics for the technology. (Turkbey et 
al., 2009, Turkbey et al., 2010, Aydin et al., 2012, Aydin et al., 2013b)  
The anatomic sequences are T1 and T2 weighted imaging, the functional sequences 
include: dynamic contrast enhanced imaging (DCE); diffusion weighted imaging (DWI); 
apparent diffusion co-efficient maps (ADC Maps), and MR spectroscopic imaging (MRSI).   
 
2.2.1 T2 Weighted Imaging 
T2 weighted imaging provides the anatomic imaging, and is considered by many the 
mainstay of mpMRI. T2 imaging clearly outlines the zonal anatomy of the prostate- the 
prostatic capsule, peripheral zone and transition zone (Hricak et al., 1987).  
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Prostate cancer on T2 imaging is characterised by hypo-intense lesions in the peripheral 
zone (PZ) replacing the normal hyper-intense signal of the PZ, or the homogenous signal of 
the transition zone (TZ). The signal intensity (SI) is one of the key features on T2 imaging 
that helps reporting radiologists determine the presence or absence of prostate cancer on 
T2. 
The presence of a hypo-intense lesion on T2 is considered highly sensitive for the presence 
of prostate cancer, however T2 weighted imaging alone suffers from poor specificity, due 
to post biopsy artefact, prostatitis, atrophy and post treatment changes (Bittencourt et al., 
2014). 
Some studies have shown a link between low signal intensity and the presence of higher 
gleason grades (Gleason 4-5) tumours (Wang et al., 2008). 
Figure 12. T2 weighted image11 
 
The presence of prostate cancer in the central and transition zone can be harder to detect 
on T2 weighted imaging because of the heterogeneity of the region, and the changes 
caused by benign prostatic hypertrophy (BPH), that can also demonstrate low T2 signal. 
Studies have shown that it is possible to detect TZ tumours on T2, but acknowledge that it 
remains more challenging as the signal intensity characteristics of the TZ and cancers can 
overlap. Detection of disease in the TZ proved more reliable the bigger the TZ lesion (Akin 
et al., 2006, Barentsz et al., 2012b). 
                                                          
11
 Image kindly reproduced from BITTENCOURT, L. K., HAUSMANN, D., SABANEEFF, N., GASPARETTO, E. L. & BARENTSZ, J. O. 
2014. Multiparametric magnetic resonance imaging of the prostate: current concepts. Radiol Bras, 47, 292-300. Accessed 
20/6/15 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4341390/#!po=2.27273 
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Despite showing some utility for the detection of prostate cancer T2 weighted imaging 
alone lacks sensitivity due to problems in detection in the central zone (CZ) and specificity 
is affected by other processes within the prostate. This leads to a range of performance 
characteristic values in the literature for T2 weighted imaging shown in Table 4. 
Table 4. T2 weighted imaging performance characteristics 
Study Number 
of 
patients 
Zone 
studied 
Sensitivity 
% 
(95% CI) 
Specificity 
% 
(95% CI) 
(Akin et al., 
2006) 
148 
(46 
control) 
TZ 
75 
(67-82) 
87 
(74-95) 
(Turkbey et 
al., 2010) 
70 PZ/TZ 
42 
(36-47) 
83 
(81-86) 
(Tan et al., 
2012) 
Meta- 
analysis 
PZ/TZ 57-62 74-78 
 
2.2.2 T1 Weighted and Dynamic Contrast Enhanced (DCE) 
Pre-contrast T1 axial images are used in the mpMRI protocol prior to DCE images. A T1W 
image allows imaging of the gland to ensure that changes seen on DCE are not due to 
biopsy-related haemorrhage. Post biopsy haemorrhage on DCE can be mistaken for 
tumour. DCE sequences are based on the MRI T1 sequences that are acquired pre contrast 
injection and then sequentially throughout the exposure to contrast for several minutes.  
DCE enables the calculation of parameters related to the microvascular properties of tissue 
angiogenesis (Bittencourt et al., 2014). The presence of increased neo-vascularity in 
prostate cancer leads to an intense and early enhancement on DCE sequences (wash in), 
(Kim et al., 2005) followed by a rapid wash out period, when intravenous contrast such as 
gadolinium is injected into the patient. The DCE images are then processed to provide 
either semi-quantitative or quantitative enhancement curves, and colour parametric maps 
to demonstrate wash-in rate, maximum intensity (ktrans, kep etc) and suspicious areas. 
The aim is to analyse the pharmokinetic behaviour of the contrast agent on the T1 images 
over time (Futterer et al., 2006, Ocak et al., 2007, Tanaka et al., 1999). 
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Simple visual examination of DCE images has been shown to be successful and is used in 
many institutions (Girouin et al., 2007). The more quantitative approaches to DCE-MRI 
interpretation require specialist computer hardware and software, and can be quite time 
consuming. 
Figure 13. Dynamic contrast enhanced image signal intensity 12 
 
‘Signal intensity versus time curve in a typical tumour lesion. The image A represents the early arterial phase of 
DCE evaluation, showing a focal area of early contrast enhancement in the peripheral zone at right (outlined by 
the red line). Normal appearing areas were also outlined in the contralateral peripheral zone (yellow) and 
internal gland (green). The resulting curves (B) show that the suspicious lesion (red curve) is characterized by a 
high and steep rise (washin), flowed by a marked decrease (washout), with a significantly different behavior 
from the other curves’. (Bittencourt et al., 2014) 
  
                                                          
12  Image kindly reproduced from  BITTENCOURT, L. K., HAUSMANN, D., SABANEEFF, N., GASPARETTO, E. L. & BARENTSZ, J. O. 
2014. Multiparametric magnetic resonance imaging of the prostate: current concepts. Radiol Bras, 47, 292-300. Accessed 
20/6/15 
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Figure 14. Semi-quantitative post processing of DCE13 
 
‘Semi-quantitative post-processing of DCE. Image A represents the parametric map generated from DCE 
evaluation of the same patient of Figure 13, corresponding to the area under the curve during the first minute 
(positive enhancement index – PEI). Note that on this map, the suspected area cited in Figure 13  is coded in red 
(arrowheads), standing out from the other portions of the prostatic parenchyma. On B, one observes a fusion 
between the DCE parametric map and the T2-weighted sequence in the axial plane, enabling better correlation 
of anatomic and functional findings’ (Bittencourt et al., 2014). 
In one study evaluating 24 men with raised PSA who underwent T2-weighted and DCE-MRI 
with 3-Tesla pelvic phased array coil before prostate biopsy compared to whole-mount 
radical prostatectomy step-sectioned histology (Villers et al. 2006). DCE MRI showed a 
sensitivity, specificity, positive predictive value and negative predictive value of 90%, 88%, 
77% and 95%, respectively for cancer lesions above 0.5cc, and 77%, 91%, 86 % and 85% 
respectively for cancer lesions above 0.2cc.  
Table 5 outlines a selection of performance characteristics for DCE as found in current 
literature. 
A number of studies have evaluated the role of DCE-MRI, DW and MRSI in detecting 
prostate cancer either prior to prostate biopsy or radical prostatectomy. These studies 
have found that a combination of DCE and DWI imaging demonstrates the most promising 
sensitivity for anterior PZ and central zone tumours (Turkbey et al., 2011). Other studies 
have shown that DCE is more useful when used in combination with T2 weighted imaging 
than alone (Turkbey et al., 2010).  
  
                                                          
13  As above Accessed 20/6/15 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4341390/#!po=2.27273 
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Table 5. DCE imaging performance characteristics 
Study Number 
of 
patients 
Zone 
studied 
Sensitivity 
% 
(95% CI) 
Specificity 
% 
(95% CI) 
PPV 
% 
(95% CI) 
NPV 
% 
(95% CI) 
(Kim et al., 
2005) 
53 PZ/TZ 96 82 82 96 
(Ocak et al., 
2007) 
50 PZ 
73 
(62-82) 
88 
(80-95) 
75 
(65-85) 
75 
(68-82) 
(Turkbey et 
al., 2010) 
70 PZ/TZ 
18 
(13-23) 
96 
(94-97) 
- - 
(Turkbey et 
al., 2011) 
45 PZ/TZ 38 98 86 87 
 
There have been suggestions that the addition of DCE improves T2W imaging specificity: if 
lesions are seen on T2, they are more likely to be due to cancer than benign processes, but 
that DCE alone is unlikely to highlight new lesions that have not been detected at T2 (Ocak 
et al., 2007). 
A meta-analysis of 24 articles investigating DCE (Tan et al., 2015) found that the AUC for 
DCE MRI alone and that for DCE and T2-weighted imaging was superior to that of T2- 
weighted imaging alone. 
DCE also has the advantage that it can be performed quickly on most MRI scanners, unlike 
MRSI. DCE imaging however, due to its dynamic nature, can be severely affected by patient 
movement, and subsequent mis-registration of the image set (Aydin et al., 2013a, Verma et 
al., 2012).  
There is also at present a lack of consensus in how DCE images should be read and 
interpreted; the previously mentioned meta-analysis  (Tan et al., 2015) did find that simple 
visual analysis of DCE performed similarly to semi quantitative approaches. 
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 Diffusion Weighted Imaging (DWI) 2.3.1
Diffusion imaging studies the random movement of water molecules by “Brownian 
motion”. In prostate cancer tissues these movements are restricted by altered cellular 
density. (Koh and Collins, 2007) DWI imaging does not require contrast and takes 
approximately 5 minutes on the MRI scanner. 
DWI images create sets depending on the “b-value” chosen. The b-value chosen for DWI 
relates to the time scale over which the DWI interrogates water movement. If more than 
two b-value images are acquired an Apparent Diffusion Co-efficient map (ADC map) can be 
made by combining the b-value sequences. Prostate cancer (PCa) is characterised by 
increased cell density and a higher nucleus/cytoplasm ratio as compared with the 
surrounding prostate tissue. This leads to impeded diffusion, with a marked reduction in 
the ADC values relative to the healthy prostate tissue. (Bonekamp et al., 2011) 
DWI has been shown to be a valuable sequence for prostate cancer in a number of studies 
in recent years. (Anderson et al., 2000, Isebaert et al., 2013, Delongchamps et al., 2011) 
Figure 15. Diffusion weighted images and ADC map14 
 
                                                          
14
 Image kindly reproduced from BITTENCOURT, L. K., HAUSMANN, D., SABANEEFF, N., GASPARETTO, E. L. & BARENTSZ, J. O. 
2014. Multiparametric magnetic resonance imaging of the prostate: current concepts. Radiol Bras, 47, 292-300. Accessed 
20/6/15  
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‘Detection of PCa with DWI. ADC map of the same patient in Figure 14 (A) showing a suspicious hypointense focal 
lesion in the right peripheral zone (arrowheads), determining restricted water diffusion, with ADC values around 750 
× 10–6 mm/s2, while the contralateral peripheral zone exhibits ADC values in the range of 1,600 × 10–6 mm/s2. 
The fusion of information from DWI with T2-weighted images (B) shows that the lesion detected on ADC map, 
coded in red (arrowheads) has topographic correspondence with suspicious areas on T2-weighted image. The 
patient underwent radical prostatectomy, and the surgical specimen was sent for ex vivo MR examination (C), 
which showed a suspicious lesion (arrowhead) in the same region as of preoperative MR examination. The whole 
mount specimen at the same level and orientation of the MR images (D) also shows the tumor area (arrowhead) on 
the same location indicated by MR images. Asterisks on C and D represent areas with BPH’. (Bittencourt et al., 
2014) 
Two recent meta-analyses of DWI have shown that the performance of DWI is better than 
that of T2WI alone (Tan et al., 2012, Wu et al., 2012) (Table 6). However, the addition of T2-
weighted images, DWI and DCE performed significantly better in some studies that T2W 
and DWI alone. (Delongchamps et al., 2011, Tamada et al., 2011, Chen et al., 2008) 
High B value images provide better contrast, and there have been suggestions of benefit to 
ultra-high b values (b1000-2000) in the determination of benign from malignant disease 
with sensitivities ranging 0.71-0.88, and specificity 0.9-0.92 (Kim et al., 2010, Tamada et al., 
2014). 
Table 6. Diffusion weighted imaging 
Study Year Number of 
patients 
Sensitivity 
% 
(95% CI) 
Specificity 
% 
(95% CI) 
(Tan et al., 
2012) 
2012 
5892 
lesions 
67-72 87-90 
(Wu et al., 
2012) 
2012 627 
76 
(65-84) 
82 
(77-87) 
 
There is also evidence to suggest DWI has a role in assessing prostate cancer 
aggressiveness. As cancers become more aggressive, they become more poorly 
differentiated and studies have suggested that this can be detected in changes in the 
DWI/ADC images, with lower ADC values more likely to represent higher grade disease 
(Itou et al., 2011, Tamada et al., 2008a, Verma et al., 2011, Woodfield et al., 2010). Within 
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the transition zone however, BPH can sometimes also demonstrate restricted diffusion and 
low ADC values  
 
2.2.3 MR Spectroscopy Imaging (MRSI) 
MR spectroscopy is slightly different from the other MRI techniques: instead of the 
anatomy of the prostate, MRSI assess the metabolic changes in tissues induced by prostate 
cancer.  
The theory behind MRSI imaging is that changes in the metabolites can be tracked over set 
regions of interest. The three main metabolites traced in MRSI imaging are citrate, choline 
and creatinine. Choline is of particular interest in prostate cancer as it has found to be 
elevated in the disease (Kurhanewicz et al., 2002). 
Figure 16 reproduced from Kim et al, demonstrate images of 62-year-old man with prostate 
cancer. The prostate cancer is not clearly identified on T2-weighted imaging; the MR 
spectroscopy, however, shows increased choline and creatine (double arrows) over citrate 
(arrow) ratio in voxels 2, 3, 6 and 7, which were confirmed as prostate cancer (Kim et al., 
2009). 
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Figure 16. MRSI images15
 
 
Results of the 2009 multi-institutional study investigating the performance characteristic of 
MRSI using an endo-rectal coil, demonstrated little benefit in performing MRSI- MRI 
imaging AUC 0.6 and combined MRI and MRSI AUC 0.58 for sextant localization of cancer 
vs. RP histology (Weinreb et al., 2009). 
However, several single institutions have shown that the addition of MRSI to MRI improves 
detection (Scheidler et al., 1999, Futterer et al., 2006). Scheidler et al found the addition of 
MRSI to MRI reading significantly improved tumour localization (reader 1 AUC 0.8 from 
0.73, and reader 2 0.77 from 0.68, both P<0.001); the sensitivity and specificity found by 
this group for the combination of MRI and MRSI was 91% and 95%, respectively. Vilanova 
et al, found in a study of 54 men (Vilanova et al., 2009) that MRSI alone had a AUC= 87.2% 
vs. MRI alone AUC=85.1%. The best detection in the study was found when incorporating 
MRI, MRSI and free-to-total PSA ratio, AUC =97.5%. Table 7 outlines MRSI performance 
characteristics. 
                                                          
15 Kindly reproduced from KIM, J. K., JANG, Y. J. & CHO, G. 2009. Multidisciplinary functional MR imaging for prostate cancer. 
Korean J Radiol, 10, 535-51. Accessed 20/06/15 
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It is likely that the difference in methodologies of the studies, also the different level of 
expertise in different centres, is responsible for the less favourable findings for MRSI in the 
multi institutional study by Weinreb et al (Weinreb et al., 2009). 
Table 7. MRSI performance characteristics 
Study Number 
of 
patients 
Zone 
imaged 
Sensitivity 
% 
Specificity 
% 
PPV % NPV % Reference 
test 
(Scheidler 
et al., 
1999) 
53 PZ 63 75 83 51 RP 
(Futterer 
et al., 
2006) 
34 PZ/TZ/CZ 77-80 84-87 64-68 91-93 RP 
(Kaji et al., 
1998) 
42 PZ/TZ/CZ 88 66 - - Biopsy 
 
However, although MRSI may be a useful addition to mpMRI, it has a number of 
weaknesses. Firstly, it is time-consuming on the MRI scanner. It provides a low signal-to-
noise (SNR) resolution and no direct vision of peri-prostatic anatomy. There is also a high 
variability in concentrations of metabolites between patients observed, leading to difficulty 
in standardised reporting - and similar to several of the other MRI techniques, MRSI can be 
affected by post-biopsy haemorrhage, making interpretation of the metabolite ratios 
unreliable (Choi et al., 2007). 
 
2.2.4 Multi-Parametric MRI Summary  
Several studies have evaluated the additional sequences of dynamic gadolinium contrast 
enhanced T1; diffusion weighted imaging and magnetic resonance spectroscopy sequences. 
Evidence is accumulating that multi-parametric MRI, using a number of different 
sequences, might be useful in accurately localising clinically significant prostate cancer. 
Indeed, most studies as discussed in previous sections, found that the addition of a 
sequence to T2- weighted imaging improved performance characteristics. 
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It is becoming widely acknowledged that the addition of functional and anatomical 
sequences to mpMRI leads to higher performance characteristics.  
Figure 17 shows the additive value of each sequence as shown by one study group. 
(Turkbey et al., 2010) 
Figure 17. Predictive value of each MRI sequence16 
 
Each MRI sequence has shown promise individually and in various combinations, but the 
literature has been limited by a number of methodological issues. These include: the use of 
an inaccurate reference test (TRUS biopsy); selection bias in using whole-mount histology 
as reference test (men with high risk, high volume disease are more likely to undergo 
radical prostatectomy); dividing the prostate into various regions of interest rather than 
evaluating data on a per patient basis (greater numbers of ROIs increases accuracy); 
studying only a portion of the gland (PZ or TZ) rather than the whole gland; small study 
numbers; retrospective analysis of data; and using only two or three MRI sequences rather 
than all four (Ahmed et al. 2007; Ahmed, Kirkham, Arya, Illing, Freeman, Allen, & Emberton 
2009; Kurhanewicz et al. 2008). 
Interestingly, in a study by Turkbey et al that examined the usefulness of T2W imaging, DCE 
and MRSI, two separate approaches to the analysis were taken - one a stringent analysis 
                                                          
16
 Reprinted from TURKBEY, B., PINTO, P. A., MANI, H., BERNARDO, M., PANG, Y., MCKINNEY, Y. L., KHURANA, K., RAVIZZINI, 
G. C., ALBERT, P. S., MERINO, M. J. & CHOYKE, P. L. 2010. Prostate cancer: value of multiparametric MR imaging at 3 T for 
detection--histopathologic correlation. Radiology, 255, 89-99. With permission from Radiological Society of North America 
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that took no account of registration errors, and a nearest neighbour analysis that allowed 
for the lesion to be located in the adjacent sectors. The nearest neighbour analysis saw an 
improvement in performance characteristics from T2 sensitivities of 0.42 on stringent 
analysis to 0.73 (Turkbey et al., 2010). This highlights the importance of understanding 
methodology when assessing the various performance characteristics reported for these 
technologies, and demonstrates how a modification in method can result in vastly different 
characteristics. 
A number of consensus meetings have been held to try to identify what are the minimum 
requirements and best practices to gain the best performance from mp-MRI (Kirkham et 
al., 2013, Dickinson et al., 2013, Barentsz et al., 2012a) and also to try and streamline 
methodologies for these studies so that they can be more easily compared. 
One of the criticisms of mpMRI is the low reproducibility of interpretation; (Barentsz et al., 
2012b) alongside the provision of guidelines and reporting scales for MRI to improve 
uniformity. 
A further current active area of research in radiology (outside the parameters of this thesis) 
is the use of computer aided detection systems to aid radiology reporting and in-depth 
discussion (Lemaitre et al., 2015, Niaf et al., 2012, Litjens et al., 2014, Litjens et al., 2015, 
Wang et al., 2014). 
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2.4 Imaging Review Summary 
Many of these emerging technologies show promise in small ‘proof of concept’ studies; 
however, there is a large variation in published literature due to differing methodologies. 
The techniques need to be validated in a prospective manner against a reference standard 
that is better than TRUS biopsy but does not rely on whole-mount histology.   
This thesis will address the technologies of HistoScanning and mpMRI for their role in 
prostate cancer detection and characterisation to answer the question: 
Can imaging be used as a biomarker to reliably rule out the presence of significant 
prostate cancer? 
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3 Prostate HistoScanning 
3.1 HistoScanning Background and Development 
HistoScanning is an advanced ultrasound technology that was developed with the intention 
of aiding the discrimination between benign and malignant tissue in a number of organs. 
HistoScanning algorithms were initially developed for both ovarian tissue and prostate 
tissue (Vaes et al., 2011). 
The HistoScanning technology uses the raw backscatter data from 3D ultrasound and via 
statistical processing aims to discriminate between benign and malignant tissue.  
As ultrasound waves pass through tissue, the different acoustic impedance of the tissue 
(which depends on tissue properties such as cell density) reflects back the ultrasound wave 
differently, and as such these ultrasound waves can be processed and images can be 
formed. Brightness (B Mode) imaging (Figure 18) is the basic mode of ultrasound that is 
usually used, and images produced by this mode are two dimensional black and white 
images. 
Figure 18. B mode Ultrasound image of the prostate –transverse and sagittal view17 
 
                                                          
17
 Image kindly reproduce with the permission of BK medical. (http://bkultrasound.com/) 
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HistoScanning technology utilises the raw ultrasound wave data, (often referred to as radio 
frequency (RF) backscatter data) which is a series of mathematical quantitative data. The 
raw data has not yet been processed to enable a grey-scale image to be determined from 
it. By processing the data through a number of mathematical algorithms the HistoScanning 
technology aims to discriminate between the properties of the tissue. HistoScanning 
algorithms were developed to allow them to be applied to discrete regions of interest (ROI) 
within the ultrasound data file - thus allowing the algorithms to be run, for example on the 
ROI that is the prostate. 
Figure 19 shows the statistical separation of HistoScanning signals when applied to prostate 
tissue (Braeckman et al., 2008a). 
Figure 19. HistoScanning algorithms18 
 
 
                                                          
18
 Reprinted from, BRAECKMAN, J., AUTIER, P., SOVIANY, C., NIR, R., NIR, D., MICHIELSEN, D., TREURNICHT, K., JARMULOWICZ, 
M., BLEIBERG, H., GOVINDARAJU, S. & EMBERTON, M. 2008b. The accuracy of transrectal ultrasonography supplemented with 
computer-aided ultrasonography for detecting small prostate cancers. BJU Int, 102, 1560-5. With permission from Wiley 
Publishing. 
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Braeckman et al describe how the histograms displayed in Figure 19 demonstrate the 
distribution of numerical patterns related to specific tissue characteristics captured by each 
algorithm. The comparison of benign and malignant areas in the prostate result in different 
distributions of numerical patterns, with distributions related to cancerous areas (in red) 
systematically shifted to the right (higher values) when compared to distributions related 
to the benign area (in green). Mathematical integration of the distributions provided by the 
three characterisation algorithms allow the definition of numerical patterns likely to be 
specific of non-malignant or of malignant prostatic tissues (Braeckman et al., 2008a). 
 
3.2 Algorithm Development 
The first trials of HistoScanning performed on the prostate were by Braeckman et al; these 
studies were required to enable the algorithms that had been developed to be further 
trained and tested on human prostate tissue. This study took place between September 
2004 and February 2006 at UZ Brussels (Braeckman et al., 2008a, Braeckman et al., 2008b).  
29 men scheduled for radical prostatectomy underwent a three-dimensional ultrasound 
with acquisition of the raw ultrasound data image prior to their radical prostatectomy. 
The aim of the study was to allow proof-of-concept work to take place: - the algorithms 
required adaption to test their ability to discriminate between benign and malignant 
prostate tissue. The study also aimed to assess if HistoScanning was able to detect and 
locate malignant prostate tissue within the prostate. 
The study was performed in two stages. The first development phase enabled further 
calibration and refinement of the algorithms by allowing the scientists at Advanced Medical 
Diagnostics access to the histopathology data. The second blinded stage was designed to 
allow testing of the algorithms with no prior knowledge of histopathology data.  
In this initial study the HistoScanning algorithms were applied to processed two-
dimensional matrices of the grey level data acquired and related to the three dimensional 
ROI. Each tissue area was = 0.08cm3, which equates to a volume of = 0.04mL. 
The study recruited non-consecutively initially to allow for further development of the 
algorithms. The first 15 patients were analysed with a degree of un-blinding to allow 
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algorithm refinement and the final 14 patients were analysed with no knowledge of the 
pathology. 
The first paper published on the study assessed 1) the maximum diameter of the index 
lesion, 2) the focality of lesions 3) the laterality i.e. unilateral or bilateral  4) the presence of 
extra prostatic extension (EPE) (Braeckman et al., 2008a). 
Data were only statistically analysed for the 14 men in the blind phase of the study. 
The results were favourable with a strong correlation in tumour volume diameter between 
HistoScanning and pathology r= 0.95, P<0.001. 100% concordance on the presence of 
multifocality and the laterality of lesions was also achieved. HistoScanning over-called the 
presence of EPE in this study on one case but correctly identified the presence of EPE in 
three other patients. 
The initial results presented in this paper demonstrated an encouraging ability of 
HistoScanning to identify prostate cancer.  
The study sample however, was very small - only 14 men, once the training cases were 
excluded.  
The pathological processing in the study was also performed in a non-standard manner to 
allow for easier registration between the index and reference test. 
Furthermore, although presenting promising results on the ability of prostate 
HistoScanning to correctly identify multifocal lesions/laterality, the study made no mention 
of its performance characteristics with relation to prostate cancer size.  
Also, it was not made explicit: - how many tumours were correctly identified by Prostate 
HistoScanning and how many cancer foci were missed. 
A second paper published on the same exploratory cohort  went someway to addressing 
the above weaknesses (Braeckman et al., 2008b). The authors explored the same data set 
to identify the ability of prostate HistoScanning to identify lesions ≥ 0.5mL and to make a 
comparison between prostate HistoScanning lesions called ≥ 0.1mL and total cancer 
volumes, compared to the histopathology findings. 
One of the fourteen blind phase patients in the study was excluded from this analysis 
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In the 13 patients assessed, 28 cancerous lesions ≥ 0.1mL were identified. HistoScanning 
correctly identified all 12 lesion ≥ 0.5cc. It incorrectly classified 3 lesions as ≥ 0.5cc and on 
histology these lesions were 0.42, 0.46 and 0.47ml.  
Performance characteristics for the detection of lesions ≥ 0.5ml were sensitivity 100% 
(n=12/12), specificity 81% (n=13/16), PPV 80% (12/15) and NPV 100% (13/13). 
The study also demonstrated a strong correlation between the volumes of the lesions as 
estimated by HistoScanning and found at the reference test of radical prostatectomy 
histopathology with a Pearson’s correlation co-efficient r = 0.98, P < 0.001. 
These findings also provided some insight into how many cancers can be detected and 
missed using HistoScanning in this cohort.  
However, there continue to be a number of limitations to this study. Firstly, the sample size 
of patients is very small- 29 overall and only 14 in the blinded assessment. Also, all the men 
are known to have cancer, a selection bias, which is a negative feature of the study. It could 
however be argued that to allow for validation of an innovative technology, the bias is a 
necessity at this stage of its development. 
Also, the patients selected were all from the same institution and were selected in a non-
consecutive manner. 
The algorithm in these studies is also only applied to a pre-processed two dimensional pixel 
of the ultrasound image, rather than the raw radio-frequency (RF) data and in a three 
dimensional voxel. The reference test applied in this study was also unorthodox, in that the 
radical prostatectomy samples did not undergo standard apical to base step sectioning but 
an unusual sagittal step sectioning-something the authors thought may enhance 
correlation between the index and reference test. 
However, despite its limitations, this preliminary work showed some promise for the 
application of prostate HistoScanning technology, suggesting that further studies would be 
useful. 
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3.3 PHS02 Study 
 Methodology of PHS02 Study 3.3.1
To further validate the technology of Prostate HistoScanning, a European multi-centre trial 
was designed. The study was ethics approved by local European ethics committees in 
Belgium, Germany, Czech Republic, Hungary and the UK. The ClinicalTrials.gov Identifier is 
NCT01191931. The study aims were to assess the ability of prostate HistoScanning to 
detect and localise prostate cancer.  
The earlier studies on Prostate HistoScanning as discussed in section 3.2 showed accurate 
localisation of disease using two dimensional grey level data as the input. By using the raw 
unprocessed RF data it was thought that higher resolutions could be obtained. The PHS02 
study was designed to adapt the tissue characterisation algorithms to this RF data and 
evaluate the use of Prostate HistoScanning using RF input against a rigorous reference test. 
The research was designed in an open phase, to allow further refinement of the 
HistoScanning algorithms and a rigorously controlled blind phase for validation. Although 
not involved in the protocol development for the study, I was involved in the data 
collection, analysis and presentation of the PHS02 open phase. I had primary responsibility 
for the analysis of the blind phase scans, the data collection and analysis was performed 
with the aid of an independent statistician. 
Men over 18 years with histologically proven prostate cancer scheduled to undergo radical 
prostatectomy and willing to undergo pre-operative transrectal ultrasound scanning were 
eligible for the study.  
For eligibility purposes the prostate cancer must have been organ confined (T1-2, Nx or N0, 
Mx or M0) and patients must not have received any prior treatment for prostate cancer, 
including any hormonal therapy. They must also have been free from major calcifications at 
transrectal ultrasound scan. 
Patients became in-eligible for analysis if they did not proceed to radical prostatectomy, or 
(for whatever reason) the ultrasound data was insufficient, or if the reference test was 
compromised in any way during prostatectomy, shipping or processing. 
Table 8 outlines the exclusion criteria for the study. 
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Table 8. PHS02 exclusion criteria  
 Criteria for exclusion 
Screening 
Failures 
Previous prostate surgery – i.e. Transurethral resection of prostate (TURP) 
Prior treatment for prostate cancer (including hormones) 
Gland unable to be captured on one ultrasound scan 
Prostate cancer not organ confined 
Problems 
with the 
Index test 
Ultrasound data insufficient for analysis 
Lack of raw backscatter ultrasound data acquired for entire prostate 
Presence of calcifications ≥ 5mm diameter 
Fault in transfer of raw ultrasound data rendering it un-analysable 
Problems 
with the 
Surgery 
Surgery does not go ahead  
Incomplete prostate excised 
Problems 
with the 
reference 
test 
Prostate unable to be processed according to standard operating 
procedure (SOP) on reaching centralised laboratory 
Prostate incomplete or damaged on arrival at the pathology laboratory 
 
 The Index test- Prostate HistoScanning 3.3.2
All patients initially underwent 3D TRUS in two modes sagittal and transverse. The 3D TRUS 
was performed by a competent medical practitioner, experienced in TRUS and trained in 
Prostate HistoScanning. For scan quality control purposes a technician from AMD was 
present at the time of all 3D TRUS acquisition.  
Following the initial phase the plane for ultrasound acquisition was defined and for the 
blinded verification phase of the study men underwent only sagittal acquisition, using a 
rotational motor. 
After the acquisition of the 3D TRUS raw RF data, this data subsequently underwent 
HistoScanning analysis, which was performed by a competent reporter, blinded to clinical 
data, centrally at the offices of Advanced Medical Diagnostics. 
In the open phase of the study the HistoScanning analysis was performed using two 
methods. The first used the embedded software in the HistoScanning technology to 
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automatically define lesion volumes, according to set criteria for contiguous positive voxels 
that is programmed into the software.  
The second method used only in the open phase was a manual estimation of volume of 
lesions, using a planimetry method designed to replicate that carried out at histopathology, 
measuring the height x width x depth of a lesion x 0.52, to get the volume of an ellipse. 
For the blind phase only the embedded software tool was used for estimating the volume 
of a lesion. 
For the blinded verification stage of the study access to the results of the reference test 
were only made available to AMD following complete analysis of the Prostate 
HistoScanning image, and once it has been received and documented by the independent 
data monitoring committee. 
 
 The Reference Test – Radical Prostatectomy step sectioned Histopathology 3.3.3
The reference test of radical prostatectomy step sections, were carried out centrally at 
Bostwick Laboratories, London, UK. The centralisation of reporting allowed for 
standardised processing and reporting across the centres. 
In the initial phase the plane for the step-sectioning was defined. Other studies 
investigating prostate HistoScanning had used a sagittal step sectioning approach to allow 
for correlation with the PHS image. However, during the initial open phase of this study a 
standard apical to base transverse step sectioned approach was decided upon.  
Prior to sectioning the specimen was inked using two colours for left and right, to aid with 
orientation of the step sections. Sections were prepared at 3mm slices, and trimmed to full 
face. Measurements of any trimmings recorded to assist correlation with the index test.  
Standard Haematoxylin and Eosin staining performed and slides cover slipped.  
Each prostatic step section was measured using callipers at 5 point locations around the 
slice. This information along with the information on trimmings was to allow for accurate 
3D reconstruction of the prostate to correlate with the Index Test. 
Each step sectioned slice was further analysed by a 5 x 5 mm grid analysis, within the grid - 
the presence or absence of cancer, the predominant and secondary Gleason grade and the 
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percentage of the grid each grade of cancer occupies were defined. In addition, the 
presence or absence of high grade prostatic intraepithelial neoplasia (PIN) and percentage 
was noted. Inflammation, both chronic and acute, atrophy, and the background stroma 
were also commented upon. 
Photographs of the gland were taken following inking and prior to sectioning (Figure 20). 
Each slice photographed and the tumour outlined upon the slice, producing a 3D tumour 
map (Figure 21). Each 5 x 5 mm grid analysis was documented and photographed (Figure 
22). 
Figure 20. Photograph of gland 
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Figure 21. 3D Tumour map 
 
 
Figure 22. 5 x 5mm Histopathology grid analysis 
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The Histopathologist reported the gland volume (cc) and, tumour volume (cc); they also 
reported on the location of Prostate cancer lesions diagrammatically on a specific 
proforma, with the prostate divided into sextants.  
 
 Data Matching and Statistics 3.3.4
An independent data monitoring committee was established and was responsible for 
matching between the index and the reference test.  In the blind phase of the study data 
pertaining to the reference test was not released until the database of HistoScanning 
results had been locked and circulated to ensure strict blinded comparison. At this point, 
Bostwick Laboratories released the Histopathology reports to the data monitoring 
committee for further processing and analysis. 
Matching for lesions ≥ 0.5 cc and ≥ 0.2 cc was performed using 2 x 2 contingency tables, 
allowing accuracy to be determined. 
 
3.4  Results of PHS02 Open Phase 
 Open Phase Analysis Plan 3.4.1
The following analyses were carried out in order to compare the index test with the 
reference test.  
(i) Whole gland analysis: The total cancer volume as estimated by the prostate 
HistoScanning embedded software tool plus manual estimation of cancer volume versus 
the total cancer volume, as determined by the reference test. 
(ii) Lesional analysis: The attribution of cancer foci at the volume thresholds of ≥ 0.5 cc and 
≥ 0.2 cc at the whole gland level. 
(iii) Sextant analysis: Analysis for cancer foci at ≥ 0.5 cc and ≥ 0.2 cc volume thresholds.  
Sextant data analysis was performed using standard 2 by 2 contingency tables for 
sensitivity and specificity analysis. Calculation of 95 % confidence intervals was done using 
the normal distribution approximation. 
Sextants were formed by subdividing the prostate into six sectors, using the midline 
urethra as an anatomical landmark for right and left lobes. Each lobe was then further 
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subdivided in an equidistant manner into apex, mid and basal sextants, generating 6 
sectors in all. A sextant was deemed positive at histology if cancer was present in ≥ 10% of 
the surface pathology. This subdivision was performed in order to estimate the Negative 
Predictive Value (NPV) of HistoScanning, as although all prostates in this series contained 
cancer, not all sectors did. 
 Open Phase Results 3.4.2
The open phase results for this study were published in the BJUI in 2012, and this section 
pertains to the results of the study as published (Simmons et al., 2012). During the 
recruitment period for the open phase of the study, 51 patients were screened, 31 eligible 
patients from 6 European institutions were included in this phase of the study (Table 9). 
Table 9. Eligible patients according to recruiting centre 
Institute City No. Patients 
Jules Bordet Institute Brussels, Belgium 3 
University Hospital Tuebingen Tuebingen, Germany  3 
Semmelweis University Budapest, Hungary 6 
UZ-Brussels Brussels, Belgium 3 
Princess Grace London, UK 3 
Olomouc University Olomuc, Czeck Rep. 13 
Total  31 
 
Figure 23 demonstrates the open phase patient study flow.  
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Figure 23. PHS02 open phase patient study flow 
 
Twenty seven men remained eligible for final analysis; figure 23 shows the reasons for non-
inclusion in the analysis. Mean age (range) was 63 (56-75) years, PSA level range was 2.6-
26ng/milk   
Table 10 outlines the patient demographic data and results of HistoScanning and 
Histopathology. 
Patients screened for eligibility for the open phase PHS02 
N= 51 
Eligible for inclusion N=31 
Reason for non-inclusion in 
analysis and (number of 
patients) 
 declined radical 
prostatectomy after 
HistoScanning™ analysis (1) 
 incomplete 3D TRUS raw 
data file (2) 
 Pathology protocol 
violation (1) 
Ineligible for inclusion N=20 
 
Reason for ineligibility and 
(number of patients) 
 undisclosed previous TURP 
discovered at TRUS (2) 
 poor quality TRUS data (3) 
 failure of backscatter data 
transfer (3) 
 calcification within the 
prostate exceeding 5 mm 
diameter discovered at TRUS 
(5) 
 incomplete/damaged radical 
prostatectomy specimen on 
arrival at Bostwick 
Laboratories (7)   
 
Suitable for 
analysis N=27 
Disqualified from analysis 
N=4 
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Table 10. PHS02 open phase data 
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1 6.47 3 + 4 3 + 4 3.38 0.78 1.68 2.92 0.42 
2 3.3 3 + 3 3 + 4 2.12 1.8 1.63 1.45 1.77 
3 4.28 3 + 4 3 + 4 0.88 0.86 0.94 0.88 0.52 
4 5.13 4 + 3 3 + 4 2.46 0.34 0.96 2.46 0.22 
5 10.2 3 + 3 4 + 3 3.85 3.08 6.96 3.85 2.43 
6 7.9 4 + 5 3 + 4 3.85 4.22 2.83 2.25 4.17 
7 21 3 + 3 3 + 4 9.5 2.32 5.28 9.5 2.25 
8 18.2 3 + 3 4 + 3 2.33 1.25 2.67 2.33 1.23 
9 9.2 3 + 4  4 + 3 6.56 1.58 5.03 6.56 1.45 
10 7.1 3 + 3 3 + 3 0.33 0.4 0.87 0.33 0.3 
11 6 3 + 3 3 + 4 0.32 1.32 0.97 0.32 0.49 
12 23.71 3 + 4 5 + 4 2.7 0 0 2.7 0 
13 4.96 3 + 3 4 + 3 3.51 3.74 3.66 2.9 3.71 
14 9 4 + 4 4 + 3 1.82 1.28 3.41 1.82 0.78 
15 4.4 3 + 4 3 + 3 0.57 0.9 2.06 0.32 0.37 
16 2.56 3 + 4 3 + 3 1.4 2.04 2.13 1.4 1.56 
17 7.35 3 + 4 4 + 3 4 1.2 3.5 4 0.66 
18 5.07 4 + 4 4 + 3 4.52 0.74 2.5 4.52 0.61 
19 3.4 3 + 4 4 + 3 3.45 1.01 2.13 3.45 0.69 
20 6.6 3 + 3 3 + 3 0.58 0.39 0.88 0.58 0.39 
21 2.64 2 + 3 3 + 3 0.33 0.26 0.89 0.33 0.15 
22 26.3 3 3 + 4 3.24 0.9 3.73 3.24 0.79 
23 16.6 3 + 4  4 + 3 7.33 1.93 5.4 7.33 1.86 
24 13.1 3 + 4 3 + 4  3.14 1.75 4.6 3.14 1.17 
25 10.98 3 + 3 3 + 4 1.71 1.49 1.29 1.71 1.2 
26 3.3 3 + 3 3 + 3 1.94 0.36 0.35 1.94 0.29 
27 16.24 2 + 4 4 + 3 2.77 1.18 2.6 2.77 0.87 
 
 
 
Key to shading 
Considered negative at PHS as embedded tool detected lesion <0.2 
Lesion ≥0.5 at pathology detected <0.5 at PHS 
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 Whole Gland Analysis 3.4.3
The open phase of the study found a strong correlation between the total cancer volumes 
found using the HistoScanning manual estimation of volume and the total cancer volume at 
histopathology.  
Prostate HistoScanning found total cancer volumes ranging from 0 to 4.22ml using the 
embedded software tool (Figure 24) and 0 to 6.96ml using the manual estimation 
planimetry method (Figure 25). Histopathology reporting of the lesions found at radical 
prostatectomy found total cancer volumes ranging from 0.32 – 9.5ml. The Pearson’s 
correlation coefficient r between the PHS volume estimation methods and histology was 
0.72 and 0.41 for the manual estimation and the embedded software tool respectively. 
Figure 24. Relationship of total cancer volume at HistoScanning (embedded 
software) and Histopathology 
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Figure 25. Relationship of total cancer volume at HistoScanning manual volume 
estimation method and Histopathology 
 
 
During the open phase of the study further analysis was performed to assess the variables 
that could have affected the correlation between volumes, specifically looking at the 
influence of the probe to gland (PG) distance. 
In the 27 patients eligible for analysis, the distance (in mm) from probe to gland measured 
on the middle part of the gland ranged from 1.8 to 12.8 mm, with a median of 3.2 mm 
(mean 3.8 mm).  
In 14 patients with index focus ≥ 0.5 cc at pathology and PG < 3.5 mm, there was only one 
false negative HistoScanning result. There were however 3 false negative results in the 9 
patients with index focus ≥ 0.5 cc at pathology but PG ≥ 3.5 mm. 
The two following graphs (Figure 26) show how the total cancer volume (TCV) is 
underestimated, mainly when the distance exceeds 3.5 mm. The manual planimetry 
method of lesion volume estimation yields the best relationship but a distance ≥ 3.5 mm 
still leads to substantial underestimation of volume. 
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Figure 26. Relationship of total cancer volume correlation with respect to probe 
gland difference 
 
A regression model was fitted on plots displayed in two previous graphs with volume at 
pathology as dependent variable and including as independent variable the volume 
predicted from HistoScanning analysis and distance PG. Results of regression models 
applied are displayed in the Table 11. 
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Table 11. Multiple linear regression of volumes predicted by HistoScanning on 
volumes found at pathology 
 
From the Table, we can derive that: 
1/ When volumes estimated by HistoScanning embedded software are used, the 
underestimation of the index focus volume is of about 1.3 cc on average (the constant), 
that increases to 1.3+1.67 = about 3 cc when the PG distance exceeds 3.5 mm.  
2/ When planimetry is used, there is a fairly good correlation between volumes when the 
PG distance is less than 3.5 mm: for instance, an index focus volume of, for instance 2 cc 
predicted by HistoScanning/planimetry would be exactly the same: that is [(0.9*2) +0.2]. 
When the PG distance exceeds 3.5 mm, volume is underestimated by about 1.6 cc. The 
same reasoning holds for total cancer volume (TCV).    
Hence, the distance is a strong source of false negative result and of underestimation of 
volume, no matter the way the HistoScanning volumes are estimated. 
 
 Lesional Analysis  3.4.4
The reference test identified prostate cancer foci ≥ 0.5 cc in 23 out of 27 patients and 
prostate cancer foci of ≥ 0.20 cc in all 27 patients.  
At the 0.5cc threshold prostate HistoScanning identified 21 of the 23 foci ≥ 0.5 cc using the 
manual planimetry volume estimation method (sensitivity 91%; 95% CI: 0.80-1.00), two 
tumours found at the reference test were not identified by HistoScanning.   
19 of the 23 foci ≥ 0.5 cc were detected (sensitivity 83%; 95% CI: 0.67-0.98) using the 
Prostate HistoScanning embedded software.  
At the 0.2 cc threshold, the Index test identified 25 of the 27 foci using both the embedded 
tool and manual method (sensitivity 91%; 95% CI: 0.83-1.00) (Simmons et al., 2012). 
Table - Multiple linear regression of volume spredicted by HistoScanning on volumes found at pathology
Model Endpoint measured by 
pathology
Distance 
3.5+ mm
Constant R-square
from PHS from 
planimetry
from PHS from 
planimetry
(1) Volume index focus 0.83 - 1.67 1.3 0.25
(2) Volume index focus - 0.90 1.56 0.2 0.65
(3) Total cancer volume (TCV) - - 1.0 - 1.61 1.1 0.31
(4) Total cancer volume (TCV) - - - 0.90 1.36 0.4 0.63
For the three independent variables, data in Table are the β-coefficients
*Taking account only foci ≥0.2 cc
Volume index focus* Total cancer volume 
(TCV)*
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 Sextant Analysis  3.4.5
The open phase analysis found that all 27 men included in the final analysis had lesions ≥ 
0.2 ml detected at RP histopathology, 23 men had lesions ≥ 0.5 ml. 
Overall 162 sextants for the 27 men were examined for the men with index lesions ≥ 0.2 cc 
and 138 sextants for those with index lesion ≥ 0.5 cc. (Table 12 and Table 13) 
In the tables below the following is true for the definitions of true positive, true negative 
etc.:- 
- True positive = Lesion present at histology, and predicted by HistoScanning 
- True negative = Lesion not present at histology and not predicted by HistoScanning 
- False positive = Lesion predicted by HistoScanning, but not present at histology 
- False negative = Lesion not predicted by HistoScanning, but present at histology 
(i.e. missed lesion) 
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Table 12. Sextant analysis for all 27 men.  
AREA True 
Positive 
True 
Negative 
False 
Positive 
False 
Negative 
 
1 (Right apex) 18 3 4 2  
4 (Left apex) 16 6 4 1  
2 (Right mid zone) 20 4 2 1  
5 (Left mid zone) 17 5 5 0  
3 (Right base) 10 12 0 5  
6 (Left base) 6 17 3 1  
Total No. of Sextants 87 47 18 10 162 
% of all areas 54 29 11 6   
 
Table 13. Sextant analysis of the 23 men with index foci ≥0.5 cc at histopathology.  
AREA True 
Positive 
True 
Negative 
False 
Positive 
False 
Negative 
 
1 (Right apex) 16 2 3 2  
4 (Left apex) 14 5 3 1  
2 (Right mid zone) 18 3 2 0  
5 (Left mid zone) 16 3 4 0  
3 (Right base) 9 9 0 5  
6 (Left base) 6 13 3 1  
Total No. of Sextants 79 35 15 9 138 
% of all areas 57 25 11 7   
 
Using the embedded software tool sensitivity of 90% and specificity of 72% were achieved 
for localisation of ≥ 0.2 ml focus within a sextant, 90% sensitivity and 70% specificity for 
localisation of ≥0.5 ml. Table 14 demonstrates the sextant analysis performance 
characteristics at the two volume thresholds. 
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Table 14. Sextant analysis sensitivity/specificity results for HistoScanning™ at 
differing volume thresholds 
Volume threshold for detection > 0.20 cc > 0.50 cc 
Sensitivity 90% 90% 
Specificity 72% 70% 
Positive Predictive Value 83% 84% 
Negative Predictive Value 82% 80% 
 
 
3.5 Results of the Blind Phase of PHS02 
The primary objective for the blind phase of the study was the same as that for the open 
phase, to assess the detection of prostate cancer on a whole gland basis using the accepted 
threshold for significance, ≥ 0.2 cc, ≥ 0.5 cc and ≥ 1.3 cc. The threshold of 1.3 cc was 
incorporated into the analysis for the blind phase because of the updated evidence from 
Wolters et al suggesting that lesions of this size may represent the boundary for when 
prostate cancer lesions become significant disease (Wolters et al., 2011).   
Primary lesion location matching analysis was performed for tumours ≥ 0.2 cc using the 
sextant containing the maximal volume of the lesion at RP and HistoScanning. A true match 
was called only when the sextant for PHS was in total agreement for the sextant containing 
the maximal volume of the tumour at RP. 
Further analysis was performed to assess for the matching of lesions between prostate 
laterality (left and right side). This compensated for differences in segmentation between 
the index and reference test. 
3.5.1 Recruitment  
68 patients were screened for the blind phase of the study and 25 were found to remain 
eligible for analysis after application of the exclusion criteria at each stage in the study 
flow. Figure 27 demonstrates the patient flow. 
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Figure 27. Recruitment flow diagram for the blind verification phase of PHS-02 study 
 
 
  Results of Blind Phase  3.5.1
Median age and PSA were 66 years (interquartile range [IQR] 63-71) and 6.95 ng/ml (IQR 
3.85- 7.75), respectively. All men were found to have cancer at RP - 14, 21 and 24 men had 
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index tumour volumes ≥ 1.3 cc, ≥ 0.5 cc and ≥ 0.2 cc, respectively. 21/25 men had primary 
or secondary pattern Gleason grade 4 at RP (Table 15). 
Table 15. Blind phase patient disease characteristics  
Patient ID PSA (ng/mL) Gleason 
grade at 
biopsy 
Gleason 
grade at 
RP 
1 24.0 4+5 4+5 
2 6.5 3+3 3+4 
3 11.0 4+3 3+4 
4 8.8 3+3 3+4 
5 5.4 4+3 3+4 
6 7.9 3+4 3+4 
7 15.4 3+5 4+5 
8 11.0 3+4 3+4 
9 3.1 3+3 3+4 
10 5.2 4+3 3+4 
11 3.5 3+3 3+4 
12 6.9 3+3 3+4 
13 19.9 3+3 4+5 
14 4.0 3+3 3+4 
15 4.9 3+3 3+4 
16 8.8 3+3 3+4 
17 4.4 3+4 3+4 
18 11.1 4+4 4+5 
19 4.5 3+3 3+4 
20 7.3 3+4 3+3 
21 7.0 3+3 3+3 
22 12.9 3+3 3+3 
23 9.8 3+4 3+4 
24 5.8 3+4 3+3 
25 5.9 4+3 3+4 
 
Table 16 demonstrates the total cancer volumes and index lesion volumes detected by 
both HistoScanning and at RP histopathology. 
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Table 16. Total cancer volume and lesion volume at histopathology and 
HistoScanning 
P
at
ie
n
t 
ID
. No of 
lesions 
Total cancer 
volume (cc) 
Lesion volume at RP 
(cc)  
Lesion volume at PHS 
(cc) 
R
P
 
P
H
S 
R
P
 
P
H
S 
In
d
ex
 
2
n
d
 
3
rd
 
To
ta
l 
In
d
ex
 
2
n
d
 
3
rd
 
To
ta
l 
1 1 2 8.2 2.0 8.20 - - 8.20 1.58 0.24 - 1.82 
2 2 3 3.5 3.4 2.30 1.20 - 3.50 2.66 0.52 0.22 3.40 
3 1 2 4.4 1.7 3.90 - - 3.90 1.33 0.26 - 1.59 
4 3 2 4.8 4.9 3.84 0.62 0.28 4.74 4.60 0.32 - 4.92 
5 2 3 4.2 3.0 3.83 0.37 - 4.20 2.32 0.34 0.30 2.96 
6 1 3 1.2 1.2 1.10 - - 1.10 0.52 0.35 0.22 1.09 
7 1 1 26.5 2.1 26.5 - - 26.5 2.02 - - 2.02 
8 1 3 0.9 2.9 0.48 - - 0.48 1.07 1.01 0.85 2.93 
9 1 1 0.9 3.7 0.80 - - 0.80 3.34 - - 3.34 
10 2 3 2.9 3.3 2.10 0.60 - 2.70 1.37 1.22 0.44 3.03 
11 1 3 0.9 0.8 0.80 - - 0.80 0.34 0.24 0.21 0.79 
12 2 2 4.5 1.9 3.40 0.70 - 4.10 0.92 0.78 - 1.70 
13 2 3 6.2 4.8 5.70 0.40 - 6.10 4.25 0.28 0.28 4.81 
14 3 3 5.2 3.2 3.61 1.00 0.26 4.87 1.65 1.08 0.43 3.16 
15 3 3 2.2 1.3 1.10 0.50 0.30 1.90 0.49 0.43 0.40 1.32 
16 1 1 1.5 2.7 1.30 - - 1.30 2.42 - - 2.42 
17 2 3 1.7 2.1 1.00 0.60 - 1.60 1.47 0.30 0.29 2.06 
18 2 3 8.5 4.6 7.80 0.30 - 8.10 2.30 1.82 0.26 4.38 
19 3 3 0.9 5.0 0.50 0.20 0.20 0.90 1.74 1.50 0.90 4.14 
20 2 1 4.1 3.8 1.27 1.27 - 2.54 3.74 - - 3.74 
21 1 3 0.2 4.1 0.16 - - 0.16 2.84 1.00 0.22 4.06 
22 1 2 0.5 3.5 0.40 - - 0.40 3.08 0.22 - 3.30 
23 2 2 5.4 3.5 3.30 0.90 - 4.20 2.82 0.72 - 3.54 
24 2 2 0.8 3.2 0.40 0.20 - 0.60 2.74 0.28 - 3.02 
25 2 3 2.1 1.3 1.30 0.50 - 1.80 0.64 0.34 0.31 1.29 
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  Total Cancer Volume Comparison 3.5.2
HistoScanning demonstrated total cancer volumes ranging from 0.8 cc to 5.0 cc, median 3.2 
cc (IQR 2.37); index lesion volumes ranged from 0.34 cc to 4.6 cc, median 2.02 cc (IQR 1.33-
2.82).  
The total cancer volumes at RP ranged from 0.2 cc to 26.5 cc with a median volume of 2.9 
cc. (IQR 0.9-4.8). The index lesion volume at pathology ranged from 0.16 cc to 26.5 cc with 
median volume of 1.3 cc (IQR 0.8-3.72).  
By plotting the distribution of total cancer volumes on a box plot it can be seen that there is 
little difference between the two median volumes; there was no statistical difference in 
median cancer volumes between the two modalities (P=0.59). (Figure 28) 
 
Figure 28. Box plot of total cancer volumes at Prostate HistoScanning and Radical 
Prostatectomy 
 
A Bland-Altman correlation for the total cancer volumes as predicted by HistoScanning and 
found at RP histopathology demonstrated a poor correlation between the two volumes 
(Bland and Altman, 1986). (Figure 29) For those not familiar with Bland-Altman plots, the 
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plot aims to demonstrate the agreement between two different measurements. The red 
bars show the limits of agreement. In figure 29 the limits of agreement are from +5 to -4.7, 
unfortunately it is clinically inacceptable to have such a variation in cancer volumes 
between the tests. 
Figure 29. Bland Altman plot indicating the agreement between RP and Prostate 
HistoScanning in assessing total cancer volume 
 
 
A scatter graph produce to show the correlation between the total cancer volumes at 
HistoScanning and those at RP histopathology (excluding patient 7 who is an outlier who 
skews the graph) also demonstrates that there is a poor correlation, the Pearson’s 
correlation coefficient R2 = 0.04. (Figure 30) 
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Figure 30. Scatter graph of correlation between HistoScanning total cancer volume 
(TCV) and RP TCV –blind phase 
 
 
 Whole Gland Analysis 3.5.3
When disease significance was defined as lesions ≥ 1.3 cc detected at RP histopathology, 
HistoScanning demonstrated sensitivity 88.2% (95% CI 63.6-98.5%) and PPV 71.4% (95% CI 
47.8-88.7%).  
Changing the disease significance level to ≥ 0.5 cc lesions on the reference test, 
HistoScanning demonstrated a sensitivity of 100% (CI 85.7-100%) and PPV 96% (CI 79.6-
99.3%).  
For detecting and ruling-out lesions ≥ 0.2 cc, HistoScanning demonstrated 100% sensitivity 
for detection of disease over this threshold. At these two thresholds no comment can be 
made on specificity as too few men tested negative at these disease thresholds (only one 
man had PHS cancer volume ≤ 0.5 cc and all had lesions ≥ 0.2 cc). 
 
0
2
4
6
8
H
P
T
C
V
1 2 3 4 5
THSVol_8818
MD (Res) Thesis       - 87 - 
 
 Page 87 of 363 
 Sextant Analysis  3.5.4
For the sextant analysis in the blind phase, the method of ‘bootstrapping’ (Walsh and 
Reznikoff, 1990) was used to account for the non-independence of prostate sectors. Table 
17 outlines the performance characteristics at each volume threshold. 
Table 17. Sextant analysis for detection of 0.5cc and 0.2cc lesions using Boot 
Strapping correction as a result of non-independence of the sectors of analysis 
 Sensitivity (CI) % Specificity (CI) % PPV (CI) % NPV (CI) % 
Volume Cut Off  
≥0.5cc 46 
(33-60) 
62 
(53-72) 
43 
(30-55) 
66 
(56-76) 
≥0.2cc 69 
(59-79) 
31 
(21-42) 
53 
(44-63) 
47 
(32-62) 
 
 
 Lesional Analysis 3.5.5
Prostate HistoScanning detected 60 lesions ≥0.2cc. There were 43 tumours ≥0.2cc found on 
RP. One patient had an index lesion <0.2cc at radical prostatectomy histopathology.  
For the primary method of lesional analysis of the 43 tumours ≥0.2cc detected at RP, 12 
lesions were detected in the same sextant (28%), 28/43 (65%) of lesions did not possess an 
exact sextant match. Three (7%) lesions found at RP histopathology were not identified by 
HistoScanning.  
Seventeen (30%) lesions were identified by HistoScanning that had no corresponding 
histological lesion at RP.  
By considering each prostate lobe as the sector of analysis, 61% (27/43) of lesions were 
correctly identified on the correct side of the prostate by PHS. 
A further, more subjective lesional analysis was performed in the blind phase analysis. In 
this analysis, two independent analysts assessed both the HistoScanning lesions and the RP 
histopathology lesions visually to decide if there was a location match. Once each analyst 
had visually assessed the location of lesions at the index and reference test and decided 
upon the location matching. Each case was then discussed, and a consensus agreement 
reached. When a consensus could not be reached a third independent urologist blinded to 
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the decisions of the consensus was asked to make a decision as to whether the lesion at 
prostate HistoScanning was confirmed on RP histopathology.  
Of the sixty tumours detected by prostate HistoScanning, consensus was reached between 
the two analysts in 57 lesions (95%). The analysts were assessing whether the lesion at 
prostate HistoScanning had a corresponding matching lesion at RP (‘a hit’) or not (‘a miss’). 
For the remaining three lesions where consensus could not be reached, a third 
independent analyst was asked to review the cases.  
Overall, 37/60 lesions were deemed ‘a hit’ at histopathology (62%), 23/60 tumours (38%) 
were deemed ‘a miss’. Of the index lesions at prostate HistoScanning, 68% were deemed a 
positive match for lesions seen at RP. 
 
3.6 PHS02 Study Design Challenges 
A number of challenges exist when trying to conduct an ideal study to verify a new 
diagnostic modality.  
 Target Patient Selection and the Ideal Reference Test  3.6.1
The patient population in this study were men undergoing Radical Prostatectomy. This 
allows for accurate verification of the Index Test against histopathology. It does however 
allow for an element of bias to be introduced into the study. By selecting men with known 
cancer we have introduced a positive selection bias as we are aware that all men have 
cancer. Additionally, men who have surgery for prostate cancer tend to have higher risk 
disease than those who do not choose surgery (Harlan et al., 2003).  
By opting for a radical prostatectomy cohort we exclude a significant proportion of men 
who have other treatments for prostate cancer, such as: - radiotherapy; brachytherapy; 
hormones; cryotherapy and high intensity focused ultrasound - as well as those men opting 
to have active surveillance. Such groups will have differing tumour burdens when 
compared with those undergoing radical prostatectomy.  
An ideal study of a diagnostic modality would apply the test to all men on whom it would 
eventually be applicable: namely, all men at risk of prostate cancer. However, in order to 
do such an ideal study, a number of men would need to be unnecessarily subjected to a 
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harmful reference test - radical prostatectomy. In a population of men who are all ‘at risk’ 
of prostate cancer and do not have confirmed disease this would be unethical. 
An alternative strategy would be to select a less invasive reference test; however, most 
other reference tests would not allow for such exact matching with the index test.  
Other possible reference standards considered were: - TRUS biopsy; Cysto-Prostatectomy 
and Transperineal Template mapping biopsy.   
TRUS Biopsy is at present the standard of care for men deemed to be at increased risk of 
prostate cancer. There are several important problems with TRUS biopsy and reasons why 
TRUS guided biopsy would serve as a poor reference test: 
TRUS guided biopsies have a false negative rate of up to 30% (Merrick et al., 2007). TRUS 
systematically under samples the anterior, the midline and the apical parts of the prostate. 
The deployment of the biopsy needle is tangential (neither sagittal nor transverse), so it is 
difficult to attribute any sample to any particular location within the prostate. This would 
prove difficult for matching with the index test. 
TRUS biopsies are unrepresentative of the true disease burden or grade of the cancer in 
more than one third of cases, and are therefore a poor indicator of prognostic factors such 
as Gleason grade and cancer burden. (Mazzucchelli et al., 2009, Crawford et al., 2005) 
Studies investigating the incidental prevalence of prostate carcinoma in cysto-
prostatectomy series vary widely in their results, ranging from 3-50% harbouring prostate 
cancer (Autorino et al., 2009).  In contrast to the radical prostatectomy series who have 
higher risk disease characteristics than the background population, patients undergoing 
cysto-prostatectomy have been shown to have low risk disease in around 80% of the cases 
with incidental prostate carcinoma identified (Mazzucchelli et al., 2009). This along with the 
significant morbidity of cysto-prostatectomy means it is not an ideal reference test. 
The reference test that closely meets the required specification for our defined population 
is transperineal template prostate mapping biopsies at 5mm intervals; however, 3D 
correlation with the Index Test using this strategy is challenging. 
Transperineal template mapping biopsy (TPM) has shown a sensitivity of 95% and negative 
predictive value of 95% for clinically significant cancers of volume >0.5cc and 76% 
sensitivity for all cancers (Crawford et al., 2005, Lecornet et al., 2012, Hu et al., 2012a, 
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Ahmed et al., 2011).  It also has the advantage over TRUS biopsy that it is able to assess the 
anterior part of the prostate and to be able to attribute each biopsy core to a particular co-
ordinate.    
However, although transperineal template mapping biopsy would be an attractive 
reference test as it could be applied to a wider population of men, the 3D matching of 
biopsy cores with ultrasound imaging would prove very difficult, and thus in the PHS02 
study Radical Prostatectomy was chosen as the reference standard.  
In addition, for the purpose of validating the prostate HistoScanning technology, as PHS02 
aimed to do, whole mount radical prostatectomy specimens are the current gold standard 
reference test. 
 
 Problems with the Reference Test 3.6.2
Radical prostatectomy operations are performed worldwide and different surgeons 
operate in subtlety different ways. Clearly, it was necessary for this study to standardise 
the reference test as much as possible. Therefore, all surgeons were required to work to a 
strict standard operating procedure (SOP): only prostates that had been successfully 
removed as a complete whole gland specimen were sent for processing. 
Despite the rigorous controls in place, problems still arose with regard to collection and 
transportation of the removed glands, rendering some of them unsuitable for further 
analysis.  
Processing was centralised to minimise inter-reporter variability and followed a rigorous 
SOP, as stated previously. Processing was performed according to the stanford protocol 
3mm slices, there is however the possibility in this slicing that small tumours could be 
missed when preparing the slices and trimming to full face.  
 
 Problems with the Index test  3.6.3
The aim of the study was to verify the ability of HistoScanning to detect and localise 
prostate cancer. 
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 For the verification of this technology it was vital that optimal images were included in this 
study. Ultrasound is a notoriously user dependent technology and as such a strict SOP for 
collection of the study images was implemented. Technicians from AMD were present with 
each operator at the time of PHS screening to advise on technique to obtain optimum 
scans.  
However, a number of scans were ineligible for further analysis as they revealed large 
amounts of calcification on the gland: ultrasound signal does not easily transmit through 
calcified areas of the prostate, and although Prostate HistoScanning is able to make a 
prediction of the presence or absence of cancer in areas behind calcification it is likely to be 
an unreliable predication. Thus, for the purposes of this verification study, men with large 
calcifications were excluded. Also, scans which failed to capture the entire gland were also 
excluded, as the whole gland is required for correlation with the reference test.  
 
 Problems with Matching between the Index and Reference Test 3.6.4
For all studies comparing new diagnostic modalities to a reference test one of the major 
challenges is how to correlate the two tests to obtain accurate information on the 
performance of the technology. Matching between the index test and the reference test 
was indeed one of the major challenges within the study. 
Histopathological specimen to image correlation is adversely affected by a number of 
processes including surgical distortion and tissue shrinkage during fixation. 
By rigorously controlled SOP’s at both the index test (prostate HistoScanning) and the 
reference test (RP Surgery and histopathological processing) the effects of any distortion to 
produce a matched cohort were limited. 
However, as a prostate gland undergoes processing, its morphology changes; the prostate 
ex-vivo and processed in formaldehyde is a different shape to the prostate in- vivo. To 
mitigate the effects of this, localisation of lesions was done using a division of the prostate 
into sextant areas. Both the reporting Histopathologist and the Prostate HistoScanning 
reporter provided reports on the volume of cancer within each sextant of the prostate. 
Images were matched by independent analysts. 
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 Defining Prostate Cancer Significance/Determining Volume Thresholds 3.6.5
It is established that not all prostate cancer is significant and there is a need to be able to 
better ‘risk stratify’ patients, but criteria for disease significance vary widely between 
studies. Ideally a diagnostic test would have the ability to detect significant cancer whilst 
not identifying too many insignificant cancers, and thus reducing the over-treatment 
burden.  
It is possible to argue that the prostate HistoScanning signal should be correlated with all 
cancer detected. However, in the knowledge that not all prostate cancer is significant, and 
given that prostate HistoScanning is not able yet to differentiate between cancers of 
different grades, a volume cut off was required. 
Stamey et al established a volume threshold for disease significance at ≥0.5cc and this 
definition has been widely used since (Stamey et al., 1993). However as previously 
mentioned,  it has recently been reported by Wolters et al after studying the ERSPC data 
that for those with low grade, low risk disease, index tumour volumes of up to 1.3 cc and 
total tumour volumes of 2.5cc may still constitute low risk disease (Wolters et al., 2011). 
Despite this recent study showing that tumours may be insignificant at more than twice the 
volume suggested by Stamey et al, PHS02 opted to use the well-established volume criteria 
of 0.5cc for disease significance for the purpose of primary analysis.  
 
3.7 Discussion of PHS02 
The PHS02 study both open and blind phases has several limitations, most of which have 
been discussed in the study design challenges section. The data from the two phases 
demonstrates reasonable performance characteristics for the technology, although the 
blind phase data shows reduced performance characteristics compared with the open 
phase. 
The rigorously controlled nature of the blind phase may have had some degree of negative 
impact on the performance characteristics. To date, there are very few if any truly 100% 
blinded comparisons between imaging and histopathology in the literature, and although 
the performance characteristics found at the blind phase of PHS02 may at first glance 
appear inferior to other imaging modalities and other studies, the impact of a truly blinded 
comparison must not be underestimated: the biases of retrospective and un-blinded 
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analysis on the performance characteristics of other test modalities - and indeed even in 
the open phase of the PHS02 study - must be recognised. These biases are likely to lead to 
an inflation of the performance characteristics.  
The PHS02 study showed a high degree of accuracy for the detection of prostate cancer 
lesions on a patient/whole gland level with sensitivity for detection of ≥ 0.5 cc volumes of 
100%. 
A limitation to the work is the volume of disease demonstrated by each man in the study: 
all men had cancer that was suitable for radical prostatectomy, and the primary analysis 
was performed on a whole gland level. As such, the very high sensitivities demonstrated by 
both the open and blind phases may account merely for the detection of false positive 
signal. Indeed, in the blind phase of the study using the sextant analysis showed a 
significant reduction in the performance characteristics.  
However, when interpreting the data from the PHS02 study it is important to remember 
that as HistoScanning cannot as yet quantify Gleason grade, lesion significance is based on 
lesion size criteria as established by current literature (Stamey et al., 1993, Epstein and 
Potter, 2001, Wolters et al., 2011).  
Data from both the open and blind phase of the study suggests that the prediction of 
volume by HistoScanning may be unreliable. The open phase data suggesting that 
depending on the quality of the scan lesion sizes may be under- or over- estimated.  
The blind phase data suggests from the analysis of the Bland-Altman that there is very little 
true correlation between the size of lesion detected at HistoScanning and that detected by 
RP histopathology. This therefore may have a great impact on the performance 
characteristic analysis of HistoScanning; which is based on lesion size criteria compared to 
RP histopathology. 
PHS02 study results demonstrate that the technology may have potential for use in the 
prostate cancer pathway, but due to a number of limitations within the study such as the 
patient group, the reference test and the significance criteria, further studies on the 
technology are warranted. Further studies are also needed to assess the reliability of the 
test. 
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3.8 HistoScanning Reliability Work 
For a diagnostic test to be valid it requires not only good performance characteristics in 
terms of sensitivity/specificity, positive and negative predictive value, it also needs to be 
reliable and reproducible, not only in terms of the technique but also in the reporting of 
the images produced by HistoScanning. 
A number of pilot experiments on the reliability of HistoScanning have been performed and 
the results are described in the following section. 
 Intra-operator Pilot Data 3.8.1
To examine the reproducibility of HistoScanning output when applied by different 
operators a small study was conducted. 
 Method 3.8.1.1
Ten men with low risk prostate cancer on TRUS guided biopsies, undergoing HistoScanning 
analysis in our institution as part of the PICTURE study and covered by the ethics of this 
trial, were approached for inclusion in the pilot. All men underwent a standard 
HistoScanning acquisition performed by a trained operator (Operator 1)- with 3 years’ 
experience at PHS, in the same session a second operator (Operator 2)- with 1 year 
experience at PHSwho was blinded to the previous scan performed a HistoScanning 
acquisition, using the same equipment and independent of the primary operator. 
Both scans were reported by a single reporter to minimise reporter variability. An analysis 
of HistoScanning images for Prostate Volume and Prostate HistoScanning signal was 
performed for both acquisitions. HistoScanning analysis is as previously discussed in this 
thesis a semi-automated process the reporter is required to define apex, base, left and 
right borders of the prostate. Delineation of the prostate outline, division into sextants, and 
analysis of ultrasound signal for presence or absence of cancer is automated. 
Linear regression was used to calculate the correlation in both gland and cancer volume 
generated by each acquisition. Cohen’s kappa statistic was performed to estimate the 
agreement for presence or absence of a focus ≥0.5cc in any one sextant. Kappa values 
ranges indicate a range of agreement, <0 indicates no agreement, 0–0.20 slight, 0.21–0.40 
fair, 0.41–0.60 moderate, 0.61–0.80 substantial, and 0.81–1 almost perfect agreement 
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 Results 3.8.1.2
60 sextants from 10 patients were analysed. Operators agreed on the presence or absence 
of a lesion ≥0.5cc within a sextant in 75% of sextants (n=45). Cohen’s kappa co-efficient was 
0.57 (95% CI: 0.30-0.72). 
Linear regression for prostate volume between the two acquisitions exhibited strong 
correlation (R2= 0.98). (Figure 31) 
Figure 31. Graph demonstrating Prostate gland size correlation 
 
For tumour volume, linear regression was also good (R2= 0.76) (Figure 32). Further analysis 
of the data revealed that scans deemed to be of poor quality by the reporter, showed a 
reduced correlation in HistoScanning lesion volume than those of good quality. 
Figure 32. Graph demonstrating HistoScanning signal correlation 
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 Conclusion:  3.8.1.3
There are clearly limitations to this work.  A very small sample size of men was examined, 
due to the pilot nature of the work, and the need for two intimate examinations in a short 
time frame. Operators also had slightly differing levels of experience. There was also no 
histological gold standard to which to compare the HistoScanning lesions. 
However, in this first reliability study of its type for Prostate HistoScanning, the outputs 
from HistoScanning analysis were stable between two operator-acquired images. The 
strength of association was greater for prostate volume than it was for tumour volume.  
Reliability in the latter was sensitive to the quality of the images obtained.  
 
  Inter-observer Reporting Work 3.8.2
Another aspect of test reliability is that the outcome when reported by different reporters 
should be stable and with minimal inter-observer variation. 
 Patients and Methods 3.8.2.1
Patients managed by active surveillance, who had undergone HistoScanning more than 
once, as part of the Rotterdam arm of the Prostate cancer Research International: Active 
Surveillance (PRIAS) study, Dutch Trial Register with ID NTR1718, were eligible for this pilot 
study. Two independent observers with 2 years’ experience each in the interpretation of 
PHS scans processed and analysed the HistoScanning outputs for each acquisition.  
Observers first contoured the prostate gland, and then HistoScanning automatically 
defined the sextants and probable cancer volumes (unrefined).  The observer then 
deselected volumes deemed unlikely to represent prostate cancer and recalculated 
volumes (refined).  
Agreement between the two observers for estimation of total cancer volume in prostates 
of the 12 patients was estimated by least square linear regression.  The kappa statistic was 
used to estimate the inter-observer agreement for presence of a focus ≥0.5 cc in any one 
sextant. Kappa values range from -1 (total disagreement) to +1 (perfect agreement), and 
zero corresponds to no agreement. 
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 Results 3.8.2.2
198 sextants generated by 33 scans from twelve patients were analysed independently by 
two observers. Both observers found a refined focus ≥0.5cc in 40 sextants and no such 
focus in 138 sextants (Table 18). Hence, both observers agreed on the presence or absence 
of focus in 90% of sextants, achieving a kappa statistic of 0.81 for unrefined and 0.73 for 
unrefined focus volumes.  
Table 18. Inter-observer variability  
  Observer 2   
   Focus  
yes 
Focus 
no 
Total 
Observer 1 Focus yes 40 11 51 
 Focus no 9 138 147 
 Total 49 149 198 
 
The least square regression for unrefined and refined volumes was 0.83 (Figure 33) and 
0.94 (Figure 34) respectively. 
 
Figure 33. Least squared regression for unrefined HistoScanning volumes 
 
 
 
R² = 0.83 
LS
 a
ve
ra
ge
 H
is
to
Sc
an
n
in
g 
vo
lu
m
e
 
(c
c)
 
 
SVDH average HistoScanning volume (cc) 
 
Least square linear regression HistoScanning 
refined volume by observer 
 
MD (Res) Thesis       - 98 - 
 
 Page 98 of 363 
Figure 34. Least squared regression for refined HistoScanning volumes 
 
The first obvious limitation to this work is once again the small numbers of patients 
involved in the study and secondly the lack of a histopathological confirmation of the 
HistoScanning signals. 
However, despite its limitations this pilot study demonstrated that Inter-observer 
agreement is high when two trained observers progress through the HistoScanning™ 
workflow to determine prostate cancer volume and presence of focus within a sextant. 
 
  Pilot Study Prostate HistoScanning Gleason Grade Discrimination 3.8.3
The HistoScanning technology at present is not able to discriminate grade of disease. 
Lesion significance is therefore based on sized criteria alone, as outlined in the PHS02 study 
results some inaccuracies between the volumes found at prostate HistoScanning and those 
found at RP histopathology exist, which may impact on the accuracy of the test. 
A pilot experiment was carried out to assess the ability of Prostate HistoScanning to 
determine Gleason grade, as if the test were able not only to predict the presence of 
prostate cancer but also to estimate grade: it would then prove a very useful tool in the 
diagnostic pathway. 
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The basis of the prostate HistoScanning technology is that it uses mathematical algorithms 
to predict whether an ultrasound radiofrequency (RF) backscatter signal has been reflected 
from normal prostate tissue of prostate cancer tissue.  
The hypothesis of this pilot experiment was that if prostate HistoScanning were able to 
differentiate between benign and malignant tissue, it could it differentiate between low 
grade (Gleason 3) disease and high grade cancer (Gleason 4 or above). 
  Methods: 3.8.3.1
Three men scheduled for radical prostatectomy, as part of the ethics approved PHS02 
study, were included in this pilot study. Standardised 3mm whole mount histopathology 
was performed. Reporting was segmented into 5mm by 5mm grids. Within each grid, if 
cancer was present, the dominant Gleason grade was quantified as a percent of the total 
(the reference test).   
Preoperative prostate HistoScanning was performed (the index test). Prostate 
HistoScanning was then used to interrogate volumes of tissue for the presence or absence 
of prostate cancer in units of 0.05 mm3 and each data point registered to its 5 x 5mm 
histological grid (Figure 35).  
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Figure 35. Prostate HistoScanning image with Gleason detection overlay and 
corresponding histopathology grid.  
 
 Blue Gleason Grade 3 
 Green Gleason Grade 4 
 
If cancer was declared present within any single grid, a prediction was made on whether 
the cancer was predominant Gleason grade 3, versus predominant Gleason grade 4 or 5. 
Statistical analysis tested the relative risk that HistoScanning could correctly attribute 
Gleason grade. 
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 Results 3.8.3.2
14 grids with prostate cancer were analysed (Table 19). Of these, 6 had a Gleason grade 4 
or more at histology. The relative risk of grids with predominant Gleason grade 4/5 being 
labelled as such compared to grids that contained predominant Gleason grade 3 is 3.2 (95% 
CI: 3.0-3.3), Chi-square p value<0.0001.  
Table 19.  Histological vs HistoScanning attribution of Gleason grade (GlG) 
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The distribution of HistoScanning™ scores generated when applying the newly developed 
tool to the RoI’s of different Gleason grades shows a predominant left shift for lower 
Gleason grade and a right shift for higher Gleason grades. The higher Gleason grades also 
demonstrate a narrower distribution relative to the lower Gleason grades. (Figure 36) 
 
 
MD (Res) Thesis       - 102 - 
 
 Page 102 of 363 
Figure 36. Graph of Prostate HistoScanning Gleason tool frequency analysis 
 
 
 
  Limitations 3.8.3.3
Although a large number of data points were analysed per patient, the sample population 
itself was small. 
In addition, although registration of Prostate HistoScanning to histopathology grids was 
performed as accurately as possible using measurements of trimmings and lengths taken at 
histopathology, there remained a risk of mis-registration between the index and the 
reference test. 
 Conclusions 3.8.3.4
This preliminary proof of concept data demonstrated that interrogation of raw 
radiofrequency ultrasound spectra by Prostate HistoScanning™ may be able to discriminate 
between prostate cancers of different histological grade.   
The ability to accurately attribute tumour grade using this non-invasive technique may 
allow for more accurate prostate biopsy and treatment planning. 
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4 Prostate Imaging Compared to Transperineal 
Ultrasound guided biopsy for significant 
prostate cancer Risk Evaluation (PICTURE) 
 
4.1 PICTURE Study Design and Objectives 
The PICTURE study is a single centre STARD compliant (Bossuyt et al., 2003) prospective 
diagnostic trial that conforms to level one evidence, that was carried out at University 
College London Hospitals (UCLH). The trial assesses the diagnostic performance of mp-MRI 
and Prostate HistoScanning against the reference test of Transperineal template mapping 
biopsies. 
The primary objective of the PICTURE study is to assess the negative predictive value of 
both imaging modalities to allow us to answer the question “could imaging allow men to 
avoid further unnecessary prostate biopsy?” 
 
 Study Objectives 4.1.1
The primary objective of the study is to assess the negative predictive value of multi-
parametric MRI and prostate HistoScanning in ruling out clinically significant prostate 
cancer.  
Main secondary objectives are: 
- To evaluate the proportion of men correctly identified by multi-parametric MRI and 
prostate HistoScanning to have no prostate cancer as determined by specificity 
and negative predictive value (NPV)  
- To evaluate the proportion of men correctly identified by multi-parametric MRI and 
prostate HistoScanning to have clinically significant prostate cancer as determined 
by sensitivity and positive predictive values (PPV) 
- To assess whether the use of MRI to US registration targeted biopsies alone is 
comparable to the use of i) systematic biopsies and ii) cognitive targeted biopsies in 
stratifying patients into prostate cancer risk groups. 
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- To assess the test – retest reproducibility of prostate HistoScanning 
 
Further PICTURE outcomes which are not the key focus of the work within this thesis 
include: 
- To evaluate the ability of urinary Engrailed 2 (EN2) to predict the presence of 
prostate cancer and to determine its ability to predict clinically significant disease. 
- To evaluate the ability of seminal citrate and zinc levels as determined by FScan to 
predict the presence of prostate cancer and to determine its ability to predict 
clinically significant disease. 
- To evaluate the diagnostic validity of multi-parametric MRI and prostate 
HistoScanning when various regions of interest are used to assess accuracy in 
detection of prostate cancer at different thresholds for clinical significance. 
- To evaluate the ability of Tissue Type Imaging (TTI) to predict the presence of 
prostate cancer 
- To evaluate using validated questionnaire’s (IPSS, IPSS QoL and IIEF-15) the impact 
of transperineal Template prostate mapping biopsy on Urinary and sexual function. 
 
 Trial Design 4.1.2
The PICTURE study followed a prospective cohort design; all men will undergo both Index 
tests (mp-MRI and PHS) and transperineal template mapping biopsies. Men remained 
blinded to the results of the Index tests prior to the reference test to prevent attrition bias, 
as if aware of a negative index test result men may choose not to undergo the reference 
test.  
Both of the index tests were reported blind to the results of each other and prior to the 
reference test of Transperineal template mapping biopsies. 
The use of TPM as a reference test allows for a unique opportunity to validate not only 
imaging as a biomarker but also other biomarkers that may be advantageous in the 
prostate cancer pathway. PICTURE therefore included optional additional tests that men 
may choose to undertake including ultrasound-based Tissue Type Imaging (TTI) (Feleppa et 
al., 2011, Feleppa et al., 2004, Feleppa, 2008), urine and semen biomarkers (urinary 
Engrailed 2 - EN2 (Morgan et al., 2011, Pandha et al., 2012) and seminal citrate and zinc 
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levels as determined by FScan (Costello and Franklin, 2009) to be performed pre-biopsy 
and the reports or assays derived blinded to the TPM result. 
Figure 37 demonstrates the PICTURE trial study flow. 
Figure 37. PICTURE trial study flow 
 
The study was partially funded by a grant from Advanced Medical Diagnostics, it also 
received supportive funding from the University of Durham (Fscan) and University of Surrey 
(EN2). 
Eligible Men 
Patient identified with clinical suspicion of prostate cancer and has 
undergone TRUS Biopsy of the prostate 
 
Visit 1 
Consent and Screen, Questionnaires 
Prostate HistoScanning (1st scan) 
(Following visit one if men have opted to produce Urine or Semen this can 
be done any time prior to visit 3.) 
Visit 2 
Multi-Parametric MRI 
Visit 3 
TTI for men who have consented to this procedure 
Prostate HistoScanning (2nd scan) 
Targeted Biopsies followed by Transperineal Template Prostate Mapping 
Biopsy (TPM) 
Visit 4 
Telephone consultation for completion of Post biopsy adverse events 
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  Inclusion/Exclusion criteria 4.1.3
 Inclusion criteria  4.1.3.1
 Men who have undergone prior trans-rectal biopsies. 
 Men undergoing further evaluation of their prostate and who are suitable for 
characterisation using transperineal template prostate mapping biopsy. 
 Exclusion criteria 4.1.3.2
 Previous history of prostate cancer treatment  
 Men unable to have MRI scan, or in whom artefact would reduce quality of MRI. 
 Men unable to have general or regional anaesthesia 
 Men unable to give informed consent 
 Withdrawal Criteria 4.1.3.3
 Men who are unfit or choose to not undergo prostate mapping biopsies after 
undergoing either or both index test.  
 Men in whom either of the index tests are inadequate for analysis due to artefact 
or image acquisition problems. 
 Men in whom the reference test is inadequate for analysis due to lack of complete 
gland sampling or inadequate sampling density.  
 
 Ethics and Registration 4.1.4
Ethical approval for the study was granted by London City Road and Hampstead National 
Research Ethics Committee REC reference 11/LO/1657 and the trial is registered with 
ClinicalTrials.gov identifier NCT01492270 
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4.2 Rationale and Methodological Discussion 
 Choice of Patient Population 4.2.1
As discussed in section 3.6, it is vital for a diagnostic study to evaluate a cohort of patients 
in whom the diagnostic test would eventually be applied. An important cohort of men in 
whom prostate cancer imaging may prove beneficial is the group of men who have 
undergone an initial TRUS biopsy for the suspicion of prostate cancer but in whom concern 
remains regarding the negative or positive status to which they have been assigned.  
PICTURE recruited men from this cohort. The first group of men eligible for PICTURE are 
those with an elevated or rising PSA despite a negative TRUS biopsy. The second group 
includes those men with low/intermediate disease on TRUS biopsy for which concern 
remains that the burden of their disease is under represented by TRUS biopsy. In the 
diagnostic pathway at University College London Hospitals (UCLH) both of these groups 
would normally be offered transperineal template mapping biopsies as a further diagnostic 
test. 
By selecting the men from this cohort both those with known prostate cancer and men 
without were included. This population is representative of the population in whom 
imaging for prostate cancer may prove beneficial in the future. The heterogeneity of the 
study population adds to the external validity of the trial.  
This population of men were selected, rather than the pre-biopsy cohort, as with the 
financial constraints of the NHS system it is likely for imaging to be adopted primarily at this 
point in the pathway. Indeed, during the evolution of this thesis NICE guidelines have 
changed to suggest the use of mp-MRI following initial TRUS biopsy and rising PSA. 
(National Institute for Health and Care Excellence, 2014b). 
Also a further study investigating the use of mp-MRI in the pre-biopsy cohort is underway 
at UCLH; the PROMIS study will investigate the utility of mp-MRI prior to biopsy and also 
the financial impact of the introduction of mp-MRI on the NHS system, and is expected to 
report in early 2016. 
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 Choice of Reference Test 4.2.2
The reference test for the PICTURE study was carefully considered to enable the 
interrogation of both of the imaging modalities, without introducing significant bias. 
The reference standards available for the study included Radical Prostatectomy step 
sectioned histopathology, cystoprostatectomy, TRUS biopsy and transperineal template 
mapping prostate biopsy (TPM). 
The use of radical prostatectomy step-sectioned histopathology, although providing 
excellent histological verification, introduces significant selection bias to any study, as to 
proceed to radical prostatectomy all men undergoing this procedure will have cancer.  Also 
those men choosing radical prostatectomy tend to have significant disease burdens, than in 
other treatment groups.  
Cystoprostatectomy series as a reference standard also introduces selection bias but not to 
the same degree as RP specimens- as within the cohorts men may or may not have 
prostate cancer: burdens of disease in this population tend to be less than in the 
population as a whole (Trpkov et al., 2010).  
TRUS biopsy does not fulfil the characteristics of a good reference standard for validation of 
these technologies as TRUS is inaccurate in sampling the whole gland, and is known to 
systematically under-sample the anterior gland (Ayres et al., 2012, Bott et al., 2002). 
The reference test that most closely meets the requirements for the study was 
Transperineal template mapping biopsy. 
Transperineal template mapping prostate biopsy, can be applied to all men at risk both 
those with known prostate cancer and those without. It has also shown a sensitivity of 95% 
for clinically significant cancer ≥ 0.5 cc and 76% sensitivity for the detection of any prostate 
cancer (Crawford et al., 2013, Ahmed et al., 2011, Crawford et al., 2005). TPM also allows 
for accurate assessment of all areas of the prostate, including the anterior portion of the 
prostate, and enables biopsies to be accurately assigned to specific areas of the prostate.  
The side-effect profile of trans-perineal template mapping biopsy is not dissimilar to that of 
TRUS biopsy, which makes it a tolerable procedure. There are two main differences to the 
side effect profile: - firstly the post procedural sepsis rate is much lower with TPM biopsy 
than TRUS biopsy as the needle is not required to traverse the rectal mucosa in TPM (<1% 
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vs. 4%); secondly, the post-procedural urinary retention rate is higher with TPM than with 
TRUS, with 5-10% of men suffering self-limiting urinary retention vs. 1% with TRUS. 
(Merrick et al., 2007). 
Although TPM provides a gold standard reference test for our chosen study population, it 
carries some potential disadvantages for both the individual and the institution. The 
potential disadvantages for the individual include the need for a general or regional 
anaesthetic, and the risk of over-detection of insignificant prostate cancer -  although the 
very accurate nature of the diagnosis of low risk disease is likely to increase both patient 
and physician confidence to carry out active surveillance (Barzell et al., 2012).  
TPM also requires additional healthcare resources when compared to TRUS biopsy, such as 
general or regional anaesthesia and an increased pathology burden of processing and 
reporting up to 80 biopsy specimens as opposed to 8-12 with TRUS. 
Despite these additional burdens, because of the accuracy with which disease risk 
stratification can be performed by TPM (Gleason grading, tumour burden and location), 
and the acceptable side effect profile, it was selected as the most valid reference test. 
 
 Definitions of Clinically Significant Disease 4.2.3
Another important consideration when designing the PICTURE study was the definition of 
clinically significant disease. Much debate exists amongst experts about the nature of 
prostate cancer disease progression and what constitutes clinically important disease 
(Berman and Epstein, 2014, Ahmed et al., 2012).  
It has been demonstrated in the USA with the introduction of PSA screening that many 
more cancers are detected using a PSA screening approach. The below graph shows a peak 
in incidence of prostate cancer at the time of introduction of PSA screening in the US, 
around 1992 (Figure 38). This increased detection of cancer did little however to alter the 
mortality rate from cancer. 
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Figure 38. SEER 9 Incidence & U.S. Mortality 1975-2012, All Races, Males. Rates are 
Age-Adjusted 19 
 
 
Year 1975 1980 1985 1990 1995 1999 2003 2007 
5-Year 
Relative 
Survival 
66.0% 70.2% 74.9% 88.4% 95.7% 99.2% 99.1% 99.7% 
 
These figures suggest that not all prostate cancers are likely to cause mortality and 
therefore it follows that not all cancers are clinically significant. 
Many studies have tried to define what constitutes clinically significant disease and as 
discussed in section 3.6.5 the most widely used definitions for disease significance are 
based on those by Stamey et al, who established a volume threshold for disease 
significance at ≥ 0.5cc and Epstein et al, who set a threshold of ≥ 0.2 cc (Stamey et al., 1993, 
Epstein et al., 1994). 
From the European Randomised Study of Screening for Prostate Cancer (ERSPC) data , of 
men with low grade, low volume disease Wolters et al summated that an index tumour 
volume of up to 1.3 cc and total tumour volume of 2.5cc may still constitute low risk 
disease (Wolters et al., 2011). 
                                                          
19
 Kindly reproduced with permission form SEER Cancer Statistics Factsheets: Prostate Cancer. National Cancer Institute. 
Bethesda, MD, http://seer.cancer.gov/statfacts/html/prost.html, accessed 20/06/2015 
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Ahmed et al defined the characteristics of clinically significant disease using TPM biopsy, by 
the use of TPM computer simulations on reconstructed RP whole mount specimens 
(Ahmed et al., 2011). 
Two main definitions of clinically significant disease were defined from this study, and 
these (Figure 39) are the definitions for significance selected for use in the PICTURE study. 
The primary definition for clinically significant disease, and that used for the study power 
calculation, will be definition one primary Gleason pattern ≥ 4 OR Maximum cancer core 
length (MCCL) ≥ 6 mm. 
Figure 39. UCL definitions of clinically significant disease 
 
 
4.3 Index Tests 
All men in the study underwent both index tests of mp-MRI and prostate HistoScanning. 
 
 Multiparametric-MRI  4.3.1
Each sequence of an mp-MRI has different properties that, when assessed by a radiologist 
can assist in the decision whether an abnormal area represents cancer or not.  
Within the PICTURE study several sequences were obtained, these include:- 
1) a T2 weighted sequence, which allows for accurate anatomical imaging of the prostate 
and surrounding tissues.  
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2) diffusion weighted imaging (DWI), which evaluates the interstitial free water and 
permeability - cancers tend to have greater cell density and demonstrate restricted 
diffusion signal. DWI images include various B value sequences, extended B value images 
(B1400 at 1.5T and B2000 at 3T) and enable the production of Apparent Diffusion Co-
efficient (ADC) maps. 
3) dynamic contrast enhanced images (DCE). These images are acquired by injecting 
gadolinium contrast agent, whilst imaging the prostate every few seconds to evaluate the 
temporal contrast properties of tissue in order to derive information on vascularity. The 
aim of DCE is to detect prostate cancers by exploiting the angiogenic nature of cancers and 
their increased vascularity. 
Full sequence information can be found in appendix 10.4. 
Due to the nature of the study, mp-MRI’s were performed primarily at 3 Tesla; however, 
for men for whom a 3T scan was not possible, a 1.5T scan was performed. 
The mp-MRI images in PICTURE were reported blinded to other imaging information, but 
the radiologist was aware of the patient’s clinical information - including prior TRUS biopsy 
result and PSA value: - this pragmatic inclusion is to reflect what would occur in daily 
clinical practice. 
The radiologist reported the MRI according to a strict SOP on a proforma, with a single 
radiologist reporting all scans within the study. Planned re-reporting of a selection of scans 
was performed to assess reliability. Figure 40 demonstrates the mp-MRI reporting form. 
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Figure 40. PICTURE mp-MRI reporting form 
 
 
The radiologist used the Likert scale for mp-MRI reporting that has been agreed in a 
number of consensus papers (Dickinson et al., 2013, Barentsz et al., 2013, Barentsz et al., 
2012a). The Likert scale assesses radiologists’ confidence levels in the presence of prostate 
cancer on the MRI with:-  
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- Score 1 = Clinically significant disease is highly unlikely to be present,  
- Score 2 = Clinically significant cancer is unlikely to be present, 
- Score 3 = Clinically significant cancer is equivocal,  
- Score 4 = Clinically significant cancer is likely to be present  and  
- Score 5 = Clinically significant cancer is highly likely to be present  
This score was used to sequentially score 12 sectors of the prostate (left and right anterior 
and posterior zones at apex, mid and base). Mp-MRI’s were reported sequentially starting 
with the T2 alone; then the DWI images, followed by DCE images and finally an overall 
impression given on the likelihood of disease and clinically significant disease. The 
incremental read of the mp-MRI will enable incremental quantification of each sequence 
and the assessment of the need for each sequence in the mp-MRI. 
Each lesion identified was scored and measured and depicted diagrammatically. The 
radiologist also gave a subjective judgement as to the Gleason grade for each lesion, and 
provided likely co-ordinates for hitting the most significant lesion at TPM. 
 
 Prostate HistoScanning 4.3.2
Prostate HistoScanning was performed using the BK ultrasound probes 8818 and 8848, 
attached to the specialist prostate HistoScanning equipment. Men underwent two sessions 
of HistoScanning to allow for assessment of reproducibility. 
Reporting of PHS was carried out using the commercially available software version 2.3, 
which has a semi-automated tool for reporting. 
The clinician reporting the PHS scans was blinded to the results of the other imaging but 
once again was aware of the patient’s clinical parameters, including previous TRUS results 
and PSA. Reporting of PHS is a semi-automated process.  The software requires that the 
analyst defines the apex and base points in the sagittal plane of the prostate and the most 
lateral left and right points on a mid-gland transverse slice of the image: this enables 
automated segmentation of the prostate into the 12 zones.  
The prostate HistoScanning analysis algorithms are applied to the selected prostate 
volume, and suspicious areas that are felt to contain prostate cancer are depicted by a red 
overlay on the grey scale ultrasound image. The PHS automated software automatically 
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assigns the three largest lesions with the prostate area. The clinician reporting the scan will 
not be able to refine the signal deemed positive by the software so as to reduce reporter 
variability.  The clinician reporting the scan assigned likely TPM biopsy co-ordinates to the 
three largest PHS lesions to enable targeted biopsy.  
Disease significance on PHS was defined by size criteria only, not using a scale, as there is as 
yet no way to assess grade on PHS. 
Figure 41. HistoScanning Reporting form 
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4.4 The Reference Test- Transperineal Template Mapping Biopsy  
Men underwent transperineal template mapping biopsies of as the reference standard.  
TPM is performed under general or regional anaesthetic. Men were placed in the lithotomy 
position and the perineum cleaned with chlorhexidine 2% prep solution. They were also all 
given Gentamycin antibiotic prophylaxis. 
Figure 42. Transperinaltemplate biopsy set up20 
 
 
The TPM was then performed to a standard operating procedure; this involved taking 
samples of the prostate using a bard 16ch biopsy needle via the perineum at 5mm spacing 
with a brachytherapy grid placed on the perineum as a guide.  
Biopsies were taken within 20 modified Barzell zones that covered the entirety of the 
prostate; they were first taken from the apical segments and then the basal sectors. 
Figure 43 demonstrates the modified Barzell Zones in which TPM is performed at UCLH.  
 
 
                                                          
20
 Kindly reprinted from Barzell WE, Whitmore WF III: How to perform transperineal saturation 
prostate biopsy. Urology Times. Available 
www.urologytimes.com/urologytimes/article/articleDetail.jsp?id=56612. 
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Figure 43. Modified Barzell Zones 
 
 
 Template Mapping Biopsy Sampling Density 4.4.1
Template mapping biopsies were chosen as the reference test for PICTURE for their high 
detection rate for clinically significant disease. A study by Le Cornet et al, that undertook a 
computer simulation of biopsy strategies in the reconstructed prostates of men that had 
undergone cystoprostatectomy found that TPM when performed at 5mm spacing had  a 
ROC AUC of 0.91 for the detection of clinically significant disease as defined by Definition 
one (Gleason score 7 or greater, and/or lesion volume 0.5 ml) (Lecornet et al., 2012). 
Figure 44 shows the ROC curves for a variety of biopsy strategies. The study aimed to test 
TPM (dark blue curve, AUC 0.91) against TRUS (all other curves). The ROC shown below also 
demonstrates the ROC curves for optimised TRUS with anterior directed cores (light blue, 
AUC 0.82), standard TRUS biopsy with a random localisation error of 10mm (yellow curve, 
AUC 0.75), and standard TRUS with a 15mm random localisation error (red AUC 0.69). 
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Figure 44. ROC curves for TPM and TRUS biopsy strategies21 
 
  
During the evolution of the PICTURE study the burden of 5mm sampling on patients was 
felt to be too high. Initially, a number of men suffer from adverse side effects such as gross 
haematuria and urine retention. The high burden of taking a full 5mm TPM; in terms of 
theatre time, histological processing time and cost, also factored into the decision making. 
Due to this, computer simulation was utilised to explore the accuracy of various 
transperineal sampling strategies for the detection of prostate cancer. The aim was to 
determine a strategy that might give accurate cancer detection rates but minimise 
sampling burden, minimise morbidity for patients and allow a reduction in biopsy cost and 
pathology processing time. 
Different patient populations carry different disease burdens, and often the way in which a 
test is interpreted is influenced by the population in which it was examined. It is well 
known that radical prostatectomy series incorporate a large degree of work up bias as all 
men have tested positive for cancer on a previous biopsy strategy and have chosen to 
                                                          
21
 Reprinted from LECORNET, E., AHMED, H. U., HU, Y., MOORE, C. M., NEVOUX, P., BARRATT, D., HAWKES, D., VILLERS, A. & 
EMBERTON, M. 2012. The accuracy of different biopsy strategies for the detection of clinically important prostate cancer: a 
computer simulation. J Urol, 188, 974-80. With permission from Elselvier 
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undergo radical surgery. Therefore, they will more likely have larger disease burdens than 
men in the population as a whole. 
The group most closely matching the background population are those who have their 
prostates removed in a cystoprostatectomy for bladder cancer. As they have not previously 
been diagnosed with prostate cancer this group can act as a good representation for the 
male population. 
The aim of this computer simulation study was to assess how the use of different 
transperineal biopsy strategies altered disease detection characteristics. Alongside 
investigating how different sampling strategies altered disease detection, an aim was to 
examine how the use of a different patient population altered the performance 
characteristics of a test. 
It was therefore decided to simulate the use of several different biopsy strategies in order 
to assess their performance characteristics for the detection of significant cancer. For this 
simulation the definition of significant cancer was defined as Definition 1 cancer 
(volume≥0.5cc and/or Gleason≥7).  Modelling was also performed for Definition 2 disease 
(Volume ≥0.2cc, or Gleason ≥7). 
The cystoprostatectomy models came from a series of 346 men identified from 1983 to 
1997 at the Department of Urology, Stanford University School of Medicine who 
underwent radical cystoprostatectomy for invasive bladder cancer. They were deemed to 
be free of clinically apparent prostate cancer before surgery. Prostate cancer was found in 
104 of 338 patients (31%).  
Due to the large volume prostate cancer occupying most of the gland 8 patients were 
excluded from analysis, leaving 96 evaluable specimens. Table 20 shows the demographic 
data for this group. The same series were used in a previous biopsy simulation by our group 
assessing varying biopsy strategies.(Lecornet et al., 2012) 
  
MD (Res) Thesis       - 120 - 
 
 Page 120 of 363 
Table 20. Demographic data for Cystoprostatectomy series for 96 men 
 
 
No. Samples/Total No. (%) 
Gleason score:  
No grade 4 88 (84) 
Grade 4 8 (8) 
Grade 4 or 5, or undifferentiated  4 (4) 
T stage:  
T2a  50 (48) 
T2b  3 (3) 
T2c  45 (43) 
T3a  2 (2) 
Site (215):  
Anterior  79 (37) 
Posterior  136 (63) 
Vol (ml):  
Less than 0.2  170 (79) 
0.2 or Greater 45 (21) 
0.5 or Greater 21 (10) 
Clinical significance definition (215):  
1  25 (12) 
2  47 (22) 
Definition 1 cohort (ng/ml PSA):  23/96 (24) 
Less than 4 or unknown 15/76 (20) 
4 or Greater  8/20 (40) 
Definition 2 cohort:  36/96 (38) 
Less than 4 or unknown  27/76 (36) 
4 or Greater  9/20 (45) 
 
The radical prostatectomy series, constituted 107 consecutive radical prostatectomies 
performed between 1999-2001. All underwent 3mm step sectioning according to the 
Stanford protocol. This cohort has also been used in a study investigating prostate cancer 
risk inflation as a consequence of targeting. (Robertson et al., 2014) Table 21 outlines 
demographics for this group. 
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Table 21. Demographic data for Radical Prostatectomy series 
Characteristic 
 
Value 
Median (mean, SD, range) 
Age, years 62 (61.1, 6.4, 44–74) 
PSA concentration, ng/ml  8.5 (9.7, 5.9, 0.8–36.2) 
Gleason score, % (n)  
</=6  57 (61) 
7  35 (37) 
>/=8 8 (9) 
Pathologic stage, % (n)  
pT2a  7.5 (8) 
pT2b  2 (2) 
pT2c  49.5 (53) 
pT3a  33.6 (36) 
pT3b  5.6 (6) 
pT4  2 (2) 
Risk groups, NCCN classification, % (n)  
Low  5.6 (6) 
Intermediate  47.7 (51) 
High  46.7 (50) 
Prostate volume, ml, median (range) 50.2 (26.8–127.7) 
No. of lesions  
Anterior 415 
Posterior  250 
Full cohort  
>/= 0.2 ml  149 
>/= 0.5 ml  97 
Low to intermediate risk  
>/= 0.2 ml  68 
>/= 0.5 ml  43 
Lesions per prostate, median (range) 5 (1–21) 
Lesion volumes, ml, median (mean, SD, range)  
All                 (n = 665) 0.031 (0.374, 1.110, 0.001–13.242) 
Index            (n = 107) 1.215 (1.895, 2.176, 0.015–13.242) 
Non index    (n = 558) 0.019 (0.082, 0.343, 0.001–1.842) 
NCCN = National Comprehensive Cancer Network; PSA = prostate-
specific antigen; SD = standard deviation. 
 
Both of the cohorts’ specimens had been processed according to the Stanford Protocol: - 
inked, fixed and sectioned as 3mm whole mount specimens, with contours of their cancer 
foci outlined. Each then underwent computerised reconstruction, with slides being digitally 
scanned and reconstructed. 3-D geometric modelling software designed at UCL was used to 
ensure accurate alignment and registration of each slice.  
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For the computer simulations a standard 15mm core length was used for all biopsies. 500 
simulations of each strategy were performed, on each prostate.  
More in depth explanations of how the simulations were performed can be found in the 
following papers Hu et al, a biopsy simulation study to assess the accuracy of several 
transrectal ultrasonography (TRUS)‐biopsy strategies compared with template prostate 
mapping biopsies in patients who have undergone radical prostatectomy and Ahmed et al, 
Characterizing clinically significant prostate cancer using template prostate mapping biopsy 
(Hu et al., 2012a, Ahmed et al., 2011). 
In order to assess and compare the diagnosis methods without considering the choice of 
the cut-off value, Receiver operating characteristic (ROC) curves were used with the 
sensitivity/specificity/PPV/NPV versus a range of sensible cut-off values plotted. ROC 
curves, are graphs that illustrates the performance of test. They are created by plotting the 
true positive rate (TPR) against the false positive rate (FPR) at various sensitivity and 
specificity settings. The sensitivity and specificity graphs at varying Maximum cancer core 
length (MCCL) in millimetres (mm) were performed to allow the decision of what the cut-
off value for MCCL should be, MCCL was measured in mm. The cut-off needed to be 
determined to have a desired balance between sensitivity and specificity, therefore being a 
complete ‘diagnostic test’. 
 Cystoprostatectomy Series Simulation 4.4.2
The following simulations were carried out for both definitions of disease significance:  
1.  5mm template (normal) – curve 1 peacock blue 
2.  10mm template – curve 2 blue 
3 ‘random 1 biopsy per barzell sector’ – curve 3 turquoise blue 
4 ‘random 2 biopsies per Barzell sector’ – curve 4 green 
5 ‘random 1 per sector in glands </=30cc and random 2 biopsies per sector in gland 
>30cc’ – curve 5 yellow 
6  ‘random 1 per sector in gland </=40cc and random 2 biopsies per sector in glands 
>40cc’- curve 6 orange 
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 Definition one disease: 4.4.2.1
Figure 45. ROC curve for Biopsy strategies for TPM in Cystoprostatectomy series 
(definition one disease) 
 
Key:  
1. 5mm template (normal) – curve 1 peacock blue 
2.  10mm template – curve 2 blue 
3. ‘random 1 biopsy per barzell sector’ – curve 3 turquoise blue 
4. ‘random 2 biopsies per Barzell sector’ – curve 4 green 
5. ‘random 1 per sector in glands </=30cc and random 2 biopsies per sector in gland 
>30cc’ – curve 5 yellow 
6.  ‘random 1 per sector in gland </=40cc and random 2 biopsies per sector in glands 
>40cc’- curve 6 orange 
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Figure 46. Sensitivity curves for Biopsy strategies for TPM in Cystoprostatectomy 
series (definition one disease) 
 
Figure 47. Specificity Curve for Biopsy strategies for TPM in Cystoprostatectomy 
series (definition one disease) 
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From this modelling in the cystoprostatectomy series it would appear that adopting a 2 
core per Barzell zone (or a 10mm) sampling strategy would not significantly negatively 
impact on detection rates.  Causing only a minimal reduction in detection rates from 0.907 
to 0.8481 or 0.8476 respectively, which is at worst a 0.0594 reduction in the ROC AUC. 
 
 Definition 2 disease: 4.4.2.2
Figure 48. ROC curve for Biopsy strategies for TPM in Cystoprostatectomy series 
(definition two disease)  
Key:  
1. 5mm template (normal) – curve 1 peacock blue 
2.  10mm template – curve 2 blue 
3. ‘random 1 biopsy per barzell sector’ – curve 3 turquoise blue 
4. ‘random 2 biopsies per Barzell sector’ – curve 4 green 
5. ‘random 1 per sector in glands </=30cc and random 2 biopsies per sector in gland 
>30cc’ – curve 5 yellow 
6.  ‘random 1 per sector in gland </=40cc and random 2 biopsies per sector in glands 
>40cc’- curve 6 orange 
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Figure 49. Sensitivity curves for Biopsy strategies for TPM in Cystoprostatectomy 
series (definition two disease) 
 
Figure 50. Specificity Curve for Biopsy strategies for TPM in Cystoprostatectomy 
series (definition two disease) 
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Again the above graphs (Figure 45, Figure 46, Figure 47) demonstrate that a reduction in 
sampling density to 10mm spacing (or two cores per Barzell zone will only decrease the 
area under the ROC curve for Definition 2 disease from 5mm Sampling AUC = 0.8976 to 
10mm Sampling AUC = 0.8235 or Random 2 cores per sector AUC = 0.821, again a minimal 
reduction. 
 Radical Prostatectomy series:  4.4.3
 Definition one disease 4.4.3.1
Figure 51. ROC curve for Biopsy strategies for TPM in Radical Prostatectomy series 
(definition one disease) 
 
Key:  
1. 5mm template (normal) – curve 1 peacock blue 
2.  10mm template – curve 2 blue 
3. ‘random 1 biopsy per barzell sector’ – curve 3 turquoise blue 
4. ‘random 2 biopsies per Barzell sector’ – curve 4 green 
5. ‘random 1 per sector in glands </=30cc and random 2 biopsies per sector in gland >30cc’ – curve 5 yellow 
6.  ‘random 1 per sector in gland </=40cc and random 2 biopsies per sector in glands >40cc’- curve 6 orange 
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Figure 52. Sensitivity curves for biopsy strategies for TPM in Radical prostatectomy 
series (definition one disease) 
 
Figure 53. Specificity curves for biopsy strategies for TPM in Radical prostatectomy 
series (definition one disease) 
 
 
From this modelling in the radical prostatectomy series it would appear that adopting a 2 
core per Barzell zone (or a 10mm) sampling strategy would not significantly negatively 
impact on detection rates.  Causing a minimal reduction in detection rates from 0.873 
to 0.839 or 0.840 respectively, on the ROC AUC. 
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 Definition two disease  4.4.3.2
Figure 54. ROC curve for Biopsy strategies for TPM in Radical Prostatectomy series 
(definition two disease)  
 
 
Key:  
1. 5mm template (normal) – curve 1 peacock blue 
2.  10mm template – curve 2 blue 
3. ‘random 1 biopsy per barzell sector’ – curve 3 turquoise blue 
4. ‘random 2 biopsies per Barzell sector’ – curve 4 green 
5. ‘random 1 per sector in glands </=30cc and random 2 biopsies per sector in gland 
>30cc’ – curve 5 yellow 
6.  ‘random 1 per sector in gland </=40cc and random 2 biopsies per sector in glands 
>40cc’- curve 6 orange 
MD (Res) Thesis       - 130 - 
 
 Page 130 of 363 
Figure 55. Sensitivity curves for biopsy strategies for TPM in Radical prostatectomy 
series (definition two disease) 
 
 
Figure 56. Specificity curves for biopsy strategies for TPM in Radical prostatectomy 
series (definition two disease) 
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Once again, altering the strategy from full 5mm sampling to 10mm sampling did not show a 
significant reduction in the ROC AUC. 
Some further work was performed looking at the ‘hit rate’ for significant lesions by each 
strategy. Table 22 demonstrates the detection rate of significant lesions when the different 
strategies are applied. 5mm sampling has over 99% detection for significant lesions in both 
cohort, which reduces slightly to an approximately 89% detection rate when sampling 
density is reduced to 10mm or 2 cores per Barzell zone. 
Table 22. Detection rates of significant disease for different biopsy strategies  
 Cystoprostatectomy data Radical Prostatectomy 
data 
 Number of 
cases 
having 
significant 
lesions  
Detection 
rate 
(excluding 
insignificant 
cases) 
Number of 
cases 
having 
significant 
lesions  
Detection 
rate 
(excluding 
insignificant 
cases) 
Standard 
template 
19 0.9988 77 0.9968 
10mm template 19 0.8996 77 0.8862 
Barzell-1 19 0.7596 77 0.7466 
Barzell-2 19 0.8945 77 0.8730 
 
In summary, the investigation into altering the biopsy density of TPM showed that a 
reduced sampling density from 5mm sampling to 10mm sampling did not significantly alter 
the ROC AUC in either cohort. There was however a reduction from near perfect detection 
of significant lesions (detection rate =0.99), with 5mm sampling to a roughly 90% detection 
rate with 10mm sampling. This was deemed to be an acceptable reduction in detection for 
the predicted benefits in terms of morbidity and cost reduction provided by the change, 
and thus it was instituted into the study after the initial 130 men. 
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4.5 Targeted Biopsies 
Prior to the standard TPM, in men with lesions detected on imaging targeted biopsies was 
taken. Three sets of targeted biopsies were obtained. MRI-USS registration biopsies, 
cognitively registered MRI targeted biopsies and cognitively registered PHS guided biopsies. 
For PHS targets the biggest lesion seen on imaging was targeted, given the co-ordinates 
stated on the PHS report and the clinician’s review of the PHS imaging the area. The lesion 
was then targeted using cognitive registration; in other words the clinician targets the 
lesion using spatial awareness of the location of the lesion within the gland without any 
image fusion technology. 
The primary MRI lesion that was identified with an MRI score of ≥3 was targeted using two 
techniques. The method of cognitive registration using the information given by the 
reporting radiologist was used as the primary method of registration. The second method 
of targeting was performed using MRI/US registration. MRI/US registration is a 
computerised process to assist with targeting lesions seen on mp-MRI - the system in 
PICTURE is a deformable system that allows for distortion of the gland by the biopsy probe 
at the time of biopsy (Hu et al., 2009, Hu et al., 2012a, Hu et al., 2011) (Hu et al., 2009).  
Registration requires that the prostate outline and the lesion on MRI are contoured on 
specially designed software. Following the delineation of the gland and lesion a 
biomechanical mesh model of each man’s prostate and lesion is developed.  At the time of 
biopsy, a 3D ultrasound volume was acquired and then 5-10 points on several images from 
the ultrasound volume were selected to allow the MRI model and ultrasound image to be 
fused/registered together. The registration system then automatically computed the most 
likely co-ordinates to obtain a maximum cancer core length through the prostate cancer 
lesion. 
Each type of targeting involved 2 targeted biopsies unless they overlapped in which case 
this was made clear. Following the targeted biopsy sampling, men had 5mm or 10mm 
sampling performed within a 20 modified Barzell zone layout. 
 
 Rationale for Targeted biopsy 4.5.1
Within the PICTURE Study, men underwent targeted sampling to areas on imaging that 
were deemed suspicious for disease, as well as the reference standard biopsy of TPM. The 
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rationale behind targeted sampling is that if imaging can accurately predict the presence of 
disease, it must be able to answer the question as to whether we can accurately sample 
that disease to correctly risk stratify patients. 
Current literature suggests that an MRI guided image biopsy technique is able to accurately 
sample prostate cancer lesions and that these are highly representative of the true tumour 
grade found at radical prostatectomy in around 88% of cases (Hambrock et al., 2012). 
Additionally, if men can be correctly attributed their risk status by a more limited biopsy 
protocol with fewer cores, this may enable the procedure to be performed similarly to 
TRUS biopsy under local anaesthetic. A reduction in the number of cores taken compared 
to current best diagnosis of template mapping biopsy, may also allow a reduction in the 
time the procedure takes, a reduced morbidity to the procedure. It is likely that by taking 
less cores men will suffer less pain and lower risk of infections. Biopsy processing time and 
cost at the histopathology laboratories would also be reduced by adopting a targeted 
approach. 
At PICTURE Study inception, no PHS biopsy advanced targeting strategy existed, so PHS 
lesions were targeted using ‘cognitive registration’ biopsies i.e. the performing clinician 
used their awareness of prostate anatomy and spatial awareness to target the biopsy 
needle towards the area of greatest PHS signal. 
Of note, since the design of the PICTURE study, a biopsy guidance system for PHS ‘True 
Targeting’ was developed and released: evidence from clinical trials of this targeting 
technology is awaited. 
For MRI imaging there exist a number of methods for targeting lesions detected on the MRI 
image. Alongside the described ‘cognitive MRI targeted biopsy’ technique there exists a 
number of different platforms that allow ultrasound/MRI registration or image fusion, and 
also MRI in bore targeted biopsy techniques have been explored. 
Image fusion is the process of combining multiple images from various sources into a single 
representative image. It requires image registration, which is a process of mapping 
equivalent points from the different imaging studies so that they correspond. Standard 
ultrasound (US) is not as good as MRI in differentiating between normal prostate and 
tumour; however ultrasound is the imaging modality used to guide most biopsy strategies.  
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Image fusion/registration using computer software is being developed with the aim of 
super-imposing an MRI image of a tumour taken prior to biopsy onto a real time US image 
so that the tumour focus can be more accurately targeted during the biopsy procedure.  
A challenge that presents itself when performing image registration for prostate biopsies is 
‘deformation’ - the change in shape that occurs to the prostate when an ultrasound probe 
is introduced into the rectum - and also when biopsies are taken due to swelling. (Hu et al., 
2012b) 
To address the issue of deformation a novel “model-to-image” registration method has 
been developed that allows automatic registration of the deformable prostate model 
surface to the TRUS images (Hu et al., 2012b, Hu et al., 2009). 
Currently, this registration method does not account for the deformation from gland 
swelling, only probe distortion. However work is in progress to assess and compensate for 
the swelling caused by prostate biopsy and incorporate this into the registration (Hu et al., 
2011).  
MRI in-bore targeted biopsies have been investigated by other groups and have found 
detection rates of approximately 40-50% (Hoeks et al., 2012, Overduin et al., 2013). 
However, there are significant cost and resource implications to these biopsies: they 
require a large amount of time within the MRI scanner, and a number of different MRI safe 
materials. 
The biopsy guidance scheme that is most likely to become widely adopted if found to be 
viable is one in which pre-biopsy imaging is performed and then fused with the ultrasound 
image at the time of biopsy.  
A deformable registration system will likely be the most accurate as it will be able to allow 
for changes in shape of the prostate when a probe is introduced at the time of biopsy. 
Within the PICTURE Study a novel prototype device of deformable MRI/US registration 
system designed by colleagues at the Centre for Medical Imaging and Computing, UCL 
(Smart Target) was used to target biopsies at the time of TPM. 
One group looked also at the use of MRI fusion systems vs. cognitive biopsies, using a 
similar methodology to that in the PICTURE Study. They found no significant improvement 
of MRI targeting by the use of fusion technology over that of MRI ‘cognitive 
targeting’.(Puech et al., 2013) 
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The objectives for the addition of targeted biopsy sampling in the PICTURE Study were to:- 
assess if PHS targeted biopsy were comparable the use of systematic biopsies stratifying 
patients into prostate cancer risk groups; if MRI ‘cognitive’ targeted biopsies were 
comparable the use of systematic biopsies in stratifying patients into prostate cancer risk 
groups and whether the use of MRI to US registration targeted biopsies alone was 
comparable the use of systematic biopsies and cognitive targeted biopsies in stratifying 
patients into prostate cancer risk groups.  
 
4.6 PICTURE Additional Procedures 
The PICTURE Study provides a unique opportunity to validate a number of other 
procedures against a high quality reference standard in a population of men who do not all 
have known disease.  
As such a urine and seminal biomarker were selected for inclusion in the study. 
 Urine Engrailed 2 (EN2) 4.6.1
Engrailed-2 is a protein that has been found to be present in the first pass urine. 
Preliminary work has shown EN2 to be expressed in prostate cancer cell lines and prostate 
cancer cells but not by normal prostate epithelial tissue. 
Initial studies have shown that an ELISA based EN2 assay can detect EN2 in urine with 
sensitivity 66% and specificity of 88.2%- when the cut off for a positive assay is set at 
42.5ng/mL. (Morgan et al., 2011) 
EN2 was also found to be easily detectable in a small sample of urine, without the need for 
digital rectal examination, which may enable it to be used as a useful diagnostic or 
screening test.  
First pass urine samples were collected from men and analysed for EN2, in order to assess 
the ability of this assay for the detection of prostate cancer, and its ability to differentiate 
between clinically significant and non-clinically significant disease.  
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 Seminal Fluid Analysis for Citrate and Zinc (FScan) 4.6.2
Another interesting metabolic relationship investigated and explored for its potential role 
in prostate cancer detection is the change in citrate and zinc levels in prostatic fluid.  In 
contrast to the normal prostatic fluid which contains very high concentrations of citrate 
and zinc, in the presence of prostate adenocarcinoma the levels of citrate dramatically 
reduce, demonstrating a 70-90% reduction in level.  
The reduction in citrate and zinc levels is due to metabolic transformation in malignant cells 
that results in their inability to accumulate zinc.  In the absence of high zinc levels m-
aconitase activity is no longer inhibited and citrate can be oxidised by the Krebs cycle 
(Medarova et al., 2014, Costello and Franklin, 2009). 
Moreover, malignant cells are proliferating cells that require citrate for cell growth and 
proliferation. These processes occur early in malignant transformation of prostate 
epithelial cells and as such may allow disease detection at early stages. 
Prostatic fluid typically constitutes between 30 and 50% of seminal fluid and is the only 
fluid component with citrate levels greater than about 5mM. Citrate levels in healthy men 
average 94 (±32) mM in prostatic fluid and 33 (±8) mM in seminal fluid (Kavanagh, 1985).  
As previously stated, as malignant cells proliferate within the prostate citrate levels fall in 
prostatic fluid, and thus in seminal fluid.  
Parker et al have developed and patented - a rapid (< 3minute) method for measuring 
microlitre samples of citrate in prostatic and seminal fluid samples, this is called FScan (Pal 
et al., 2011). 
The FScan method is based on the emission intensity ratio of two bands in the 
luminescence spectrum of a europium complex that binds citrate selectively in the 
presence of competing ions such as lactate, phosphate and carbonate.  This seminal fluid 
assay was incorporated in PICTURE as an optional test for the patients. The aim was to 
analyse the relationship between the assay and its ability to rule out prostate cancer as 
determined by negative predictive value. 
Also, in men who test positive for prostate cancer using FScan, can the assay provide an 
indication of clinical disease significance? 
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4.7 PICTURE Study Size Calculation  
Consecutive prospective recruitment of patients from a clinically relevant population with 
masked test results will minimise bias ensured that the results from this study have clinical 
applicability.  
Patients who fulfilled the eligibility criteria were selected so that the study sample has a 
disease prevalence that was representative of the population of interest. This is particularly 
important as predictive values depend on the disease prevalence in the population.  Both 
patients and assessors were blinded to the test results until both index tests were 
completed and reported.  
The biopsy tests were carried out once MRI and HistoScanning™ reporting was completed 
and results of the tests were disclosed simultaneously to each patient, in order to prevent 
attrition bias. 
Sample size calculations were undertaken for both definitions of clinically significant 
disease- definition 1 (red disease) and definition 2 (amber disease).   
Unpublished data from UCLH shows a disease prevalence of 38% definition 1 (red) disease 
and 65% clinically significant (definition 1 and 2, red and amber disease) in men undergoing 
transperineal template prostate mapping biopsy following an initial trans-rectal biopsy.  
 
  Sample Size Calculation 4.7.1
The sample size calculation was performed for the primary objective of calculation of the 
negative predictive value of the imaging modalities, using a precision based estimate. 
For definition 1 disease the prevalence within our population was 38%.  Targeting a NPV of 
90% for definition one disease, for a 95% confidence interval with a confidence width 10% 
the number of patients needed with a negative test was 139.  
Assuming the performance characteristics of mp-MRI and PHS equated to sensitivity and 
specificity of 70% - a sample size of 254 patients would allow for 139 patients with a 
negative test. Allowing a 10% drop out rate from the study it was aimed to recruit 280 
patients. 
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Table 23. Numbers for precision based estimates with 95% Confidence level with 
varying confidence widths  
 
width of interval 
  
 
0.1 0.15 0.2 0.3 
0.7 323 144 81 36 
0.75 289 129 73 33 
0.8 246 110 62 28 
0.85 196 88 49 22 
0.9 139 62 35 16 
 
To allow us to tailor the sample size to the disease prevalence we have used the following 
formula to provide the factor which must be applied to the precision based estimate.   
NPV factor = ((1- Sensitivity)*Disease prevalence)+((Specificity)*(1-disease prevalence)) 
The following tables (Table 24 and Table 25) demonstrates what happens to the sample 
size if the performance characteristics of the test alter. Numbers shaded light green are 
those that our chosen sample size (highlighted yellow) will cover. 
For definition one disease- this has a prevalence of 38% in our population: 
Table 24. Sample size calculation- calculated for 95% CI around NPV- assuming 
sensitivity and specificity of 70% 
Factor=0.548 width of interval 
  
 
0.1 0.15 0.2 0.3 
0.7 589.4160584 262.7737226 147.810219 65.69343066 
0.75 527.3722628 235.4014599 133.2116788 60.2189781 
0.8 448.9051095 200.729927 113.1386861 51.09489051 
0.85 357.6642336 160.5839416 89.41605839 40.1459854 
0.9 253.649635 113.1386861 63.86861314 29.19708029 
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Table 25. Sample size calculation- Calculated for 95% CI around NPV- assuming 
sensitivity and specificity of 80% 
Factor=0.572 width of interval 
  
 
0.1 0.15 0.2 0.3 
0.7 564.6853147 251.7482517 141.6083916 62.93706294 
0.75 505.2447552 225.5244755 127.6223776 57.69230769 
0.8 430.0699301 192.3076923 108.3916084 48.95104895 
0.85 342.6573427 153.8461538 85.66433566 38.46153846 
0.9 243.006993 108.3916084 61.18881119 27.97202797 
 
For definition two disease, which has a prevalence of 65% in our population, tables Table 
26 and Table 27 outline the numbers of test subjects required. 
 
Table 26. Sample size calculation-calculated for 95% CI around NPV- assuming 
sensitivity and specificity of 70% 
 
width of interval 
  
 
0.1 0.15 0.2 0.3 
0.7 734.0909091 327.2727273 184.0909091 81.81818182 
0.75 656.8181818 293.1818182 165.9090909 75 
0.8 559.0909091 250 140.9090909 63.63636364 
0.85 445.4545455 200 111.3636364 50 
0.9 315.9090909 140.9090909 79.54545455 36.36363636 
 
 
 
MD (Res) Thesis       - 140 - 
 
 Page 140 of 363 
Table 27. Sample size calculation -Calculated for 95% CI around NPV- assuming 
sensitivity and specificity of 80% 
 
width of interval 
  
 
0.1 0.15 0.2 0.3 
0.7 787.804878 351.2195122 197.5609756 87.80487805 
0.75 704.8780488 314.6341463 178.0487805 80.48780488 
0.8 600 268.2926829 151.2195122 68.29268293 
0.85 478.0487805 214.6341463 119.5121951 53.65853659 
0.9 339.0243902 151.2195122 85.36585366 39.02439024 
 
 
4.8 Statistical Analysis 
Baseline demographic data of all men was assessed, for a number of factors, including: - 
age; PSA; gland size, and pre-study TRUS risk category. 
Clinical validity was evaluated on a whole-gland basis using each patient as the unit of 
assessment. Sensitivity, specificity, positive and negative predictive values were calculated 
for all eligible men with binomial 95% confidence intervals. 
 
 Analysis of Multi-parametric MRI and Prostate Mapping Biopsy Results 4.8.1
For MRI primary analysis calculations used both an MRI-score of 3 or greater and MRI score 
4 or greater as a positive test and histological definition 1 as the target condition on the 
reference TPM biopsy.  
Results are presented in a 2 by 2 tables (Table 28) and estimates presented together with 
95% confidence intervals (CI). 
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Table 28. 2 by 2 tables to demonstrate accuracy of MRI with respect to TPM 
  MRI   
  +ve -ve Total 
TPM +ve a b a+b 
 - ve c d c+d 
 
Specificity = d / (c+d) where, d = number of men testing negative on MRI and negative for 
clinically significant cancer on TPM, c = number of men testing positive on MRI who have 
clinically insignificant cancer on TPM. 
Negative Predictive Value (NPV) = d / (b+d) where, d = number of men testing negative on 
MRI and negative for clinically significant cancer on TPM, b= number of men testing 
negative on MRI who have clinically significant cancer on TPM. 
Sensitivity = a / (a+b) where, a = number of men testing positive on MRI and positive for 
clinically significant on TPM, b = number of men testing negative for MRI who have 
clinically significant cancer on TPM. 
Positive Predictive Value (PPV) = a / (a+c) where, a = number of men testing positive on 
MRI and positive for clinically significant on TPM, c = number of men testing positive on 
MRI who have clinically insignificant cancer on TPM. 
 
 Varying the Definitions of Clinical Significance at TPM 4.8.2
2 by 2 tables were constructed for MRI comparison to TPM at patient level for: 
Definition 1 disease 
Definition 2 disease 
All cancer 
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 MRI Targeted Biopsy Analysis  4.8.3
Targeted biopsies were analysed as both separate targeting strategies and pooled targeted 
sampling using both methods to assess validity. The detection rate of cancer and the 
proportion of clinically significant disease detected or missed by targeting were assessed. 
Overall accuracy was assessed using receiver operating characteristic curves.  
Additionally, these performance characteristics were assessed when the MRI score 
threshold was changed from 4 to 3. Each targeted biopsy strategy was also evaluated 
separately, and as pooled targeted approach. 
 Secondary Analysis 4.8.4
Inter-observer variability was assessed using kappa agreement. STATA version 3.0 software 
was used with any tests of significance using p=0.05 as the threshold for statistical 
significance.  
Further analysis of targeted cores was performed to assess whether targeted sampling 
errors were a result of inaccurate localisation by MRI (Out of field miss) or were due to a 
likely mis-registration/Targeting error (In-field errors). For this analysis each individual case 
was assessed to establish the zone in which the targeted biopsy was aimed at, compared 
with the zone in which the maximal Gleason grade/UCL risk score at TPM was obtained. 
 
4.9 Analysis of Prostate HistoScanning™ and Transperineal Template 
Prostate Mapping Biopsy Results 
The visit one HistoScanning report was used for the main analysis and the second 
HistoScanning examination results were used only for test reproducibility analysis. 
Results were presented in a 2 by 2 tables (as shown below Table 29) and estimates 
presented together with 95% confidence intervals (CI). 
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Table 29. 2 by 2 tables to demonstrate accuracy of HistoScanning with respect to 
TPM 
  PHS   
  +ve -ve Total 
TPM +ve a b a+b 
 - ve c d c+d 
 
Specificity = d / (c+d) where, d = number of men testing negative on HistoScanning™ and 
negative for clinically significant cancer on TPM, c = number of men testing positive on 
HistoScanning™ who have clinically insignificant cancer on TPM. 
Negative Predictive Value (NPV) = d / (b+d) where, d = number of men testing negative on 
HistoScanning™ and negative for clinically significant cancer on TPM, b= number of men 
testing negative on HistoScanning™ who have clinically significant cancer on TPM. 
Sensitivity = a / (a+b) where, a = number of men testing positive on HistoScanning™ and 
positive for clinically significant on TPM, b = number of men testing negative for 
HistoScanning™ who have clinically significant cancer on TPM. 
Positive Predictive Value (PPV) = a / (a+c) where, a = number of men testing positive on 
HistoScanning™ and positive for clinically significant on TPM, c = number of men testing 
positive on HistoScanning™ who have clinically insignificant cancer on TPM. 
 
 Varying the Definitions of Clinical Significance at TPM 4.9.1
2 by 2 tables were constructed for HistoScanning™ comparison to TPM at patient level for 
Definition 1 disease, Definition 2 disease and all cancer. 
 
 PHS Targeted Biopsy Analysis 4.9.2
The ability of PHS to accurately locate cancer using targeted biopsy was assessed. The 
detection rate of cancer and the proportion of clinically significant disease detected or 
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disease missed by targeting was assessed. Overall accuracy was assessed using receiver 
operating characteristic curves. 
 HistoScanning Test Re-Test Reproducibility 4.9.3
The test retest reproducibility of HistoScanning was assessed using kappa analysis for the 
strength of agreement between the two scans and paired test (McNemar) to measure 
variability between the two HistoScanning reports.  
This was done for both the variability between the 8818 and 8848 at the consent visit 
In addition, the 8818 T0 at consent and the 8818 T2 performed at the time on template 
biopsy, and also the 8848 probe performed at the two time points T0 and 8848 T2 were 
compared. 
 
 Biomarker Analysis 4.9.4
For both the urine biomarker EN2 and the seminal marker (FScan), performance was 
assessed by calculation of the AUROC for the technology. 
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5 PICTURE Results 
The PICTURE study aimed to assess the use of imaging to accurately detect and localise 
prostate cancer. The primary outcome results include the whole gland analysis of both of 
the index imaging tests, (mp-MRI and Prostate HistoScanning) for their ability to accurately 
rule out significant prostate cancer.  An important secondary analysis is the ability of each 
imaging modality to give an accurate location for targeted sampling of the gland. 
Therefore, this chapter is structured to first address the overall demographic data, and 
then to address each modality in turn for its primary outcome result sensitivity and NPV, 
and to also address its ability to accurately guide targeting. 
Further secondary outcomes are discussed in a second results chapter (Chapter 6). 
5.1 Recruitment 
Picture recruited at University College Hospitals London, consecutively from 11th January 
2012 and completed recruitment on 29th January 2014. Figure 57 demonstrates the 
PICTURE recruitment STARD flow diagram. 
Overall, 330 men were recruited to the study. A number of men were withdrawn leaving 
249 for final study analysis. 
The reasons for withdrawal included: - 61 men who had a gland sizes too large to allow 
adequate sampling density, 9 men who were withdrawn at their own request, 4 men were 
withdrawn for medical reasons and 7 men withdrew for other reasons. 
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Figure 57. PICTURE recruitment STARD flow diagram. 
 
 
5.2 Baseline Demographic Data 
Three-hundred and thirty men were enrolled with mean (SD) age of 63 (7) years.  Median 
(IQR) PSA at consent was 7.4 (5.3-10.7) ng/ml. Median (IQR) number of previous biopsies 
was 1 (1-2), with men having had from 1 to 5 prior prostate biopsies (Table 30). Pre-study 
TRUS biopsy Gleason grade date is shown inTable 31.  
81 men withdrew leaving 249 for primary analysis. Men eligible for analysis had mean (SD) 
age 62(7) years, median (IQR) PSA 6.8 (4.98-9.50) ng/ml and median (IQR) number of 
previous biopsies 1 (1-2) and mean (SD) gland size 37ml (15.5).  
Median (IQR) number of days between mp-MRI and biopsy was 78 (43-107).  
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Table 30. PICTURE Patient demographics 
 All men  
n=330 
Men eligible for analysis 
n=249 
Characteristic Median (IQR) Median (mean, SD, range) 
Age, years 63 (42-83) 62 (62.0, 7.16, 42-83) 
PSA concentration at 
consent, ng/ml  
7.4 (0.7-58.05) 6.8 (7.81, 4.26, 0.7-30.3) 
 Mean (SD) Mean (SD) 
Number of previous 
biopsies 
1.49, (0.79) 1.41 (0.69) 
Number of previous 
negative biopsies 
0.69 ( 0.96) 0.51 (0.79) 
Number of previous 
positive biopsies 
0.79 (0.65) 0.87 (0.62) 
MRI Prostate volume, cc 46.48 (26.53) 39.1 (15.5) 
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Table 31. Study entry TRUS biopsy Gleason grading 
Gleason score on pre-study 
TRUS biopsy 
All men 
 n=330 
Number of men (%) 
Men eligible for analysis 
n=249 
Number of men (%) 
Missing info 22 (6.7) 12 (4.8) 
Benign 101 (30.6) 64 (25.7) 
3+3 147 (44.6) 121 (48.6) 
3+4 55 (16.7) 48 (19.3) 
4+3 5 (1.5) 4 (1.61) 
Total 330 249 
 
5.3 Template Mapping Biopsy (TPM) Results 
Following template biopsy 40 men (16%) were found to be benign, 41% of men (n=103) had 
Definition one disease detected at TPM.   A mean of 48.7 (SD 12.3, range 15-86) cores were 
taken per man at TPM. Maximum cancer core length detected was 15mm. 
Disease characteristics on the reference test, TPM biopsy, are shown in Table 32. 
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Table 32. Template biopsy disease distribution for eligible men n=249 
 Mean (SD) 
Total number of cores 48.69 (12.3) 
Number of cancer cores 6.88 (5.95) 
MCCL (mm) 4.65 (3.59) 
 
Gleason Risk group n (%) Number % 
Benign 40 16.1 
3+3 66 26.5 
3+4 or 4+3 139 55.8 
>/= 4+4 3 1.2 
(3+5) 1 0.4 
 
UCL Risk group  Number of men % 
Benign 40 16.1 
Insignificant (G3+3 or MCCL</=3mm) 41 16.5 
Intermediate  
(Definition 2= G3+4 or MCCL>4mm) 
168 67.5 
High  
( Definition 1= G4+3 or MCCL>6mm) 
103 41.4 
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5.4 Whole Gland MRI Results 
 Report Demographics 5.4.1
57% of men (n=142) were considered highly unlikely or unlikely to have significant prostate 
cancer, 16% (n=39) of men were equivocal and 27% (n=68) were felt likely of highly likely to 
have clinically significant disease according to the MRI consensus agreed scoring system 
used in PICTURE (Dickinson et al., 2011)  
50 men did not have a lesion on MRI. Of those with a lesion average size of index lesion 
was 11.7mm (SD 6.7).  (Table 33) 
Of the lesions reported the majority 50.6% (n=126) were thought to contain Gleason 3+4 
disease. 
Table 33. MRI characteristics 
Overall MRI score for UCL definition 1 
disease 
n= % 
1-2                highly unlikely/unlikely 142 57 
3                                            equivocal 39 16 
4-5                         likely/highly likely 68 27 
MRI lesion details 
0 50 20 
1 198 79.5 
2 74 29.7 
3 14 5.6 
Index lesion estimated Gleason grade   
Benign 7 2.8 
3+3 43 17.3 
3+4 126 50.6 
4+3 22 8.8 
4+4 1 0.4 
Any pattern 5 0 0 
 Mean SD 
Index lesions size (mm)  11.7 6.7 
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 Primary Outcome 1 5.4.2
First, using mpMRI score ≥ 4 as a positive test, mpMRI demonstrated sensitivity of 80.6% 
(95% CI 71.6-87.7) and specificity 68.5% (95% CI 60.3-75.9), NPV 83.3% (95% CI 75.4-89.5) 
and PPV 64.3% (95% CI 55.4-72.6), for the detection of clinically significant disease.  Area 
under ROC curves was 0.76 (95% CI 0.69-0.80). (Figure 58) 
Secondly, incorporating mpMRI score>/=3 (equivocal) as a positive test sensitivity was 
97.1% (95% CI 92-99), specificity 21.9% (95% CI 15.5-29.5), NPV 91.4% (95% CI 76.9-98.1) 
and PPV 46.7% (95% CI 35.2-47.8). (Table 34) 
 
Table 34. mpMRI performance characteristics for Definition 1 disease  
 Sensitivity 
% 
 (95% CI) 
Specificity 
%  
(95% CI) 
PPV  
% 
(95% CI) 
NPV 
 % 
(95% CI) 
Positive 
likelihood 
ratio 
(95% CI) 
Negative 
likelihood 
ratio 
(95% CI) 
mpMRI 
Score  
≥4 
80.6 
(71.6-87.7) 
68.5 
(60.3-75.9) 
64.3 
(55.4-72.6) 
83.3 
(75.4- 
89.5) 
2.56 
(1.98-3.31) 
0.28 
(0.19-
0.43). 
mpMRI 
Score 
≥3 
97.09 
(92-99) 
21.92 
(15.5-29.5) 
46.73 
(35.2-47.8) 
91.4 
(76.9- 
98.1) 
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Figure 58. ROC curve analysis for mpMRI detection of disease 
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5.5 MRI Targeting Results 
The analysis of the MRI targeting results has been divided to first analyse each targeting 
strategy according to all men targeted for MRI score 3 or above. This has been done for 
each modality ‘Cognitive MRI’ targeting, ‘MRI/US registration’ targeting and pooled results 
of both modalities, for Definition one disease. These results are outlined in sections 5.5.1 to 
5.5.4. 
Results have then been explored for altering the target group to only include those men 
targeted for lesions scoring 4 or above on MRI and therefore deemed ‘likely’ or ‘highly 
likely’ to be malignant on the mp-MRI likert scoring scale, once again results are given for 
Definition one disease. These results are outlined in sections 5.5.5 onwards. 
 
 MRI ‘Cognitive’ Targeted Results - MRI Score ≥3   5.5.1
In the 199 men who underwent MRI cognitive targeted biopsy, sensitivity was 47.9% (95% 
CI 37.9-58.4), specificity 88.3% (95% CI 80.5-93.8), NPV 64.5% (95% CI 56.0-72.4) and PPV 
79.3% (66.6-88.8), for the detection of UCL definition 1 disease, when using MRI score ≥ 3 
as the cut off (Table 35).  
MRI cognitive targeted biopsies identified 14/58 (21%) men as clinically significant who had 
been incorrectly classified as insignificant or benign at TPM biopsy. Cognitive MRI biopsies 
incorrectly classified 50 men (52%) as benign or insignificant when they were found to have 
significant disease on TPM. (Table 35) 
Table 35. MRI Cognitive vs TPM biopsies by UCL risk criteria 
  Template  Mapping biopsies  
  Benign Insignificant Definition 2 Definition 1 Total 
MRI 
cognitive 
targeted 
biopsies 
No MRI 
target 
22 12 9 7 50 
Benign 15 22 24 12 73 
Insignificant 0 3 11 12 26 
Definition 2 0 3 13 26 42 
Definition 1  3 1 8 46 58 
 Total 40 41 65 103 249 
Key to shading 
No MRI target 
Significant disease missed by TPM 
Significant disease missed by targeting  
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 MRI/US Registration Targeted Results - MRI Score ≥3  5.5.2
In the 169 (30 cases had technical failure of the software) who had MRI/US fusion targeted 
biopsies sensitivity was 51.8% (95% CI 40.6-62.9), specificity 88.4% (95% CI 79.7-94.3), NPV 
65.5% (95% CI 56.1-74.1) and PPV 81.8% (95% CI 68.0-90.6), when using MRI score ≥ 3 as 
the cut off (Table 36).  
MRI/US fusion targeted biopsies identified 10/53 (18.8%) men as clinically significant who 
had been incorrectly classified as insignificant or benign at TPM biopsy. Fusion targeted 
biopsies incorrectly classified 40 men (38.8%) as benign or insignificant when they were 
found to have significant disease on TPM.  
Table 36. MRI/US registration targeted biopsy 
  Template biopsies  
  Benign Insignificant Definition 2 Definition 
1 
 
MRI/US 
registration 
targeted 
biopsies 
No MRI/US 
target 
25 16 19 20 80 
Benign 13 21 16 11 61 
Insignificant 0 2 8 10 20 
Definition 2 0 1 15 19 35 
Definition 1  2 1 7 43  53 
  40 41 65 103 249 
Key to shading 
No MRI target 
Significant disease missed by TPM 
Significant disease missed by targeting  
 
 Pooled MRI Targeted Results - MRI Score ≥3  5.5.3
Using the pooled MRI targeted data for 200 men having targeted biopsies for an MRI score 
≥3; there was 78% direct agreement in cancer classification between targeted biopsy and 
TPM, with targeting and TPM agreeing on the presence or absence of disease in 156 men. 
Demographic data for these men is shown in Table 37. 
18/81 (22%) men with clinically significant disease were found to be incorrectly risk 
stratified by TPM; 3 of these had been classified as benign at TPM. Pooled MRI targeting 
failed to identify 34/103 (33%) of men with clinically significant disease identified by TPM. 
(Table 38) 
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Table 37. MRI pooled targeted biopsy demographics n=200 
 Mean (SD) 
Total number of cores 4.26 (2.37) 
Number of cancer cores 1.87 (1.03) 
 
Gleason Risk group n (%) Number % 
Benign 56 28.0 
3+3 38 19.0 
3+4 83 41.5 
4+3 18 9.0 
>/= 4+4 5 2.5 
 
Table 38. Pooled MRI Targeted results 
  Template  Mapping biopsies  
  Benign Insignificant Definition 
2 
Definition 
1 
 
MRI 
targeted 
biopsies 
No MRI 
target 
22 12 9 6 49 
Benign 15 19 15 7 56 
Insignificant 0 4 10 8 22 
Definition 2 0 4 18 19 41 
Definition 1  3 2 13 63 81 
  40 41 65 103 249 
Key to shading 
No MRI target 
Significant disease missed by TPM 
Significant disease missed by targeting  
 
Further analysis of pooled MRI targeted data was performed to identify the source of error- 
MRI miscalls vs. target registration error. This analysis demonstrated that in the 55 men 
who underwent MRI targeted sampling that did not yield a cancer diagnosis; 15 (30%) of 
these had no cancer on the reference test of TPM. They were therefore correctly classified 
by the targeted sampling.  
Analysis of MRI scores for these men revealed that 10/15 men (66.6%) were felt to be 
unlikely and highly unlikely of having significant disease (MRI score 1 and 2), and 4/15 men 
(26.6%) were rated equivocal (MRI score 3). Only one man (6%) was incorrectly rated as 
likely to have significant disease (MRI score 4) 
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Of the 40 men who had cancers detected at TPM and therefore were incorrectly classified 
by MRI targeting as benign, only 5 of these men (12.5%) had clinically significant disease 
according to UCL definition 1 criteria.  
22 out of 40 (55%) were in-field targeting errors (i.e. target localisation errors/mis-
registration) and thus the MRI localisation of disease was correct. 21 out of 22 (96%) were 
targeted to the correct quadrant in which the reference test detected the maximal cancer 
burden. One patient had disease in the quadrant targeted but maximal cancer burden in a 
different area. 
18 of those for whom MRI targeting was benign (45%) were out of field errors and thus 
represent mis-localisation by MRI. 9 of these were called on the incorrect hemi-prostate. 9 
were targeted to the correct hemi-prostate but were directed to the incorrect quadrant 
(anterior/posterior). 
 
 Summary MRI Targeting Results - MRI Score ≥3  5.5.4
MRI-targeted biopsies had a detection rate of 78.6% (95% CI 69.9-82.1) for clinically 
significant cancer when lesions scoring 3 or greater on mpMRI were considered. 
Two analyses were carried out: one including all the men who had not undergone targeted 
biopsy and assuming them to be benign; the other including only those men targeted.  
When assessing the performance characteristics for MRI targeted biopsy in the cohort 
(including those not targeted) sensitivity was 61.2% (95%CI 51.1-70.6), specificity 87.7 
(95%CI 81.2-92.5), NPV 76.2 (95%CI 69.0-82.4) and PPV 77.8 (95%CI 69.0-82.4). (Table 39) 
By excluding those men without a target on MRI and assessing only those who had a 
targeted biopsy, an increase in sensitivity was seen, but a decrease in specificity and NPV.  
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Table 39. MRI Targeted performance characteristics for detection of UCL Definition 
1 disease for MRI score ≥3. (Including men not targeted and assuming non targeted 
are benign) 
 Sensitivity 
% 
(95% CI) 
Specificity 
% 
(95% CI) 
PPV 
% 
(95% CI) 
NPV 
% 
(95% CI) 
AUC 
 
(95% CI) 
MRI Cognitive  44.7 
(34.9-54.8) 
91.8 
(86.1-95.7) 
79.3 
(66.6-88.8) 
70.2 
(63.1-76.5) 
0.68 
(0.63-0.74) 
MRI/US fusion 41.7 
(32.1-51.9) 
93.2 
(87.8-96.7) 
81.1 
(68.0-90.6) 
69.4 
(62.4-75.8) 
0.67 
(0.62-0.78) 
MRI Targeted 
Pooled results 
61.2 
(51.1-70.6) 
87.7 
(81.2-92.5) 
77.8 
(67.2-86.3) 
76.2 
(69.0-82.4) 
0.74 
(0.69-0.80) 
 
Table 40. MRI Targeted performance characteristics for detection of UCL Definition 
1 disease, excluding non-targeted men, for MRI score ≥ 3 
 Sensitivity 
% 
(95% CI) 
Specificity 
% 
(95% CI) 
PPV 
% 
(95% CI) 
NPV 
% 
(95% CI) 
AUC 
 
(95% CI) 
MRI Cognitive  47.9 
(37.6-58.4) 
88.3 
(80.5-93.8) 
79.3 
(66.6-88.8) 
64.5 
(56.0-72.4) 
0.68 
(0.62-0.74) 
MRI/US fusion 51.8 
(40.6-62.9) 
88.4 
(79.7-94.3) 
81.1 
(68.0-90.6) 
65.5 
(56.1-74.1) 
0.70 
(0.64-0.76) 
MRI Targeted 
Pooled results 
64.9 
(54.6-74.4) 
82.5 
(73.8-89.3) 
77.8 
(67.2-86.3) 
71.4 
(62.4-79.3) 
0.74 
(0.68-0.80) 
 MRI Cognitive Targeted Results - MRI Score ≥ 4  5.5.5
When the target condition for biopsy was changed to exclude those men deemed equivocal 
on MRI (MRI score= 3), and to only include those men with lesions ‘likely’ (MRI score 4) or 
‘highly likely’ (MRI score 5) to involve significant disease, there were 137 men who 
underwent MRI cognitive targeting.  
For the 137 men who underwent MRI cognitive targeted to MRI lesions ≥ 4 biopsy, 
sensitivity was 51.8% (95% CI 40.7-62.7), specificity 80.8% (95% CI 67.5-90.4), NPV 50.6% 
(95% CI 39.4-61.8) and PPV 81.5% (95% CI 68.6-90.7, for the detection of UCL definition 1 
disease. (Table 44) 
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MRI cognitive targeted biopsies identified 10/54 (19%) men as clinically significant who had 
been incorrectly classified as insignificant or benign at TPM biopsy. Cognitive MRI biopsies 
incorrectly classified 41 men (29%) as benign or insignificant when they were found to have 
significant disease on TPM. (Table 41) 
Table 41. MRI Cognitive (MRI score ≥ 4) vs TPM biopsies by UCL risk criteria 
  Template  Mapping biopsies  
  Benign Insignificant Definition 
2 
Definition 
1 
 
MRI 
cognitive 
targeted 
biopsies 
Benign 3 6 13 8 30 
Insignificant 0 1 8 9 18 
Definition 2 0 3 8 24 35 
Definition 1  3 1 6 44 54 
Totals 6 11 35 85 137 
Key to shading 
Significant disease missed by TPM 
Significant disease missed by targeting 
 
 MRI/US Registration Targeted Results - MRI Score ≥ 4  5.5.6
In the 137 men who had MRI/US fusion targeted biopsies for MRI lesions ≥ 4, biopsy 
sensitivity was 56.0% (95% CI 44.1-67.5), specificity 83.3% (95% CI 68.6-93.0) , NPV 51.5% 
(95%CI 39.0-63.8), and PPV 85.7 (95% CI 72.8-94.1) (Table 44).  
MRI/US fusion targeted biopsies identified 7/49 (14.2%) men as clinically significant who 
had been incorrectly classified as insignificant or benign at TPM biopsy. Fusion targeted 
biopsies incorrectly classified 33 men (38.8%) as benign or insignificant when they were 
found to have significant disease on TPM.  
Table 42. MRI/US registration targeted biopsy- MRI score ≥ 4 
  Template biopsies  
  Benign Insignificant Definition 2 Definition 1 Total 
MRI/US 
registration 
targeted 
biopsies 
No MRI/US 
target 
2 2 6 10 20 
Benign 2 7 9 7 25 
Insignificant 0 1 5 9 15 
Definition 2 0 0 11 17 28 
Definition 1  2 1 4 42 49 
Total 6 11 35 85 137 
Key to shading 
No MRI/US target 
Significant disease missed by TPM 
Significant disease missed by targeting  
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 Pooled MRI Targeted Results - MRI Score ≥ 4  5.5.7
Using the pooled MRI targeted data for the 137 men having targeted biopsies for an MRI 
score ≥ 4, there was 57% direct agreement in cancer classification between targeted biopsy 
and TPM, with targeting and TPM agreeing on the presence or absence of disease in 
77/137 men.  
14/74 (18.9%) men with clinically significant disease were found to be incorrectly risk 
stratified by TPM. Three of these had been classified as benign at TPM. Pooled MRI 
targeting failed to identify 25/85 (29%) of men with clinically significant disease identified 
by TPM. (Table 43) 
Table 43. Pooled MRI Targeted results- MRI score ≥4 
  Template  Mapping biopsies  
  Benign Insignificant Definition 
2 
Definition 
1 
Total 
MRI 
targeted 
biopsies 
Benign 3 5 7 2 17 
Insignificant 0 1 6 6 13 
Definition 2 0 3 13 17 33 
Definition 1  3 2 9 60 74 
Total 6 11 35 85 137 
Key to shading 
Significant disease missed by TPM 
Significant disease missed by targeting 
 
 Summary MRI Targeting Results MRI score ≥ 4 5.5.8
Table 44 demonstrates the MRI targeted biopsy characteristics for those men targeted for 
an MRI lesion ≥ MRI score 4.  
Table 44. MRI Targeted performance characteristics for detection of UCL Definition 
1 disease excluding non-targeted men, for MRI score ≥4 
 Sensitivity 
% 
(95% CI) 
Specificity 
% 
(95% CI) 
PPV 
% 
(95% CI) 
NPV 
% 
(95% CI) 
AUC 
 
(95% CI) 
MRI Cognitive  
51.8 
(40.7-62.7) 
80.8 
(67.5-90.4) 
81.5 
(68.6-90.7) 
50.6 
(39.4-61.8) 
0.66 
(0.46-0.74) 
MRI/US fusion 
56.0 
(44.1-67.5) 
83.3 
(68.6-93.0) 
85.7 
(72.8-94.1) 
51.5 
(39.0-63.8) 
0.70 
(0.62-0.78) 
MRI Targeted 
Pooled results 
70.6 
(59.7-80.0) 
73.1 
(59.0-84.4) 
81.1 
(70.3-89.3) 
60.3 
(47.2-72.4) 
0.72 
(0.64-0.80) 
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 Altering the MRI Threshold for Biopsy 5.5.9
Table 45 has been included to allow easy comparison between the performance 
characteristics of the two thresholds for MRI targeted biopsy. 
As anticipated sensitivity for the detection of clinically significant disease is increase with 
increasing MRI reporter confidence on the likelihood of disease (i.e. higher MRI likert scale 
scores). The increase in sensitivity is possible without a gross impact on other performance 
characteristics, and with similar percentages of men undergoing incorrect classification as 
benign by targeted biopsy in comparison to TPM (29% for MRI target ≥ 4 vs. 33% for MRI 
target ≥ 3). 
 
Table 45. Comparison of performance characteristics between targeting for MRI 
leison≥3 and MRI lesion≥4 
 Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
PPV 
(95% CI) 
NPV 
(95% CI) 
AUC 
(95% CI) 
MRI Cognitive 
MRI score ≥3 
47.9 
(37.6-58.4) 
88.3 
(80.5-93.8) 
79.3 
(66.6-88.8) 
64.5 
(56.0-72.4) 
0.68 
(0.62-0.74) 
MRI Cognitive 
MRI score ≥4 
51.8 
(40.7-62.7) 
80.8 
(67.5-90.4) 
81.5 
(68.6-90.7) 
50.6 
(39.4-61.8) 
0.66 
(0.46-0.74) 
MRI/US fusion 
MRI Score ≥3 
51.8 
(40.6-62.9) 
88.4 
(79.7-94.3) 
81.1 
(68.0-90.6) 
65.5 
(56.1-74.1) 
0.70 
(0.64-0.76) 
MRI/US fusion 
MRI score ≥4 
56.0 
(44.1-67.5) 
83.3 
(68.6-93.0) 
85.7 
(72.8-94.1) 
51.5 
(39.0-63.8) 
0.70 
(0.62-0.78) 
MRI Targeted 
Pooled results 
MRI score ≥3 
64.9 
(54.6-74.4) 
82.5 
(73.8-89.3) 
77.8 
(67.2-86.3) 
71.4 
(62.4-79.3) 
0.74 
(0.68-0.80) 
MRI Targeted 
Pooled results 
MRI score ≥4 
70.6 
(59.7-80.0) 
73.1 
(59.0-84.4) 
81.1 
(70.3-89.3) 
60.3 
(47.2-72.4) 
0.72 
(0.64-0.80) 
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5.6 Whole Gland Prostate HistoScanning Results 
 Report Demographics 5.6.1
Due to a combination of hardware technical failure and loss of PHS data prior to analysis 29 
men who remained in the study did not have PHS scans available for analysis: Figure 59 
outlines the patient flow for PHS patients in the PICTURE study. 
Figure 59. PICTURE Prostate HistoScanning flow diagram 
 
The reference test (TPM) found cancer meeting the target definition for significance in 
41.8% of men (n=92), further disease characteristics at TPM are shown in Table 46. 
Prostate HistoScanning cancer volumes were on average 3.4cc (SD 2.27), with the primary 
most significant lesion volumes averaging 2.7cc (SD 2.3).PHS found 174 men to have cancer 
volumes greater than 1.3cc. 
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Table 46. Template biopsy disease distribution for all study eligible men n=249, and 
men eligible for PHS analysis n=220 
 Mean (SD) 
Total number of cores 48.69 (12.3) 
Number of cancer cores 6.88 (5.95) 
MCCL (mm) 4.65 (3.59) 
 All study eligible men 
N=249 
For men in PHS 
analysis n=220 
Gleason Risk group n (%) Number % Number % 
Benign 40 16.1 28 12.7 
3+3 66 26.5 63 28.6 
3+4 or 4+3 139 55.8 125 56.8 
>/= 4+4 3 1.2 3 1.4 
(3+5) 1 0.4 0 0 
 
UCL Risk group  Number 
of men 
% Number 
of men 
% 
Benign 40 16.1 28 12.7 
Insignificant (G3+3 or MCCL</= 3mm) 41 16.5 38 17.3 
Intermediate (Definition 2= G3+4 or MCCL> 
4mm) 
168 67.5 165 75.0 
High ( Definition 1= G4+3 or MCCL> 6mm) 103 41.4 92 41.8 
 
 Primary Outcome 1 5.6.2
Prostate HistoScanning showed 70.3% (95% CI 59.8-79.5) sensitivity for the detection of 
cancer volumes ≥1.3cc. Specificity, positive predictive and negative predictive values were 
14.7% (95% CI 9.1-22.0), 36.8% (95% CI 29.6-44.4) and 41.3% (95%CI 27.0-56.8) 
respectively. 
When the target condition was changed to ≥0.5cc cancer volumes sensitivity was 93.4% 
(95% CI 86.2-97.5) and specificity dropped to 0.8% (95% CI 0.00-4.2). (Table 47) 
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Table 47. PHS Performance Characteristics for Definition 1 Disease  
 Sensitivity  
% 
(95% CI) 
Specificity  
% 
(95% CI) 
PPV 
% 
(95% CI) 
NPV 
% 
(95% CI) 
AUC 
 
(95% CI) 
PHS lesion  
≥1.3cc 
70.3 
(59.8-79.5) 
14.7 
(9.1-22.0) 
36.8 
(29.6-44.4) 
41.3 
(27.0-56.8) 
 
0.43 
(0.37-0.48) 
PHS lesion 
≥0.5cc 
93.4 
(86.2-97.5) 
0.8 
(0.0-4.2) 
39.9 
(33.3-46.8) 
14.3 
(0.4-57.9) 
0.47 
(0.44-0.50) 
 
5.7 Prostate HistoScanning Targeting Results 
213 of 220 men had PHS lesions targeted. Sensitivity was 13.6% (95%CI 7.3-22.6), specificity 
97.6% (95%CI 93.1-99.5), NPV 61.6% (95%CI 54.5-68.4) and PPV 80% (95%CI 51.9-95.7). 
(Table 48) 
Of the 213 men targeted with PHS targeted biopsy, 23% showed direct correlation with the 
TPM biopsy result (Table 49). 76 men (36%) were incorrectly classified as benign or 
insignificant at Definition 1 threshold when they actually harboured Definition 1 
significance disease at TPM. Three men (1.4%) were found to have significant disease at 
PHS biopsies that were incorrectly classified as insignificant at TPM. 
Table 48. PHS Targeted performance characteristics for detection of UCL Definition 
1 disease (excluding non-targeted men) 
 Sensitivity  
% 
(95% CI) 
Specificity  
% 
(95% CI) 
PPV 
% 
(95% CI) 
NPV 
% 
(95% CI) 
AUC 
 
(95% CI) 
PHS target  
13.6 
(7.3-22.6) 
97.6 
(93.1-99.5) 
80 
(51.9-95.7) 
61.6 
(54.5-68.4) 
0.55 
(0.51-0.59) 
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Table 49. PHS Targeted results for definition one disease  
  Template  Mapping biopsies  
  Benign Insignificant Definition 
2 
Definition 
1 
Totals 
PHS 
targeted 
biopsies 
Benign 26 32 44 58 160 
Insignificant 0 4 8 9 21 
Definition 2 0 0 8 9 17 
Definition 1  1 0 2 12 15 
 Totals 27 36 62 88 213 
Significant disease missed by TPM 
Significant disease missed by targeting  
 
5.8 Discussion of Prostate HistoScanning Results 
The Prostate HistoScanning results from the PICTURE study have shown that PHS has a 
poor ability to discriminate benign from malignant tissue. The AUC for PHS is worse than 
chance.  
Although PHS seems to portray high acceptable sensitivity for disease detection, when 
assessing the whole gland performance characteristics this sensitivity can be seen to rise as 
the lesion size decreases from 1.3cc to 0.5cc: this is likely to be the effect of the false 
positive HistoScanning signal that plagues the modality. 
The targeting results show that 75% of lesions targeted by PHS are found to be benign, with 
62% of these being incorrectly assigned to the benign group. Also, by adopting a PHS 
targeted biopsy strategy, 36% of men with Definition 1 clinically significant disease would 
be incorrectly classified. 
Only 23% of men (n=50/213) had direct correlation between their disease status at TPM 
and PHS targeted biopsy.   
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6 Secondary PICTURE Results 
6.1 MRI Inter-Reporter Reproducibility Results 
As previously stated, for a test to be useful as a valid diagnostic test, it requires not only 
adequate performance characteristics for the detection of disease but also must be 
reproducible when interpreted by different analysts. 
To assess the inter-reporter reproducibility of mpMRI, a selection of 50 mpMRI’s within the 
PICTURE Study were re-reported by a second radiologist. The reporter was blinded to 
previous reports and TPM histopathology but had necessary clinical details available, 
namely pre-study PSA and biopsy result. 
Tables were constructed to assess agreement between the reporting radiologist, for any 
cancer, definition 2 disease, and definition 1 disease. Percentage agreement and Kappa 
values were calculated for each agreement. 
Kappa values allow for a measure of agreement - measuring direct 
agreement/disagreement. Weighted kappa values try to account for the difference in levels 
of disagreement; namely, an MRI score of 3 to 4 is less of a disagreement, than an MRI 
score of 1 to 5, weighted kappa values allow for this. 
Kappa agreements can be interpreted as follows (Altman, 1991): 
Table 50. Kappa Values 
Value of K Strength of agreement 
<0.2 Poor 
0.21-0.40 Fair 
0.41-0.60 Moderate 
0.61-0.80 Good 
0.81-1.00 Very good 
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Table 51. MRI Comparison for Any Disease 
  MRI Reporter 2  
  MRI Score 
2 
MRI Score 
3 
MRI Score 
4 
MRI Score 
5 
Total 
MRI 
reporter 
1 
MRI Score 2 0 0 0 0 0 
MRI Score 3 1 15 4 1 21 
MRI Score 4 0 1 7 0 8 
MRI Score 5 0 3 6 12 21 
 Totals 1 19 17 13 50 
Key 
Direct MRI score agreement 
 
For any disease the two MRI reporters demonstrated a direct agreement in 34/50 MRI’s, 
equating to a direct agreement of 68% (Table 51). Kappa values for this agreement = 0.53, 
with standard error= 0.09, demonstrating moderate agreement. 
Using weighted kappa, agreement increases to 90%. With kappa values of 0.59, standard 
error was 0.11.   
Table 52. MRI comparison for Definition 2 Disease 
  MRI Reporter 2  
  MRI Score 
2 
MRI Score 
3 
MRI Score 
4 
MRI Score 
5 
Total 
MRI 
reporter 
1 
MRI Score 2 2 4 1 1 8 
MRI Score 3 1 15 3 0 19 
MRI Score 4 0 4 4 3 11 
MRI Score 5 1 0 3 8 12 
 Totals 4 23 11 12 50 
Key 
Direct MRI score agreement 
 
Assessing the agreement when radiologists were asked to score for the likelihood of 
definition 2 disease cancer (Table 52), agreement worsened slightly to 58% (n=29/50), with 
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Kappa values = 0.41, standard error = 0.08 (moderate agreement). Weighted agreement = 
87%, K=0.52, standard error=0.10 (moderate agreement). 
Table 53. MRI reporter comparison for Definition 1 Disease 
  MRI Reporter 2  
  MRI 
Score 1 
MRI 
Score 2 
MRI 
Score 3 
MRI 
Score 4 
MRI 
Score 5 
Total 
MRI 
reporter 
1 
MRI Score 
1 
3 1 4 0 1 9 
MRI Score 
2 
0 13 8 1 0 22 
MRI Score 
3 
0 1 3 0 1 5 
MRI Score 
4 
0 0 3 3 0 6 
MRI Score 
5 
0 0 1 2 5 8 
Totals 3 15 19 6 7 50 
Key 
Direct MRI score agreement 
 
For definition 1 disease agreement on MRI score between the two reporters was 54% (n= 
27/50), K= 0.41, standard error= 0.067 (moderate agreement). Weighted agreement was 
83.5%, K=0.53, standard error=0.089 (moderate agreement) (Table 53). 
When comparing MRI scores for each reported to histology on TPM, there were minimal 
differences between each reporter in terms of AUROC analyses (Table 54). 
Table 54. AUROC curve analysis for each reporter  
 Reporter 1 ROC (95%CI) Reporter 2 ROC (95%CI) 
Any Cancer 0.61 
(042-0.79) 
0.60 
(0.37-0.82) 
Definition 2 0.76 
(0.63-0.89) 
0.75 
(0.61-0.89) 
Definition 1  0.72 
(0.58-0.86) 
0.70 
(0.56-0.84) 
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 Discussion of Multiparametric MRI Reliability Results 6.1.1
The mpMRI inter-reporter reliability analyses showed an acceptable level of agreement 
between two independent radiologists when scoring MRI using consensus agreed MRI 
‘likert’ scale reporting. Kappa values for all definitions of disease significance demonstrate 
moderate agreement. 
Also, there was little variation in AUROC curves for disease detection (sensitivity and 
specificity) between each observer for all definitions of significance. 
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6.2 Prostate HistoScanning Reproducibility Results 
 Test re-test Reliability - 8818 to 8818 Comparison 6.2.1
70 men had both 8818 scans at consent and prior to TPM. Mean gland volumes at consent 
were 39.43cc (SD 1.73); prior to TPM, mean gland volumes were 41.7cc (SD 1.82).  
t= 3.28, Pr (T<t) =0.9992 Pr (|T|>|t|) =0.0016 Pr (T>t) =0.0008 
Figure 60 shows a Bland Altman plot showing limits of agreement for gland volume, for 
gland volume on probe 8818 the average difference between the 2 time points was 2.3 and 
the lower and upper limits of agreement were -9.0 and 13.6. 
 
Figure 60. Bland Altman plot of 8818 gland volume at consent and prior to TPM 
 
 
Predicted cancer volume agreement (Figure 61a) between the two scans showed a mean 
difference -0.5cc, with lower and upper limits of agreement of -4.99 and 4.89 respectively. 
Index lesion volumes showed a mean difference 0.07cc lower and upper limits of 
agreement of -5.42 to 5.57 respectively (Figure 61b). 
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Figure 61. Bland Altman plot of 8818 total predicted cancer (totvol) volume and 
lesion (l1vol) volume at consent and prior to TPM 
 
  
 8818 vs. 8848 Probe Comparison 6.2.2
201 men had both 8818 and 8848 scan at baseline. Paired t test of prostate volume showed 
t=0.0748, Pr (T<t) =0.5298 Pr (|T|>|t|) =0.9405 Pr (T>t) =0.4702. 
Average difference between gland volumes was 0.02cc with lower and upper limits of 
agreement of -8.38 and 8.43 respectively (Figure 62). 
Cancer volumes demonstrated a mean difference -2.07cc, with lower and upper limits of 
agreement of -8.90-4.76 (Figure 63a). Lesion volumes showed an average difference -
2.18cc, with lower and upper limits of agreement of -9.40 to 5.04 (Figure 63b). 
 
 
 
a 
b 
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Figure 62. Comparing probes 8818 & 8848 at baseline- Gland Volume 
 
Figure 63. Comparing probes 8818 & 8848 at baseline-  
a) Total cancer volume (totvol0m), b) Index lesion volume (l1Vol0m) 
 
a 
b 
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 Discussion of HistoScanning Reliability Results 6.2.3
In summary, the PHS reliability work in PICTURE showed that the results of PHS, both in 
terms of gland size and lesion volume, were not stable between two time points using the 
same probe. In fact, gland volume varied by as much as -9.0 and 13.6cc. 
For a test to be reliable it needs to demonstrate not only high performance characteristics 
for the detection of disease but also it needs to be reliable when applied sequentially 
across time points. 
The high variability in both the volume of the prostate gland and the volume of prostate 
lesions seen using prostate HistoScanning in this cohort deem the test almost unusable. For 
example, if Prostate HistoScanning were to be employed in an active surveillance cohort, 
there would be no way of detecting if the growth in lesion size seen was true growth, or if it 
was simply as a result of the unreliability of the test over several time points.  
The 8848 side fire probe was, included in the PICTURE Study and used at the time of 
consent to scan each patient’s prostate. As part of the secondary analysis for the PICTURE 
study the volumes of the gland and lesion at 8818 scan and 8848 scan both performed at 
the same time period were assessed; once again, the Bland Altman plots for the 
comparison between these two tests showed a large degree of difference, suggesting that 
the PHS software is not stable across different ultrasound probes.   
When comparing between the two different ultrasound probes (8818 and 8848) it is worth 
considering that the developers of HistoScanning deemed the PHS algorithm for the 8848 
Prostate HistoScanning probe incomplete at the time of the PICTURE Study, and this may 
have impacted on its’ abilities. 
 
6.3 Biomarker Analysis 
 Engrailed 2 Urine Biomarker  6.3.1
The urine biomarker in the PICTURE Study was Engrailed 2 (EN2).  Participation in the 
biomarker analysis aspect of the study was optional. Overall 64 men participated in EN2 
analysis. Mean EN2 values 14.4 (SD 7.07), Median 12 (IQR 9.3-18.05). 
Table 55, Figure 64 and Figure 65 displays the AUROC for EN2 for the detection of both 
definition one and definition 2 disease, respectively. 
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Unfortunately no reliable pattern of EN2 value was found to predict disease. Previous 
studies had found that a cut off value of 42.5ng/mL had sensitivity and specificity of 66% 
and 88%, our work did not support these findings (Table 56). 
Table 55. Engrailed 2, Citrate and Zinc Performance AUROC analysis 
Marker  Definition 1 cancer   
 
Definition 2 cancer  
 AUROC (95% CI) N (%)  
with cancer 
AUROC (95% CI) N (%)  
with cancer 
EN2  n=64 0.62 (0.48, 0.76) 30 (47%) 0.68 (0.54, 0.81) 41 (64%) 
Citrate n=77 0.51 (0.37, 0.64) 34 (44%) 0.42 (0.29, 0.56) 55 (71%) 
Zinc n=77 0.52 (0.39, 0.66) 34 (44%) 0.46 (0.32, 0.60) 55 (71%) 
 
Figure 64. EN2 vs. Definition one cancer 
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Figure 65. EN2 vs. Definition two cancer 
 
Table 56. EN2, Citrate and Zinc levels at varying disease thresholds 
 Stats EN2 Citrate Zinc 
Definition one cancer  
Benign 
Mean 
(SD) 
13.31 
(6.9) 
37.13 
(30.37) 
2.14 
(2.16) 
Definition one cancer 
Mean 
(SD) 
15.73 
(7.06) 
32.11 
(20.05) 
1.99 
(1.76) 
Definition two cancer  
Benign 
Mean 
(SD) 
15.74 
(6.86) 
36.51 
(28.11) 
2.24 
(2.13) 
Definition two cancer 
Mean 
(SD) 
14.44 
(7.07) 
34.91 
(26.28) 
2.08 
(1.98) 
Scores by Gleason grade  
Gleason <7 
Mean 
(SD) 
13.3 
(7.35) 
31.26 
(19.78) 
1.68 
(1.38) 
Gleason≥7 
Mean 
(SD) 
15.34 
(6.80) 
37.38 
(29.83) 
2.34 
(2.27) 
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 FScan 6.3.2
Unfortunately, poor results for the FScan citrate and zinc assay were also found in our 
patient population, with the AUROC curve for both definition one and definition two cancer 
being around 50% (Table 55). Our results did not support the earlier findings that a lower 
citrate and zinc level was predictive of prostate cancer, nor was any correlation seen with 
cancer grade. 
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7 PICTURE Discussion 
7.1 PICTURE Study Limitations 
Prior to the summation and discussion of the PICTURE Study results, it is important to 
highlight some important limitations of the study that have direct implications for the 
application of the study’s findings in the prostate cancer pathway. 
1. The main limitation is that the PICTURE Study investigated men in whom a prior TRUS 
biopsy had already been performed but diagnostic uncertainty remained.  
Although the investigation of imaging at this time point in the prostate cancer pathway 
captures a large group of men for whom imaging may be useful, it does not fully address 
the issue of prostate cancer detection in all men at risk.  By this time point in the pathway a 
subset of men will have already gone on to treatment or been classified (correctly or 
incorrectly) as benign by their first prostate biopsy. 
There are, however, many stages at which imaging may be a useful triage test in the 
prostate cancer pathway.  For the cohort of men for whom a first TRUS biopsy has 
delivered uncertainty of diagnosis, the addition of mpMRI imaging to the pathway is 
attractive, and the results of the work within this study suggest it would be a useful 
addition. 
2. The single centre nature of the PICTURE Study is also a limitation to the applicability of 
our findings. Whilst it is encouraging that within an expert centre high performance 
characteristics for the detection of clinically significant disease were demonstrated, 
one of the major criticisms of mpMRI to date is that results are not easily replicated 
outside of expert centres. 
Further limitations of the PICTURE Study relates to the various methodological flaws.  
3. All men in the study had been through the process of TRUS guided biopsy of the 
prostate prior to enrolment. It is acknowledged that prior prostate biopsy can cause 
alteration of the MRI images for a considerable amount of time post biopsy- with some 
literature suggesting that biopsy artefact can last up to one year (Qayyum et al., 2004, 
Tamada et al., 2008b, White et al., 1995). 
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Within the PICTURE Study no formal time limit was set on the time between MRI and 
biopsy; however; due to the work flow in the study, men had normally had 3-6 months 
from the time of their biopsy before enrolment. There may still, however, from the prior 
biopsies have been some element of image degradation that may have affected the 
performance characteristics demonstrated. 
4. The PICTURE Study mpMRI’s were performed predominantly on the 3 tesla MRI 
scanner at University College London Hospitals, where the 3T scanner was installed 
shortly prior to the commencement of the study.  
The first 50 - 100 cases recruited to the PICTURE Study were a part of the familiarisation 
process and learning curve for this scanner. It is widely held that MRI magnets require 
slight ‘tweaks’ to their programming to ensure the best image acquisition; also scans 
performed at different field strengths and on different magnets may appear slightly 
different and as such the radiologist is required to ‘learn’ the interpretation of these 
mpMRI images. The familiarisation process for the new scanner may have impacted on the 
PICTURE results. 
5. A further limitation to the work of this study relates to the targeting system used for 
the MRI/US fusion biopsies. The hardware and software used within the study were 
part of an early prototype device for the technology that had been designed at UCL. Its 
use within the PICTURE Study was to enable further refinement of the technology and 
start the validation process. It is important to consider this when assessing the MRI/US 
targeted results. 
 
6. Another factor that may have impacted on the interpretation of the targeted results is 
the fact that targeted sampling was limited to only the largest lesion on PHS and the 
most suspicious lesion on mpMRI reporting: not all lesions seen were targeted. 
Targeted sampling was limited as well to the 2-3 cores per targeting methodology, per 
lesion; this low number of cores is likely to be unrepresentative of what would be 
required in everyday practice.  
 
7. The PICTURE study did not include any cost effectiveness modelling. In today’s 
economic climate this is a major flaw, as the addition of any new diagnostic test to a 
pathway needs to be evaluated not only for its value but also for its economic impact. 
A recent meta-analysis by Willis et al (Willis et al, 2015) has looked at the paucity of 
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data in this area, finding only 5 studies that relate to the cost impact of mpMRI on the 
prostate cancer pathway.  
 
7.2 Summary of PICTURE Study Results 
Prostate HistoScanning demonstrated poor ability in the discrimination of benign from 
malignant tissue. The AUC seen in the PICTURE Study for PHS is worse than chance 
(AUC=0.43). Although demonstrating 70.3% (95% CI 59.8-79.5) sensitivity for the detection 
of cancer volumes ≥ 1.3cc, specificity was only 14.7% (95% CI 9.1-22.0).  
PHS targeted biopsies demonstrated only a 23% disease concordance with transperineal 
template mapping biopsies, thus only 1 in 5 men were correctly classified by this technique. 
Also, poor reproducibility of PHS for the detection of lesion size between two time periods 
was demonstrated.  
Conversely, mpMRI has shown promising disease detection characteristics, with mpMRI 
demonstrating 80.6% (95% CI 71.6-87.7) sensitivity and 68.5% (95% CI 60.3-75.9) 
specificity, for the detection of clinically significant disease.  The area under ROC curves for 
mpMRI was 0.76 (95% CI 0.69-0.80). 
Whilst these results are very encouraging, being far better than the diagnostic performance 
characteristics for the current tests available for prostate cancer. In terms of diagnostic 
tests more globally mpMRI has not shown excellent specificity, and one should consider 
that although mpMRI may be at present our best diagnostic hope, Urologists should 
continue to strive for improvements in the diagnostic accuracy of the test.  
MRI-targeted biopsies had a detection rate of 78.6% (95% CI 69.9-82.1) for clinically 
significant cancer when lesions scoring 3 or greater on mpMRI were considered. 
Further analysis of the pooled MRI targeting data demonstrated that the majority of 
targeting errors seen in the PICTURE Study (55%) were classified as in-field targeting errors 
(i.e. correctly called on mpMRI however incorrectly localised/targeted at the time of 
sampling). 
The mpMRI inter-reporter reliability analyses showed little variation in AUROC curve 
analysis for the two reporters in a subset of PICTURE Study mpMRI’s. For all definitions of 
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disease significance kappa values indicating moderate agreement between two 
independent radiologists when scoring mpMRI using consensus agreed MRI ‘likert’ scale 
reporting, was found.  
 
7.3 PICTURE Study Conclusions 
The PICTURE Study results demonstrate that mpMRI may be a useful imaging tool in the 
prostate cancer diagnostic pathway, and that mpMRI targeted biopsy is a technique that 
allows accurate risk stratification with fewer biopsy cores. The further analysis of the 
targeted data within PICTURE demonstrating predominantly in-field targeting errors 
suggests that mpMRI targeted biopsy strategies may be even more accurate once further 
refinement is carried out to the technique of MRI/US guidance. 
Results for prostate HistoScanning have demonstrated that PHS is not a useful tool in the 
detection of prostate cancer, and the PICTURE Study results do not support further 
adoption of this technique. 
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8 Critical Analysis of Work and Thesis Discussion 
8.1 Main Limitations 
The main limitations of the studies within this body of work have been discussed in the 
previous chapters regarding the limitations of the PHS02 and PICTURE studies.  
With regards to the PHS02 study, a limitation that has not previously been addressed is the 
commercially sponsored nature of the study and the possible bias that this may have 
introduced.  
PHS02 was a company funded study developed to validate the technology, although the 
study was run in an objective and methodologically sound manner. With input from 
independent monitors and rigorous blinding within the blind phase, there is a possibility 
that influence of the developers on patient selection criteria could have led to biased 
results. 
The very strict patient selection criteria imposed in the study by the company does not 
reflect the nature of everyday prostate cancer detection and therefore limits the 
applicability of the results of the study to current practices in prostate cancer diagnosis. 
A key limitation to the applicability of the findings of the PICTURE study to current prostate 
cancer pathways pertains to the single centre nature of the study. Whilst the results of the 
PICTURE Study for the use of mpMRI are sufficiently promising as to suggest that 
widespread adoption of the technique of mpMRI, and that of mpMRI targeted biopsy, it is 
vital that the results are replicated in large multi-centre trials. 
 
8.2 Novel Contributions  
This research has examined the role of prostate cancer detection using innovative imaging 
namely, Prostate HistoScanning and Multiparametric magnetic resonance imaging. Through 
the evolution of the studies that have formulated this thesis, some of the many challenges 
that face the adoption of a new technique in the prostate cancer pathway have been 
highlighted. 
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The findings of this thesis can be summarised as follows:- 
 Prostate HistoScanning has no role in prostate cancer detection 
Prostate HistoScanning was a new and promising technology at the start of this research. 
Through the experiments performed using the prostate HistoScanning technology for 
prostate cancer detection - firstly in validation studies against radical prostatectomy and 
latterly in verification testing against template mapping biopsy, a less biased reference test 
-  a disappointing failure of the technology to accurately identify disease has been seen. 
Throughout the time given to this research the results for the technology became less and 
less reliable: with the PICTURE Study revealing that prostate HistoScanning was no more 
use in predicting prostate cancer than chance. The poor results for PHS from the PICTURE 
Study have also been replicated by other independent research groups (Javed et al., 2013, 
Schiffmann et al., 2014b, Schiffmann et al., 2015, Schiffmann et al., 2014a).  
Whilst disappointing that a technology could show such promise only to be found to be 
unreliable the tale of prostate HistoScanning is informative to the rapidly changing face of 
medicine, biomarkers and medical devices. It has highlighted the importance of thorough 
and rigorous clinical testing of biomarkers and medical devices prior to the implementation 
of their use on a wider clinical scale.  
 
 Multiparametric MRI is a useful tool for men in whom 
diagnostic uncertainty remains following primary biopsy 
This thesis in part aimed to assess the role of mpMRI for men in whom diagnostic 
uncertainty remained regarding their prostate cancer risk stratification. The PICTURE Study 
results demonstrated that for this group of men mpMRI is a useful tool to enable further 
risk stratification. 
The PICTURE Study showed that men with a negative MRI have a low likelihood of 
harbouring significant prostate cancer (NPV 83.3%), and that mpMRI demonstrated has a 
high sensitivity for the detection of clinically significant disease - 80.6%. 
These promising performance characteristics for mpMRI have proven the thesis’ hypothesis 
that imaging in the prostate cancer pathway can be a useful tool, and that it may afford 
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men (who have undergone previous biopsy) – a better more accurate risk stratification 
without immediate further biopsy. 
Multi-parametric MRI has demonstrated that for men who have a negative mpMRI, further 
biopsy could be safely avoided; additionally, for those with an mpMRI lesion the results of 
PICTURE suggest that a targeted biopsy approach may enable accurate risk stratification 
with far fewer biopsy cores than template mapping prostate biopsy. 
The findings of this thesis are in keeping with the recommendations made by prominent 
advisory bodies for urology during the evolution of this study: namely, that imaging should 
be used for men in whom diagnostic uncertainty remains (National Institute for Health and 
Care Excellence, 2014b, Heidenreich et al., 2014).   
 
 Multiparametric MRI targeted biopsy provides accurate risk 
stratification, with fewer cores than TPM biopsy 
Alongside the usefulness of mpMRI in sparing men with a negative test the morbidity 
associated with repeat prostate biopsy, the work evaluating the role of targeted biopsy has 
shown the mpMRI targeted biopsies can detect most cancers found at template mapping 
biopsy with far fewer biopsy cores, and thus greater sampling efficiency. 
This targeted approach could in the future lead to a diagnostic pathway that places a 
smaller burden in terms of morbidity on the patient (fewer cores are likely to lead to less 
infection, pain and other side effects).  
Image directed targeted biopsy would allow for faster, more efficient biopsies to be 
performed - most likely under local anaesthetic - and the reduction in cores will mean a 
lesser burden not only on the patient but also on histopathology processing times and 
costs.  
There were, as discussed in the previous chapter, a number of limitations to the targeted 
biopsy work within the PICTURE Study, which may have negatively affected the 
performance characteristics of targeting and led to the ultimate conclusion that as yet 
systematic biopsy cannot be disregarded. With further development of MRI/US registration 
technologies, it is likely that this technology will become the most preferred method for 
prostate cancer detection globally. 
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It is important to remember that all biopsy strategies will miss some disease, as shown in 
chapter 4.4, when modelling biopsy techniques, even the most stringent 5m template 
biopsy strategy did not detect all disease.  Financially it is unsustainable within the NHS to 
focus on a transperineal template mapping biopsy techniques as they have such a high 
burden - in terms of operating time (requires general anaesthetic and theatre time), 
histological processing time and side effect profile.  
Therefore, it is important that researchers do not strive for the ‘perfect’ test, but instead 
that techniques are adopted that allow a high degree of accuracy, in a manner that is both 
feasible economically and logistically. Multiparametric-MRI targeted biopsy strategies have 
shown great potential in being able to offer this, with the results of the PICTURE Study 
demonstrating detection rates almost in keeping with full 5mm TPM, with on average 4.2 
biopsy cores rather than the average 48 cores taken at TPM. 
 
8.3 Impact and Future Directions 
The impact of the results of this thesis has already been evidenced by the change in 
practice at University College Hospitals London. There has been an adoption of the practice 
of a local anaesthetic ‘cognitive’ targeted transperineal targeted biopsy following mpMRI 
for men at risk of prostate cancer.  
This research has however highlighted several areas for further work and development of 
the technology of mpMRI and also MRI guided targeted biopsy. 
Firstly, it is vital that a large multi-centre trial is performed to assess the use of mpMRI in 
men prior to biopsy. Such a study should not only assess the performance characteristics of 
the test but should assess the cost implications for the adoption of MRI at this early stage 
in the pathway. 
Such a study is already underway in the UK and publication of the results is anticipated in 
early 2016 (El-Shater Bosaily et al., 2015).  
For mpMRI to remain a viable option for prostate cancer diagnosis it will need to continue 
to demonstrate the high performance characteristics found in the PICTURE study for 
mpMRI in men who have not undergone previous TRUS biopsy. 
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The multi-centre nature of such a study should allay any concern regarding the inability of 
lower volume, less specialist centres to be able to reproduce the mpMRI imaging results of 
more specialist centres. The economic modelling of the study is also vital in the current 
economic climate. 
Another area for further research that has been highlighted by this study is the need for 
continued development of the novel MRI/US platform for the use in targeting areas seen 
on mpMRI.  
The results from the PICTURE Study did not demonstrate a great improvement in detection 
by the use of MRI/US fusion over ‘cognitive targeting’; this may however be due to the 
prototype device used in the study, or the expertise of those performing the ‘cognitive’ 
biopsy.  
With further investigation and refinement of MRI/US fusion technology however, it seems 
likely that it might prove to be useful and become a widely adopted technique amongst 
urologists.  
There currently is a number of MRI/US biopsy platforms on the market (ARTEMIS/ Eigen 
fusion etc.) none, however, has the ability to deform to a prostate as that developed at 
University College London and used within PICTURE.  
A study that targets all lesions seen at MRI (and not just the primary as taken in PICTURE), 
using a more developed prototype of the UCL Smart Target system, is required. Currently 
this study is underway at UCL/UCLH as part of a Welcome study grant. 
It would also seem prudent to examine the use of mpMRI targeted biopsy vs. the gold 
standard systematic TRUS biopsy.  
Several other areas, for further research and development were identified in the evolution 
of this research. 
Many of the studies investigating imaging in prostate cancer divide the prostate into 
multiple sectors to obtain the results. Further work is required to assess the effect of such a 
methodology on the performance characteristics of a test.  
The added value of each of the mpMRI sequences for the detection of disease also needs 
to be assessed. As discussed when reviewing the MRI literature in chapter two, several 
groups have looked at a couple of the sequences of mpMRI. By assessing the additive value 
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of each of the sequences included in an mpMRI by assessing sequential reporting it can be 
determined if each sequence is required in the mpMRI pathway. If, for example, DCE 
imaging was found to have little additive diagnostic value, it may be able to be avoided in 
mpMRI; thus, reducing the time taken to perform mpMRI and the cost in doing so - also the 
need not to require intravenous contrast is attractive. 
A further element of study that is required is the development of a computer aided 
diagnosis (CAD) mpMRI reporting system. It is felt that by adding CAD to mpMRI reporting 
improved reporter accuracy and reduced inter-reported variability may be enabled. Such a 
technique may be able to rapidly decrease the learning curve of radiologists and enable 
easier widespread adoption of mpMRI for prostate cancer detection. Work is underway at 
UCL/UCLH to try and develop such a system. 
 
8.4 Summary 
Prostate cancer remains a large problem facing today’s society. A large number of men will 
be labelled with the disease and suffer the morbidity and concern that the diagnosis and its 
investigations entails. Currently, there exists no consensus amongst experts on the use of 
imaging in the prostate cancer diagnostic pathway, however momentum is gathering in the 
support for this paradigm shift and the adoption of an imaging biomarker. This momentum 
is evidenced by statements from NICE guidance suggesting the use of mpMRI for men with 
previous negative TRUS biopsy (National Institute for Health and Care Excellence, 2014b).  
The history of prostate cancer diagnosis draws many parallels to that of breast cancer 
diagnosis; however, the urological community seem some decades behind their breast 
surgical colleagues. Blind random sampling of breast tissue without imaging has not been 
performed since the introduction of the use of mammograms in the late 1980’s. 
It has been argued that breast cancer screening with mammography and ultrasound 
altered the landscape of breast cancer diagnosis for the better; however, at the time of its 
inception, and still, there remain supporters both for and against its introduction (Otto and 
Blecher, 2014, Fuller et al., 2015).  
Similarly now, within the urological community there are supporters both for and against 
imaging in the diagnostic pathway.  It is generally agreed upon by experts that not all 
prostate cancers require treatment (Wilt, 2012), indeed, it may be better for  men with low 
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volume, low risk disease if they are never diagnosed and attributed a prostate cancer 
diagnosis. It has also been acknowledged that there is a lack of clear risk stratification for 
men - with many men undergoing either immediate upgrading or downgrading of disease 
on subsequent biopsies or at the time of their treatment.  
The body of evidence for the use of imaging in the prostate cancer pathway, especially 
mpMRI is growing. However, there remains a scepticism surrounding it’s widespread 
adoption,  in part because of the criticism that mpMRI not only misses low volume low 
grade disease but also because it is difficult to reproduce high quality mpMRI images and 
reports in every centre. 
Although, the work in this thesis does not overcome all of the barriers to adoption that 
imaging for prostate cancer faces. It could be argued that the results of the PICTURE Study 
are sufficiently promising as to warrant much more widespread adoption of mpMRI and 
mpMRI targeted biopsy.  
To the criticism that mpMRI does not detect all disease, it appears that it is not important 
to detect the very low volume, low risk disease that MRI is likely to miss: in fact, these men 
may be better off without a diagnosis of prostate cancer.  
With regards to the difficulty of performing these technique outside of specialist prostate 
centres, it seems that with the correct training and motivation radiologists can improve 
their proficiency in reading an mpMRI scan (Gaziev et al., 2014, Latchamsetty et al., 2007), 
and therefore this should not be allowed to become a barrier to a test that may ultimately 
help men globally. 
Finally, a word of caution with regards to the uptake of new technologies. During this 
research, a number of novel forms of prostate cancer diagnosis were presented – it is after 
all, a politically and financially attractive area of work for many entrepreneurs: this thesis, 
however, has demonstrated that rigorous testing of all biomarkers (imaging and biological) 
is required before widespread adoption.  
Urologists must ensure that there is high quality level 1 evidence available for these 
technologies before they become of general use; allowing devices or biomarkers to 
become part of our routine practice prior to this rigorous testing could have harmful 
implications economically and medically for a large number of men. 
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